https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/introduction10
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genomic-profiling-is-driving-the-precision-oncology
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/lung-cancer-diagnostic-test-needs-perspective-from-a-thoracic-oncologist
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/establishment-of-a-large-scale-asian-genomic-screening-platform-to-identify-non-small-cell-lung-cancer-with-rare-driver-oncogenes-and-clarify-drug
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ntrk-ret-and-other-fusion-biomarkers-testing-latest-developments
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/program-and-speaker-introduction
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/precision-medicine-in-the-era-of-emerging-biomarkers
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-perspectives-on-a-patient-with-advanced-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-perspectives-on-a-patient-with-advanced-pancreatic-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-perspectives-on-a-patient-with-advanced-thyroid-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-24-september-2020-17-00-17-302
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-24-september-2020-17-30-18-00
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-15-september-2020-09-30-10-00
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-22-september-2020-17-00-17-302
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-14-september-2020-15-30-16-00
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/flattening-the-curve-consequences-for-the-management-of-prostate-cancer-in-the-ongoing-covid-19-pandemic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-18-september-2020-17-00-18-00
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/introduction
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/optimizing-treatment-strategies-in-first-line-mcrc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/extending-the-continuum-of-care-beyond-second-line-mcrc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/summary-and-close2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/welcome-and-introduction4
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/latest-updates-in-molecular-testing-in-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/egfr-nsclc-a-personalised-sequencing-approach
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/alk-and-ros1-nsclc-optimising-patient-outcomes
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/taking-the-pulse-of-personalised-healthcare-today
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tracing-our-path-with-current-tools
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/if-tissue-is-the-issue-think-blood
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/welcome-and-introduction9
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/treatments-after-progression-in-the-first-line-of-non-mutated-nsclc-adenocarcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-regulator-perspective-rwe-and-real-world-data-rwd-in-drug-approvals-and-label-expansions
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-payer-perspective-utilising-rwd-to-determine-the-value-of-drugs
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/panel-discussion
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/welcome-and-introduction3
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/deepening-our-understanding-of-dual-checkpoint-inhibition
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-lessons-learned-from-the-use-of-dual-i-o-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exploring-treatment-advancements-in-arcc-with-ctla-4-and-pd-1-inhibition
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/summary-and-close2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/welcome-and-introduction4
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/latest-updates-in-molecular-testing-in-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/egfr-nsclc-a-personalised-sequencing-approach
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/alk-and-ros1-nsclc-optimising-patient-outcomes
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/taking-the-pulse-of-personalised-healthcare-today
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tracing-our-path-with-current-tools
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/if-tissue-is-the-issue-think-blood
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/welcome-and-introduction9
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/treatments-after-progression-in-the-first-line-of-non-mutated-nsclc-adenocarcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/uncommon-egfr-mutations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-future-of-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/key-insights-and-closing-remarks
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/current-status-of-i-o-for-the-treatment-of-metastatic-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/i-o-for-upper-gi-cancers-where-are-we-today
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/case-study-workshop-expert-insights-into-i-o-therapy-for-gi-cancers
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/summary-and-close
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/welcome-and-introduction2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-patient-perspective-the-relevance-of-rwe-in-patient-decision-making
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-physician-perspective-using-rwe-to-inform-clinical-decisions-in-day-to-day-practice-and-drug-discovery
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-regulator-perspective-rwe-and-real-world-data-rwd-in-drug-approvals-and-label-expansions
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-payer-perspective-utilising-rwd-to-determine-the-value-of-drugs
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/panel-discussion
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/welcome-and-introduction3
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/deepening-our-understanding-of-dual-checkpoint-inhibition
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-lessons-learned-from-the-use-of-dual-i-o-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exploring-treatment-advancements-in-arcc-with-ctla-4-and-pd-1-inhibition
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/summary-and-close2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/welcome-and-introduction4
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/latest-updates-in-molecular-testing-in-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/egfr-nsclc-a-personalised-sequencing-approach
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/alk-and-ros1-nsclc-optimising-patient-outcomes
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/taking-the-pulse-of-personalised-healthcare-today
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tracing-our-path-with-current-tools
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/if-tissue-is-the-issue-think-blood
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/welcome-and-introduction9
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/treatments-after-progression-in-the-first-line-of-non-mutated-nsclc-adenocarcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/uncommon-egfr-mutations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-future-of-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/key-insights-and-closing-remarks
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/challenges-in-the-treatment-of-prostate-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/maximizing-outcome-with-nhts
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/expanding-the-potential-of-parp-inhibitors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/summary
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/optimising-care-for-individual-patients-with-metastatic-hormone-sensitive-prostate-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/non-metastatic-castration-resistant-prostate-cancer-translating-benefit-to-clinical-practice-choosing-the-right-pathway-in-the-current-and-future
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/conclusion4
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/overall-survival-in-nmcrpc-translating-recent-data-into-a-plan-of-action
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/mitigating-and-managing-adverse-events-associated-with-androgen-receptor-targeted-therapies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/quality-of-life-as-a-therapeutic-goal-for-nmcrpc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/framing-the-shot-examining-current-practice-in-hr-her2-abc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/changing-perspectives-exploring-the-patient-focus-in-hr-her2-abc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/views-from-the-clinic-challenges-choices-and-confidence-when-treating-your-patients-with-germline-brca-mutated-her2-la-or-mbc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/welcome
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-innovative-early-treatment-landscape
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/access-availability-and-uptake-of-combination-therapies-in-europe
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/panel-discussion-moderated-by-bettina-ryll
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/welcome-and-introductions4
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tracking-the-recent-advances-within-the-field-of-unresectable-hcc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/reviewing-the-latest-phase-iii-efficacy-data-for-unresectable-hcc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exploring-key-safety-data-for-cancer-immunotherapy-combinations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/moving-into-the-clinic-how-will-these-data-inform-our-clinical-decisions
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/panel-discussion6
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/welcome-and-introduction14
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/brief-overview-of-immuno-oncology-in-hcc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/io-combinations-in-first-line-advanced-hcc-current-evidence-and-ongoing-trials
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/io-combinations-early-or-intermediate-stage-hcc-current-evidence-and-ongoing-trials
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/putting-it-all-together-case-discussions
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/summary-final-thoughts-and-audience-question-and-answer-session
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/panel-discussion5
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/summary-and-close5
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-18-september-2020-16-15-16-45
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-23-september-2020-10-00-10-30
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-22-september-2020-17-00-17-30
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-29-september-2020-10-30-11-00
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-15-september-2020-09-30-10-00
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-22-september-2020-17-00-17-302
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-14-september-2020-15-30-16-00
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/flattening-the-curve-consequences-for-the-management-of-prostate-cancer-in-the-ongoing-covid-19-pandemic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-18-september-2020-17-00-18-00
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/an-overview-of-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/uncommon-egfr-mutations-in-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-24-september-2020-17-00-17-302
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/optimizing-treatment-strategies-in-first-line-mcrc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/extending-the-continuum-of-care-beyond-second-line-mcrc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/welcome-and-introduction11
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/conclusion3
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-23-september-2020-11-30-12-00
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genome-mining-aided-biosynthesis-overcomes-temozolomide-resistant-glioblastoma-via-negatively-regulating-ciap-mediated-degradation-of-pacs2-and-er
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/synergistic-activity-of-parp-inhibitor-and-atr-inhibitor-in-melanoma-cell-lines-may-depend-on-braf-v600-mutation-status
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/targeting-angiomotin-p130-reverse-resistance-to-antiangiogenic-therapies-in-breast-cancer-by-inhibition-of-vasculogenic-mimicry
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/preclinical-evaluation-of-ds-2087b-a-novel-and-selective-inhibitor-of-egfr-her2-exon-20-insertions
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/modulation-of-mcf-7-cell-sensitivity-to-anticancer-agents-by-targeting-glycolysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/study-on-the-mechanism-of-apatinib-reversing-tamoxifen-resistance-in-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/development-of-novel-combination-of-imatinib-and-thymoquinone-on-colon-cancer-cell-line
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/engineering-and-expression-of-constitutive-activators-of-the-pd-1-and-lag-3-signaling-pathways
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prolonged-in-use-stability-of-reconstituted-atezolizumab-in-commercial-intravenous-bags
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/deep-eutectic-solvent-mixture-formed-from-2-deoxy-d-glucose-and-metformin-targets-cancer-cell-metabolism-and-induces-apoptosis-in-breast-cancer-cel
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/urethane-induced-lung-carcinogenesis-in-genetically-edited-c57bl-6-mice-with-chek2-and-gprc5a-heterozygous-inactivating-mutations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/salicylidene-acylhydrazides-attenuate-sh-sy5y-neuroblastoma-cell-survival-through-mitotic-regulator-speedy-ringo-and-erk-mapk-pi3k-akt-pathways
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/dab2ip-inhibits-metastasis-in-nsclc-by-governing-cell-matrix-and-cell-cell-adhesions
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/identification-of-zfp161-as-a-regulator-of-the-c-myc-oncogene-in-human-cells
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-role-of-speedy-ringo-in-between-mapk-and-akt-pathways-in-sh-sy5y-neuroblastoma-cells
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/coexpression-of-e-and-n-cadherins-as-a-sign-of-epithelial-mesenchymal-transition-emt-in-prostate-cancer-pca
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/laryngopharyngeal-reflux-affects-tumour-immune-microenvironment-in-carcinoma-of-larynx
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/frequency-and-spectrum-of-founder-and-non-founder-brca1-2-mutations-in-a-large-series-of-russian-breast-cancer-and-ovarian-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genomic-features-of-chinese-lung-squamous-cell-carcinoma-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-prevalence-of-loss-of-heterozygosity-at-human-leukocyte-antigen-locus-in-chinese-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/accurate-detection-of-hrd-status-in-multiple-cancer-types-using-somatic-mutation-pattern
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparison-of-fully-automated-microsatellite-instability-test-to-immunohistochemistry-for-mismatch-repair-protein-expression-in-endometrial-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/blast-guided-mappability-knowledgebase-facilitates-accurate-detection-of-somatic-variants
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/molecular-markers-of-response-to-different-chemotherapeutic-agents-in-ras-braf-mutated-colon-cancer-cell-lines
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exploring-a-machine-learning-approach-to-predict-tumour-type-from-targeted-panel-dna-sequence-data
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-dual-role-of-nicotine-in-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/melatonin-reverses-the-warburg-dependent-effect-in-ovarian-cancer-cell-by-binding-to-the-mt1-and-mt2-receptors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/study-on-human-plasma-concentration-and-serosal-permeation-of-oral-apatinib-mesylate
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/analysis-of-bloodstream-infections-in-oncological-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/trends-of-elevated-cancer-prevalence-among-inhabitants-of-agrarian-landscapes-in-punjab-northwestern-india
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/incidence-of-cancer-trend-with-the-age-and-distribution-among-the-cities-in-kosovo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genetic-polymorphism-of-lncrna-pcat1-and-gastric-cancer-risk
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/usefulness-of-the-framingham-risk-score-to-predict-cardiotoxicity-in-breast-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/role-of-dna-methylation-and-non-coding-rna-in-ink4b-arf-ink4a-locus-expression
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparative-expression-profiling-of-mir-21-155-and-221-in-benign-and-malignant-breast-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/adherence-to-treatment-recommendations-from-multidisciplinary-tumour-boards
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-novel-serum-microrna-based-diagnostic-panel-for-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/macrophage-derived-exosomal-micrornas-regulate-macrophage-cancer-communications
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ultrasound-guided-screening-of-gallbladder-cancer-in-healthy-volunteers-a-prospective-study-from-northern-india
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/role-of-micrornas-in-a-panel-of-human-cervical-cancer-cell-lines
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/role-of-biliary-extracellular-vesicles-in-diagnosing-various-pancreatobiliary-malignancies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/modified-folfirinox-versus-cisgem-as-first-line-chemotherapy-for-advanced-biliary-tract-cancer-results-of-amebica-prodige-38-randomized-phase-ii-t
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/toripalimab-with-chemotherapy-as-first-line-treatment-for-advanced-biliary-tract-tumors-a-preliminary-analysis-of-safety-and-efficacy-of-an-open-l
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-and-safety-of-futibatinib-in-intrahepatic-cholangiocarcinoma-icca-harboring-fgfr2-fusions-other-rearrangements-subgroup-analyses-of-a-p
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/adjuvant-gemcitabine-based-chemotherapy-for-biliary-tract-cancer-pooled-analysis-of-the-bcat-and-prodige-12-studies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/anti-pd1-antibody-toripalimab-lenvatinib-and-gemox-chemotherapy-as-first-line-treatment-of-advanced-and-unresectable-intrahepatic-cholangiocarcino
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/third-line-chemotherapy-in-advanced-biliary-cancers-abc-pattern-of-care-treatment-outcome-and-prognostic-factors-from-a-multicenter-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/quality-of-life-qol-outcomes-with-futibatinib-treatment-in-foenix-cca2-a-phase-ii-study-in-patients-pts-with-intrahepatic-cholangiocarcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/evolution-of-adjuvant-therapy-in-radically-resected-carcinoma-gallbladder-gbc-over-a-decade-a-real-world-experience-from-a-regional-cancer-centre
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/epidemiology-and-patterns-of-care-of-intrahepatic-cholangiocarcinoma-icca-in-france-real-life-data-from-the-french-national-hospital-discharge-s
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/gender-and-race-ethnicity-differences-in-outcomes-of-biliary-cancers-bc-a-seer-database-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-significance-of-baseline-neutrophil-lymphocyte-ratio-nlr-platelet-lymphocyte-ratio-plr-and-systemic-immune-inflammation-index-sii
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/multicentre-match-paired-analysis-of-advanced-biliary-cancer-abc-long-term-survivors-the-bilong-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/hematologic-indices-of-inflammation-as-prognosticators-in-gallbladder-cancer-a-meta-analysis-and-systematic-review
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-role-of-pecs2-index-in-advanced-biliary-tract-cancer-btc-patients-treated-with-first-line-chemotherapy-training-and-validation-cohorts
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/preoperative-predictors-of-long-term-outcomes-for-resectable-intrahepatic-cholangiocarcinoma-icca-is-there-a-space-for-neoadjuvant
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/fgfr2-fusion-in-resectable-intrahepatic-cholangiocarcinoma-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/analysis-of-dna-damage-repair-ddr-pathway-genes-in-biliary-tract-cancer-and-correlation-with-immunogenic-biomarker
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pd-l1-expression-as-a-prognostic-marker-in-patients-with-advanced-biliary-tract-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genomic-landscape-and-efficacy-of-precision-medicine-in-biliary-tract-cancers
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ntrk-gene-fusions-in-bilio-pancreatic-cancers
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genetic-landscape-of-intrahepatic-cholangiocarcinoma-in-chinese-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/long-term-follow-up-of-bintrafusp-alfa-a-bifunctional-fusion-protein-targeting-tgf-v-and-pd-l1-in-patients-with-pretreated-biliary-tract-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/targeting-mitochondria-as-a-novel-therapeutic-strategy-in-biliary-tract-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/association-of-epstein-barr-virus-and-cholangiocarcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-distribution-of-tumor-mutational-burden-in-idh-mutant-solid-tumors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-characteristics-and-therapeutic-implications-of-palb2-variants-in-patients-with-advanced-solid-tumors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/keynote-966-trial-in-progress-pembrolizumab-plus-gemcitabine-and-cisplatin-for-advanced-biliary-tract-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ii-iii-randomized-placebo-controlled-study-of-bintrafusp-alfa-with-gemcitabine-plus-cisplatin-as-first-line-treatment-of-biliary-tract-ca
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/global-phase-iii-study-of-nuc-1031-plus-cisplatin-vs-gemcitabine-plus-cisplatin-for-first-line-treatment-of-patients-with-advanced-biliary-tract-ca
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/changes-in-immune-function-and-prognosis-in-advanced-perihilar-cholangiocarcinoma-patients-treated-with-immunotherapy-combined-with-different-topic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/machine-learning-models-predict-selinexor-tolerability-and-efficacy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/abnormal-breast-detection-by-an-improved-alexnet-model
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/transcriptomic-mapping-of-integrins-and-immune-activation-in-basal-like-and-her2-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-prognosis-and-predictive-value-of-the-negative-estrogen-positive-progesterone-breast-cancer-profile-er-pr-moroccan-experience
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/irf4-gene-promoter-methylation-predicts-efficacy-of-luminal-b-breast-tumours-neoadjuvant-chemotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/coexpression-of-pi3k-akt-signaling-components-and-breast-stem-cells-markers-potential-contributions-in-resistance-to-tamoxifen-treatment
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/promising-biomarkers-for-therapeutic-targets-and-prognosis-of-triple-negative-breast-cancer-tnbc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/validation-for-clinical-use-of-ngs-based-assay-to-detect-circulating-tumor-dna-ctdna-in-patients-pts-with-various-types-of-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-panel-of-methylation-markers-for-multi-cancer-detection-from-plasma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/an-exploration-of-arid1a-mutations-in-circulating-cell-free-dna-cfdna-from-68-000-advanced-cancer-patients-implications-for-tumour-biology-and-t
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pan-tumor-characterization-of-kras-mutations-krasm-detected-in-circulating-tumor-dna-ctdna-and-concordance-with-paired-tissue
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/evaluation-of-the-circulating-stromal-biomarker-vicm-reflecting-m1-like-macrophage-activity-in-metastatic-melanoma-patients-treated-with-anti-pd-1
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/accuracy-of-detecting-pik3ca-mutations-on-circulating-tumour-ct-dna-as-compared-to-tumour-tissue-tt-in-breast-cancer-bc-patients-pts-resul
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-genomic-characteristics-of-jak-family-in-11159-chinese-solid-tumour-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/chemotherapy-induced-neutropaenia-as-a-marker-for-overall-survival-os-in-non-small-cell-lung-cancer-nsclc-patients-undergoing-gemcitabine-carbo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/angiogenesis-related-factors-and-clinical-outcomes-in-combination-therapy-with-paclitaxel-ptx-ramucirumab-ram-plus-nivolumab-nivo-for-advanc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/dynamic-change-in-blood-derived-variant-allele-frequency-as-a-predictive-marker-for-response-from-checkpoint-inhibitor-based-therapies-among-metast
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immune-checkpoint-proteins-as-a-prognostic-biomarker-of-overall-survival-in-non-small-cell-lung-cancer-a-meta-analysis-and-systematic-review
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immune-checkpoint-inhibitor-icpi-resistance-genes-stk11-and-keap1-a-comparative-comprehensive-genomic-profiling-cgp-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pembrolizumab-in-pre-treated-advanced-non-small-cell-lung-cancer-nsclc-patients-pts-impact-of-blood-based-biomarkers-on-survival-outcomes
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/subpopulations-of-peripheral-blood-lymphocytes-and-response-to-immunotherapy-across-cancer-types
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-value-of-compartmental-spatial-analysis-of-tumour-infiltrating-lymphocytes-in-triple-negative-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/adenosine-pathway-and-exhaustion-markers-in-peripheral-t-cell-correlate-with-benefit-from-immunotherapy-in-advanced-non-small-cell-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-clinical-parameters-on-cd8-and-cd4-lymphocyte-distribution-in-patients-with-non-small-cell-lung-cancer-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/c-reactive-protein-crp-levels-in-immune-checkpoint-inhibitor-response-and-progression-in-advanced-non-small-cell-lung-cancer-a-bi-center-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pd-l1-prevalence-and-association-with-clinical-outcomes-among-metastatic-renal-cell-carcinoma-patients-treated-with-targeted-therapies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pd-l1-expression-landscape-and-microsatellite-instability-status-in-chinese-endometrial-and-cervical-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pd-l1-expression-profile-and-microsatellite-instability-status-in-chinese-gastric-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tumour-mutation-burden-and-response-to-immune-checkpoint-inhibitors-in-solid-tumors-a-systematic-review-and-meta-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/correlation-between-pd-l1-expression-tmb-and-immune-cell-infiltration-a-pan-cancer-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-pan-cancer-study-on-difference-of-homologous-recombination-deficiency-and-tumour-mutational-burden-between-chinese-and-western-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/predictive-biomarkers-for-hyper-progression-in-response-to-immune-checkpoint-inhibitors-therapy-analysis-of-somatic-alterations-by-ngs
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/relationship-between-different-mutation-type-in-jak1-2-3-and-b2m-with-other-biomarkers-for-immunotherapy-in-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/serum-pdl-1-in-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-prognostic-role-of-lymphocyte-count-for-treatment-response-in-immune-checkpoint-inhibitor-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/serum-parameters-as-prognostic-biomarkers-for-anti-pd-1-pd-l1-therapy-in-patients-with-solid-tumours-a-retrospective-data-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/association-of-tumour-cd4-positive-lymphocytes-with-prognosis-in-non-small-cell-lung-cancer-patients-treated-with-epidermal-growth-factor-receptor
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/personalizing-treatment-in-colorectal-cancer-by-monitoring-bevacizumab-blood-levels-and-icam-1-polymorphisms
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-value-of-blood-based-fibrosis-biomarkers-in-patients-with-metastatic-colorectal-cancer-receiving-chemotherapy-and-bevacizumab
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exploratory-analysis-of-the-prognostic-value-of-rotational-thromboelastometry-in-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comprehensive-analysis-of-dna-damage-repair-deficiency-across-10-613-pan-cancer-patients-implications-for-drug-development-and-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ptch1-genomic-alterations-ga-in-human-malignancies-a-pangenomic-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ntrk1-2-3-fusions-in-secretory-versus-non-secretory-breast-cancers
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/trking-ptc-patients-ntrk-gene-fusion-frequency-and-clinical-characteristics-of-a-finnish-papillary-thyroid-cancer-cohort
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/her2-transcription-status-of-diverse-solid-tumours-with-clinical-implications
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/in-search-of-novel-synthetic-lethality-sl-anti-cancer-drug-targets-mtap-genomic-alterations-ga-in-human-malignancies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/c-ros-oncogene-1-receptor-tyrosine-kinase-ros1-partners-identified-by-next-generation-sequencing-in-chinese-patients-with-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/evaluation-of-a-regularly-updated-knowledge-base-and-automated-variant-interpretation-tool-for-somatic-mutations-detected-in-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/braf-mutation-testing-and-results-among-french-patients-with-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/talapro-1-talazoparib-tala-monotherapy-in-men-with-dna-damage-response-alterations-ddralt-and-metastatic-castration-resistant-prostate-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/rearranged-during-transfection-ret-partners-identified-by-next-generation-sequencing-in-chinese-patients-with-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/kmt2c-kmt2d-kmt2c-d-promising-biomarkers-for-immunotherapy-in-gastric-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-landscape-of-brca1-2-mutations-in-chinese-patients-with-ovarian-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/correlation-between-histological-pattern-and-hotspots-egfr-mutations-in-moroccan-lung-adenocarcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prevalence-of-brca1-2-mutations-in-patients-with-ovarian-cancer-in-the-gulf-region-the-predict-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/analysis-of-genomic-alterations-detected-by-next-generation-sequencing-based-tissue-and-circulating-tumour-dna-assays-in-mexican-patients-with-dive
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/identification-of-the-methylated-onecut2-gene-through-real-time-methylation-specific-polymerase-chain-reaction-assays-for-the-non-invasive-detectio
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-new-biomarker-of-microbe-italic-akkermansia-muciniphila-italic-in-lung-adenocarcinoma-tissues-may-predict-lymph-node-metastasis-in-lung-adeno
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exosomes-microrna-sequencing-identifies-mir-363-5p-as-non-invasive-biomarker-of-axillary-lymph-node-metastasis-and-prognosis-in-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-three-mirna-signature-as-promising-prognostic-biomarker-for-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-implications-of-serum-mi-rna-155-and-mi-rna-92a-in-diffuse-large-b-cell-lymphoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/association-of-hormone-sensitive-mirnas-expression-with-main-clinicopathologic-characteristics-of-er-pr-positive-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prevalence-of-anaplastic-lymphoma-kinase-alk-non-small-cell-lung-cancer-nsclc-in-the-middle-east-and-north-africa-mena
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/children-s-exposure-to-rare-earth-elements-and-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-systemic-inflammation-response-index-siri-is-a-prognostic-factor-that-correlates-with-tumor-burden-in-advanced-pancreatic-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/investigation-of-pd-l1-expression-and-tislelizumab-efficacy-in-gastroesophageal-adenocarcinoma-using-a-novel-tumor-and-immune-cell-score-with-venta
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/molecular-profiles-and-response-among-metastatic-renal-cell-carcinoma-patients-treated-with-targeted-therapies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/high-tlr3-expression-predicts-improved-survival-in-patients-with-clear-cell-renal-cell-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/search-for-new-markers-of-thyroid-carcinogenesis-associated-with-er-ar-and-pr-receptor-status
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/bioitalee-molecular-features-of-postmenopausal-women-with-hormone-receptor-positive-hr-her2-negative-her2-pik3ca-mutated-advanced-breast-ca
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/v2-adrenergic-receptor-gene-expression-as-a-prognostic-and-predictive-biomarker-in-her2-positive-early-stage-breast-cancer-patients-enrolled-on-the
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/avoid-systemic-overtreatment-of-postmenopausal-breast-cancer-patients-with-ultralow-mammaprint-result
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/gene-expression-in-early-breast-cancer-ebc-patients-pts-with-relapse-despite-pathologic-complete-response-pcr-an-intra-and-interindividual
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-impact-of-progesterone-receptor-levels-in-luminal-like-her2-early-breast-cancer-patients-a-retrospective-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genomic-testing-biomarkers-and-treatment-patterns-in-early-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-role-of-body-mass-index-bmi-in-patients-with-human-epidermal-growth-factor-receptor-2-her2-positive-early-breast-cancer-treated-with
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/germline-mutation-status-and-therapy-response-in-patients-with-homologous-recombination-deficient-her2-negative-early-breast-cancer-results-of-th
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-plasma-biomarker-panel-of-micrornas-for-early-breast-cancer-diagnosis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/her2-neu-655-a-g-polymorphism-is-associated-with-higher-cardiotoxicity-but-not-with-less-efficacy-of-trastuzumab-in-her2-positive-breast-cancer-pa
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-impact-of-body-composition-bc-changes-during-neoadjuvant-chemotherapy-nact-in-breast-cancer-patients-pts
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/development-of-prognosis-prediction-model-using-cytokeratin-19-mrna-copy-number-of-sentinel-lymph-node-metastasis-in-breast-cancer-a-multicenter-s
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-use-of-ki67-testing-and-scoring-in-hr-her2-early-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/identification-of-a-low-risk-luminal-breast-cancer-cohort-that-may-not-benefit-from-multi-gene-testing
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-value-of-high-mesenchymal-epithelial-transition-factor-gene-met-expression-in-patients-with-estrogen-receptor-positive-er-human-ep
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-prognostic-significance-of-aldh-1-and-sox9-expression-in-early-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognosis-of-t1bn0-breast-cancer-according-to-subtype-korean-breast-cancer-registry-data
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/oncologists-agreement-on-adjuvant-therapy-recommendations-and-the-need-of-21-gene-recurrence-score-assay-in-hr-her2-early-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-oncotype-dx-on-agreement-and-confidence-in-adjuvant-treatment-decision-making-in-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/breast-cancer-risk-factors-in-iran-a-systematic-review-meta-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-prognostic-value-of-androgen-receptor-in-triple-negative-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-chemotherapy-for-early-stage-breast-cancer-on-quality-of-life-in-older-adults-results-from-2811-women-enrolled-in-the-bridging-the-age-g
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/therapeutic-drug-monitoring-of-tamoxifen-to-improve-adjuvant-treatment-of-hormone-sensitive-breast-cancer-the-totam-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-association-between-endocrine-therapy-use-and-osteoporotic-fracture-among-post-menopausal-women-treated-for-early-stage-breast-cancer-in-ontari
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/adjuvant-capecitabine-containing-chemotherapy-is-effective-in-both-brca1-like-and-non-brca1-like-early-stage-tnbc-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neoadjuvant-immunotherapy-plus-chemotherapy-in-early-triple-negative-breast-cancer-a-meta-analysis-of-randomized-controlled-trials
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neoadjuvant-chemotherapy-nact-use-and-response-in-us-patients-with-early-stage-triple-negative-breast-cancer-in-the-national-cancer-database-ncdb
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neoadjuvant-and-adjuvant-chemotherapy-nact-act-treatment-tx-patterns-in-a-real-world-cohort-of-us-pts-with-early-triple-negative-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparative-safety-of-epirubicin-and-cyclophosphamide-versus-docetaxel-and-cyclophosphamide-in-lymph-node-negative-hr-positive-her2-negative-brea
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patient-oncologist-preferences-for-adjuvant-cdk4-6i-therapy-in-hr-her2-early-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/relation-between-cyp2d6-polymorphisms-and-survival-in-breast-cancer-treated-with-tamoxifen
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/lipid-changes-during-endocrine-therapy-in-breast-cancer-patients-the-results-of-a-5-year-real-world-retrospective-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/70-gene-signature-to-select-breast-cancer-patients-for-neoadjuvant-endocrine-treatment
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/role-of-micrometastases-in-sentinel-lymph-node-biopsy-after-neoadjuvant-chemotherapy-in-breast-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparison-of-two-pathologic-response-evaluation-classification-after-neoadjuvant-chemotherapy-in-patients-with-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/metformin-with-neoadjuvant-chemotherapy-in-stage-ii-iii-breast-cancer-a-phase-ii-clinical-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/influence-of-green-tea-consumption-on-endoxifen-steady-state-concentration-in-breast-cancer-patients-treated-with-tamoxifen
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/significance-of-the-effects-of-chemotherapy-on-programmed-death-ligand-1-expression-in-triple-negative-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/10-year-real-world-outcomes-with-neoadjuvant-systemic-therapy-in-non-inflammatory-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/treatment-outcomes-in-early-breast-cancer-patients-undergoing-neoadjuvant-chemotherapy-in-a-multidisciplinary-setting.-an-analysis-of-273-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-of-autologous-fat-grafting-in-breast-cancer-a-multicenter-italian-study-among-17-senonetwork-breast-units
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/2d-echocardiography-strain-vs.-cardiac-mri-strain-using-deep-learning-a-prospective-cohort-study-in-her2-positive-breast-cancer-patients-undergoin
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/is-axillary-lymph-node-dissection-necessary-in-breast-cancer-patients-with-mastectomy-and-false-negative-frozen-section-in-sentinel-lymph-node-biopsy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-role-of-18f-fdg-pet-ct-with-specific-breast-protocol-as-a-prognostic-biomarker-of-invasive-breast-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/use-of-2d-strain-for-early-detection-of-myocardial-dysfunction-in-patients-receiving-epirubicin
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-chemotherapy-and-hormonotherapy-on-acute-skin-toxicity-of-hypofractionated-breast-cancer-radiotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/identifying-the-best-ki67-cut-off-for-determining-luminal-breast-cancer-subtypes-using-immunohistochemical-analysis-and-pam50-genomic-classification
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-impact-of-pregnancy-associated-breast-cancer-pabc-according-to-immunohistochemical-ihc-subtype-a-matched-case-control-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/heterogeneity-of-pd-l1-expression-at-the-protein-and-mrna-levels-in-early-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparison-of-gene-mutations-between-chinese-male-and-female-breast-cancer-patients-through-next-generation-sequencing
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/relationship-among-pdl1-androgen-receptor-ar-and-tumour-infiltrating-lymphocytes-tils-in-early-triple-negative-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/long-term-outcomes-of-patients-with-node-negative-3cm-her2-breast-cancer-bc-enrolled-in-altto
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/annotating-mammaprint-and-blueprint-gene-profile-to-the-hallmarks-of-cancer-and-understanding-the-biology-of-mammaprint-extreme-risk-groups
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/rates-of-cardiac-adverse-events-in-older-versus-younger-adults-receiving-trastuzumab-for-her2-positive-early-breast-cancer-results-from-931-patien
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-tolerability-of-subcutaneous-trastuzumab-h-sc-self-administered-at-home-via-single-use-injection-device-sid-in-patients-pts-with-h
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neoadjuvant-pyrotinib-plus-trastuzumab-docetaxel-and-carboplatin-in-patients-with-her2-positive-early-breast-cancer-a-single-group-multicenter
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ii-study-of-pyrotinib-plus-albumin-bound-paclitaxel-and-trastuzumab-as-neoadjuvant-treatment-in-her2-positive-early-or-locally-advanced-breas
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-bmi-on-outcome-and-cardiac-safety-in-her2-positive-breast-cancer-patients-treated-with-adjuvant-trastuzumab-results-of-a-monocentric-obs
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cardiotoxicity-in-her2-positive-breast-cancer-patients-treated-with-trastuzumab
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pathologic-response-to-neoadjuvant-antiher2-therapy-in-her2-equivocal-overexpression-with-fish-amplification
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/can-immunogloblun-steroid-treatment-protect-trastuzumab-cardiotoxicity-a-rabbit-model-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pathologic-response-to-neoadjuvant-therapy-in-her2-positive-oestrogen-receptor-positive-breast-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-of-fertility-treatments-in-breast-cancer-survivors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/voice-analysis-of-cancer-experiences-among-patients-with-breast-cancer-voice-bc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sexual-dysfunction-among-premenopausal-breast-cancer-survivors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/germline-mutations-in-index-patients-with-ductal-carcinoma-in-situ-dcis-a-single-center-retrospective-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/breast-cancer-and-perceived-discrimination-in-the-workplace-a-longitudinal-cohort-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/changes-in-eating-habits-and-food-preferences-in-breast-cancer-patients-undergoing-adjuvant-chemotherapy-the-change-prospective-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/breast-cancer-risk-in-patients-with-polycystic-ovary-syndrome-a-mendelian-randomization-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/beneficial-effects-of-exercise-in-oncology-movis-movement-and-health-beyond-care
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-clinical-characteristics-patients-perception-of-treatment-goals-and-endocrine-therapy-history-on-hrqol-in-hr-her2-early-stage-breast
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-multinational-real-world-study-on-hr-her2-early-stage-breast-cancer-patients-disease-awareness-satisfaction-and-involvement-in-treatment-de
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/germline-genetic-features-of-chinese-patients-with-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/reclassification-of-variants-of-unknown-significance-in-brca-1-2-genes-for-the-improvement-of-care-quality-in-oncological-genetic-council-units
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/uk-experience-of-the-management-of-pregnancy-associated-breast-cancer-a-national-retrospective-review-of-practice
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/breast-cancer-in-young-women-bcyw-real-world-data-to-fill-the-gap-and-find-the-needs
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/breast-cancer-in-young-women-bcyw-clinical-impact-of-diagnosis-in-asymptomatic-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-survey-of-breast-cancer-patients-attitudes-toward-the-breast-reconstruction-based-on-breast-implant-associated-anaplastic-large-cell-lymphoma-b
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/population-based-testing-for-hereditary-breast-and-ovarian-cancer-in-a-cohort-of-1-346-patients-from-southern-italy-sicily-when-historical-backg
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-randomized-double-blind-phase-iii-trial-of-neoadjuvant-chemotherapy-nact-with-atezolizumab-placebo-in-patients-pts-with-triple-negative-bre
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-prospective-phase-ii-matched-case-control-study-to-evaluate-the-frozen-glove-therapy-to-prevent-chemotherapy-induced-nail-pigmentation-in-patient
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/fdg-pet-ct-in-high-risk-primary-breast-cancer-a-prospective-study-of-stage-migration-and-clinical-impact
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/characteristics-and-overall-survival-of-an-advanced-breast-cancer-cohort-in-finland
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/survival-outcomes-of-brca-carriers-with-pregnancy-associated-breast-cancer-pabc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/preliminary-report-on-survival-outcomes-of-brca-mutation-carriers-with-triple-negative-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/different-patterns-of-distant-recurrence-depending-on-the-expression-of-hormone-receptor-in-breast-cancer-patients-with-pathological-complete-respo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/predictive-factors-of-distant-recurrence-disease-in-breast-cancer-patients-achieving-pathological-complete-response-to-neoadjuvant-chemotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/risk-of-cns-metastasis-after-neoadjuvant-chemotherapy-pathological-complete-response-may-not-be-enough
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/parity-and-molecular-breast-tumour-sub-types-a-study-conducted-in-libya
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/goserelin-for-ovarian-protection-in-premenopausal-breast-cancer-patients-receiving-cyclophosphamide-containing-chemotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-influence-of-diabetes-mellitus-and-diabetic-management-on-breast-cancer-outcomes-in-indigenous-women-of-western-australia
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-predictive-and-prognostic-values-of-neutrophil-lymphocyte-ratio-in-inflammatory-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-novel-dose-dense-alternating-regimen-of-docetaxel-cyclophosphamide-with-epirubicin-cisplatin-dddcep-as-neoadjuvant-chemotherapy-nact-for-high
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/breast-cancer-recurrence-prognostic-factors-and-the-relation-with-adherence-to-medical-standards
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/concurrent-radiation-therapy-rt-and-dual-her2-blockade-in-breast-cancer-assessment-of-toxicity
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neutrophil-to-lymphocyte-ratio-as-a-prognostic-factor-for-neoadjuvant-chemotherapy-for-locally-advanced-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/circulating-pik3ca-mutation-detection-at-diagnosis-in-non-metastatic-inflammatory-breast-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/association-of-metabolic-comorbidity-clustering-with-elevated-risks-of-progression-into-distant-metastasis-in-breast-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/frequency-of-mutant-alleles-based-on-intra-tumoural-genetic-heterogeneity-related-to-tumour-shrinkage-modes-after-nac-in-breast-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tackling-tgf-v-mediated-doxorubicin-chemoresistance-by-azd5069-in-triple-negative-breast-mammospheres
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-treatment-patterns-and-clinical-outcomes-associated-with-palbociclib-combination-therapy-in-five-european-countries-results-from-the-ir
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/apatinib-added-to-taxanes-and-platinum-neoadjuvant-chemotherapy-for-patients-with-triple-negative-and-her2-positive-breast-cancer-a-multicenter-r
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/mapk-pathway-inhibition-as-a-rational-therapeutic-strategy-for-mir-138-5p-paqr3-dysregulation-mediated-epirubicin-resistance-in-triple-negative-bre
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/dual-layer-spectral-detector-ct-clinical-performance-in-patients-with-locally-advanced-breast-cancer-treated-neoadjuvant-with-aromatase-inhibitors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/interest-of-a-multidisciplinary-approach-in-the-initiation-of-oral-therapies-in-metastatic-breast-cancer-mbc-experience-of-a-french-comprehensiv
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/interest-of-a-multidisciplinary-approach-in-the-initiation-of-oral-therapies-in-metastatic-breast-cancer-mbc-experience-of-a-french-comprehensiv
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/artificial-intelligence-analysis-of-advanced-breast-cancer-patients-from-a-phase-i-trial-of-trastuzumab-deruxtecan-t-dxd-her2-and-histopathology
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-safety-and-pharmacokinetics-of-a-proposed-trastuzumab-biosimilar-hlx02-compared-with-trastuzumab-in-metastatic-breast-cancer-a-global-ph
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/final-results-from-peruse-a-global-study-of-pertuzumab-p-trastuzumab-h-and-investigator-s-chosen-taxane-as-first-line-therapy-for-her2-positi
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/risk-factors-for-interstitial-lung-disease-in-patients-treated-with-trastuzumab-deruxtecan-from-two-interventional-studies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/from-the-cleopatra-study-to-real-life-final-results-from-the-g.o.n.o.-super-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/trastuzumab-emtansine-in-her2-positive-metastatic-breast-cancer-after-pertuzumab-and-trastuzumab-tdm1rm-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/evaluation-of-the-cardioprotective-effects-of-l-carnitine-and-silymarin-in-cancer-patients-receiving-anthracycline-containing-chemotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-tucatinib-on-progression-free-survival-in-patients-with-her2-metastatic-breast-cancer-and-stable-or-active-brain-metastases
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pyrotinib-and-capecitabine-for-her2-positive-metastatic-breast-cancer-patients-with-previously-untreated-brain-metastases-a-single-group-multicent
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/physiologically-based-pharmacokinetic-pbpk-modeling-of-the-central-nervous-system-cns-pharmacokinetics-of-tucatinib-in-patients-with-breast-can
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tumour-mutational-burden-and-clinical-outcomes-with-first-line-atezolizumab-and-nab-paclitaxel-in-triple-negative-breast-cancer-exploratory-analys
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sp142-immunohistochemistry-ihc-pd-l1-inter-and-intra-pathologist-agreement-in-triple-negative-breast-carcinoma-tnbc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/differences-in-the-mutational-profile-between-primary-breast-carcinomas-and-their-cutaneous-metastasis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/micrornas-related-to-immune-response-as-markers-in-the-prognosis-of-metastatic-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/association-between-the-neutrophil-to-lymphocyte-and-platelet-to-lymphocyte-ratios-and-efficacy-of-cdk-4-6-inhibitors-in-advanced-breast-cancer-th
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sodium-glucose-cotransporter-2-sglt-2-inhibitors-for-alpelisib-alp-induced-hyperglycemia-a-report-of-6-cases-from-solar-1
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/utility-of-lymphocyte-monocyte-ratio-lmr-for-predicting-progression-free-survival-pfs-in-patients-with-hr-her2-metastatic-breast-cancer-mbc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/use-of-ca-15.3-for-the-detection-of-secondary-metastatic-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/esr1-mutations-and-outcomes-in-brca1-2-or-palb2-germline-mutation-carriers-receiving-first-line-aromatase-inhibitor-palbociclib-ai-p-for-metast
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patterns-of-acquired-mutations-in-estrogen-receptor-positive-metastatic-breast-cancer-mbc-patients-identified-by-comprehensive-genomic-profiling
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-life-management-and-prognosis-of-young-women-40-yo-with-de-novo-metastatic-breast-cancer-in-the-multicenter-national-observational-esme-pr
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-evidence-of-cdk4-6-inhibitor-combination-effects-on-assessing-outcome-with-different-sequence-of-treatment-among-adult-patients-with-hr
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-outcomes-among-her2-metastatic-breast-cancer-patients-with-brain-metastases
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-effectiveness-of-alpelisib-alp-fulvestrant-ful-compared-with-standard-treatment-among-patients-pts-with-hormone-receptor-positiv
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/overall-survival-with-cyclin-dependent-kinase-4-6-inhibitors-plus-endocrine-therapy-in-breast-cancer-a-meta-analysis-of-randomized-controlled-trials
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pooled-analysis-of-prospective-observational-studies-evaluated-the-effectiveness-and-safety-of-bevacizumab-and-paclitaxel-as-the-first-line-chemoth
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-rw-multi-country-study-of-brca1-2-mutation-brca1-2mut-testing-trends-among-adult-patients-pts-with-her2-advanced-breast-cancer-abc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-multi-country-study-of-treatment-trends-among-patients-pts-with-her2-brca1-2-mutated-brca1-2mut-advanced-breast-cancer-abc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-rw-multi-country-study-of-brca1-2-testing-in-adult-patients-pts-with-her2-advanced-breast-cancer-abc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/trends-in-breast-cancer-mortality-between-2001-and-2017-an-observational-study-in-eu-and-uk
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-treatment-patterns-and-clinical-effectiveness-outcomes-of-eribulin-in-metastatic-breast-cancer-patients-in-community-oncology-centers-in
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/updated-results-from-the-canadian-sub-population-of-the-phase-iiib-compleement-1-ribociclib-letrozole-hr-her2-advanced-breast-cancer-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-real-world-hellenic-disease-management-patterns-with-everolimus-eve-for-women-with-hormone-receptor-positive-hr-human-epidermal-growth-fa
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognosis-for-patients-with-oligometastatic-breast-cancer-who-achieve-ned-status-after-systemic-and-local-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/oligometastatic-breast-cancer-incidence-and-clinical-presentation-at-diagnosis-about-131-cases
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/first-line-treatment-patterns-in-hr-her2-locally-advanced-or-metastatic-breast-cancer-in-europe
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-factors-for-overall-survival-os-in-patients-with-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-advanced
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-retrospective-study-of-evaluating-the-status-and-security-of-re-biopsy-in-advanced-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/what-affects-the-choice-of-first-line-treatment-for-hormone-receptor-positive-her2-negative-advanced-breast-cancer-data-from-the-german-research
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/characteristics-of-patients-with-her2-negative-advanced-metastatic-gbrca-associated-breast-cancer-who-achieved-durable-response-in-the-phase-iii-br
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exploratory-analysis-of-treater-ight-a-canadian-prospective-real-world-observational-study-in-hr-advanced-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/treatment-sequencing-in-hr-her2-locally-advanced-or-metastatic-breast-cancer-a-real-world-retrospective-study-in-france-germany-italy-and-spain
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patient-reported-outcomes-of-a-switch-to-maintenance-endocrine-therapy-following-induction-chemotherapy-versus-continuation-of-chemotherapy-in-er-p
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ribociclib-rib-in-patients-pts-with-hr-her2-advanced-breast-cancer-abc-and-resistance-to-prior-endocrine-therapy-et-in-the-monaleesa-ml
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-ribociclib-rib-dose-reduction-on-overall-survival-os-in-patients-pts-with-hr-her2-advanced-breast-cancer-abc-in-monaleesa-ml
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparative-effectiveness-of-ribociclib-plus-fulvestrant-rib-ful-versus-palbociclib-plus-letrozole-pal-let-as-first-line-1l-treatment-tx-of
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/treatment-emergent-te-neutropenia-and-related-hospitalizations-and-medication-discontinuations-in-patients-pts-with-metastatic-breast-cancer-m
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ribociclib-rib-letrozole-let-in-subgroups-of-special-clinical-interest-with-hormone-receptor-positive-hr-human-epidermal-growth-factor-re
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/lerociclib-g1t38-a-continuously-dosed-oral-cdk4-6-inhibitor-with-fulvestrant-in-hr-her2-advanced-breast-cancer-patients-updated-phase-ii-res
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/resistance-to-cdk4-6-inhibitors-clinical-practice-use-of-liquid-biopsy-to-identify-kras-mutations-in-ctdna-and-overexpression-of-cdk9-in-plasma-de
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pi3k-pathway-biomarkers-and-clinical-response-in-a-phase-i-ib-study-of-gdc-0077-in-hormone-receptor-positive-her2-negative-breast-cancer-hr-her2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-of-everolimus-plus-exemestane-in-cdk-4-6-inhibitors-pretreated-or-naive-hr-positive-her2-negative-breast-cancer-patients-a-secondary-anal
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/defining-pathway-a-novel-analysis-of-geriatric-indigenous-women-with-breast-cancer-impacting-survival-and-outcomes
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-blood-glucose-levels-on-the-efficacy-of-everolimus-exemestane-in-patients-with-advanced-hr-positive-her2-negative-breast-cancer-the-ever
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patient-preferences-for-her2-targeted-treatment-of-advanced-or-metastatic-breast-cancer-in-the-united-states
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/does-race-impact-outcomes-in-triple-negative-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/different-modalities-of-detection-breast-cancer-recurrences-a-5-year-retrospective-cohort-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/metronomic-oral-vinorelbine-mov-combined-with-tremelimumab-t-durvalumab-d-efficacy-and-safety-preliminary-results-of-the-advanced-breast-c
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-outcomes-of-platinum-based-polichemotherapy-in-patients-with-advanced-breast-cancer-a-10-year-single-institutional-experience
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/optimal-dose-of-eribulin-as-first-line-treatment-in-elderly-patients-70-years-with-advanced-breast-cancer-a-multicenter-phase-ii-trial-sakk-25-14
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-of-the-phase-ib-dose-escalation-study-of-men1611-a-pi3k-inhibitor-combined-with-trastuzumab-t-fulvestrant-f-for-her2-pik3ca-mutant
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-i-study-of-the-liposomal-formulation-of-eribulin-e7389-lf-results-from-the-her2-negative-breast-cancer-expansion
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/first-findings-from-synergy-a-phase-i-ii-trial-testing-the-addition-of-the-anti-cd73-oleclumab-o-to-the-anti-pd-l1-durvalumab-d-and-chemothera
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/epik-b3-a-phase-iii-randomised-double-blind-db-placebo-pbo-controlled-study-of-alpelisib-alp-nab-paclitaxel-nab-ptx-in-advanced-tripl
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-iii-trial-of-capivasertib-and-fulvestrant-versus-placebo-and-fulvestrant-in-patients-with-hr-her2-breast-cancer-capitello-291
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/solti-1507-a-phase-ib-study-of-ipatasertib-and-anti-her2-therapy-in-her2-positive-advanced-breast-cancer-with-pik3ca-mutation-ipather
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/epik-b2-a-phase-iii-study-of-alpelisib-alp-as-maintenance-therapy-with-trastuzumab-t-and-pertuzumab-p-in-patients-pts-with-pik3ca-mutated
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/her2climb-02-a-randomized-double-blind-phase-iii-study-of-tucatinib-or-placebo-with-t-dm1-for-unresectable-locally-advanced-or-metastatic-her2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/unraveling-trastuzumab-emtansine-resistance-in-her2-positive-advanced-breast-cancer-geicam-katia-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ii-iii-open-label-randomized-trial-of-pembrolizumab-olaparib-vs.-pembrolizumab-chemotherapy-after-induction-with-pembrolizumab-chem
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-iii-study-of-gdc-0077-or-placebo-pbo-with-palbociclib-p-fulvestrant-f-in-patients-pts-with-pik3ca-mutant-hormone-receptor-positive
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sgnlva-002-single-arm-open-label-phase-ib-ii-study-of-ladiratuzumab-vedotin-lv-in-combination-with-pembrolizumab-for-first-line-treatment-of-t
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ib-ii-study-of-antibody-drug-conjugate-sacituzumab-govitecan-in-combination-with-the-parp-inhibitor-talazoparib-in-metastatic-triple-nega
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/international-phase-iii-trial-balixafortide-a-cxcr4-antagonist-eribulin-versus-eribulin-alone-in-patients-with-her2-negative-locally-recurren
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/temozolamide-tmz-rechallenge-at-standard-or-metronomic-dose-versus-other-treatments-in-patients-pts-with-high-grade-glioma-with-tmz-free-interv
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/chemotherapy-options-for-recurrent-glioblastoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-efficacy-and-safety-of-cyberknife-combined-with-bevacizumab-and-temozolomide-in-the-treatment-of-recurrent-high-grade-glioma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/long-term-survival-following-photodynamic-therapy-for-malignant-glioma-depending-on-mgmt-status
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/mgmt-status-influences-prognosis-of-patients-with-idh-wild-type-grade-iii-gliomas
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-mgmt-and-abcb1-single-nucleotide-polymorphisms-on-temozolomide-induced-thrombocytopenia-in-newly-diagnosed-glioblastoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ten-year-experience-of-the-vall-d-hebron-institute-of-oncology-early-drug-development-unit-vhio-uitm-treating-patients-pts-with-primary-cns-tum
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/adult-brainstem-gliomas-clinicopathological-profile-and-outcomes-of-a-single-center-10-year-cohort
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-potential-utility-of-end-binding-protein-1-eb1-as-response-predictive-biomarker-for-lisavanbulin-final-results-from-a-phase-i-study-of-lisav
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-mass-spectrometry-based-assay-for-molecular-profiling-of-gliomas-and-its-validation-on-real-world-clinical-samples
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immunotherapy-with-autologous-dendritic-cells-as-part-of-the-complex-treatment-of-patients-with-malignant-gliomas
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/molecular-profiling-and-molecular-features-of-progression-in-chinese-glioma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/oncogenic-fusions-in-cns-gliomas-assessed-by-next-generation-sequencing-the-real-world-experience
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/detection-of-1p-19q-deletion-in-gliomas-with-high-accuracy-by-combining-sequencing-depth-and-heterozygous-snv-allele-frequency
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/preclinical-study-of-anthraquinone-derived-small-molecule-compound-in-inhibiting-brain-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/investigation-of-osimertinib-sensitive-egfr-mutations-in-brain-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/spiritual-well-being-in-brain-tumour-patients-an-insight
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cognitive-impairment-in-primary-brain-tumour-patients-receiving-systemic-therapy-a-cross-sectional-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/incidence-mortality-and-survival-trends-of-central-nervous-system-tumours-in-cali-colombia-from-1962-to-2019-a-population-based-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/financial-toxicity-in-patients-undergoing-systemic-therapy-in-brain-tumours-a-cross-sectional-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/reversing-the-trend-of-friday-peak-for-metastatic-spinal-cord-compression-referrals
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/long-term-effect-of-peripheral-sensory-neuropathy-psn-of-3-or-6-months-oxaliplatin-based-adjuvant-chemotherapy-for-high-risk-stage-ii-colon-cance
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-single-arm-prospective-open-label-study-of-injected-temozolomide-plus-hypofractionated-radiation-therapy-for-metastatic-brain-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-prospective-controlled-trial-of-the-efficacy-of-uracil-and-tegafur-leucovorin-for-stage-ii-colon-cancer-with-risk-factors-for-recurrence-using-pr
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/causes-of-mortality-in-elderly-uicc-stage-iii-colon-cancer-cc-patients-pts.-tumor-related-death-and-competing-risks-from-the-colopredict-plus
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/extent-of-lymph-node-ln-resection-and-tumour-sidedness-in-operable-colon-cancer-cc-stage-and-survival
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-randomized-open-label-parallel-design-phase-iii-study-to-compare-adjuvant-5-fu-plus-oxaliplatin-mflox-versus-observation-in-locally-advanced
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/six-year-updated-results-of-japan-clinical-oncology-group-study-jcog0910-randomized-phase-iii-study-of-adjuvant-chemotherapy-with-s-1-versus-cap
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/risk-factors-for-recurrence-in-patients-with-high-risk-stage-ii-colon-cancer-after-curative-resection
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/identification-of-a-stemness-related-gene-signature-for-predicting-prognosis-of-patients-with-adjuvant-chemotherapy-in-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-effect-of-postoperative-serum-carcinoembryonic-antigen-cea-combined-with-t4-versus-t3-tumors-in-patients-with-high-risk-stage-2-colon
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-novel-prognostic-tool-based-on-lymphocyte-ratios-in-patients-with-stage-iii-colon-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/lymph-node-ln-retrieval-as-a-high-risk-factor-in-stage-ii-and-iii-colon-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/analysis-of-the-efficacy-of-cytokine-induced-killer-cell-therapy-in-adjuvant-treatment-of-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/minimal-residual-disease-mrd-detection-in-colorectal-cancer-crc-using-a-plasma-only-integrated-genomic-and-epigenomic-circulating-tumor-dna-ct
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/minimal-residual-disease-detection-and-tracking-tumour-evolution-using-ctdna-in-stage-i-iii-colorectal-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/upfront-chemotherapy-vs.-surgery-for-very-low-lying-locally-advanced-rectal-cancer-without-preoperative-chemoradiation-the-nair-phase-ii-iii-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/age-and-pathological-complete-response-after-neoadjuvant-chemoradiation-crt-with-or-without-oxaliplatin-in-locally-advanced-rectal-cancer-larc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/gut-microbiome-predicts-a-response-after-preoperative-chemoradiation-in-rectal-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/could-total-neoadjuvant-therapy-tnt-become-a-new-standard-in-locally-advanced-rectal-cancer-larc-a-systematic-review-and-meta-analysis-ma-of
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/statins-increase-pathological-response-in-locally-advanced-rectal-cancer-larc-treated-with-chemo-radiation-crt-a-multicentric-experience
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-preoperative-chemoradiotherapy-on-tumor-infiltrating-lymphocytes-in-locally-advanced-rectal-cancer-the-smart-star-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/value-of-magnetic-resonance-diffusion-weighted-imaging-in-the-identification-of-complete-responder-patients-with-rectal-cancer-treated-with-neoadju
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/association-between-three-dimensional-transrectal-ultrasound-findings-and-tumor-response-in-locally-advanced-rectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/feasibility-and-toxicity-of-hypofractionated-radiotherapy-5x5-gy-with-a-simultaneous-integrated-boost-5x6-gy-in-locally-advanced-rectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/serial-ctdna-circulating-tumour-dna-for-detection-of-genomic-changes-during-neoadjuvant-chemoradiotherapy-nacrt-in-locally-advanced-rectal-canc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-randomized-phase-iii-trial-comparing-primary-tumor-resection-plus-chemotherapy-with-chemotherapy-alone-in-incurable-stage-iv-colorectal-cancer-u
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/toxicity-and-efficacy-of-1st-line-cetuximab-cetux-based-therapy-in-ras-wildtype-wt-older-patients-pts-with-metastatic-colorectal-cancer-mcrc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ib-ii-clinical-trial-of-tolerability-safety-and-efficacy-of-regorafenib-in-combination-with-toripalimab-a-pd-1-antibody-in-patients-with
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-molecular-markers-status-on-treatment-effects-comparing-egfr-and-vegf-monoclonal-antibodies-mabs-in-untreated-metastatic-colorectal-can
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/bevacizumab-bev-continuation-with-folfiri-or-switch-to-aflibercept-afli-with-folfiri-as-second-line-treatment-l2-after-first-line-of-folfox-b
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ib-ii-study-of-the-polo-like-kinase-1-plk1-inhibitor-onvansertib-in-combination-with-folfiri-and-bevacizumab-for-second-line-treatment-of
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/designing-clinical-profiles-that-influence-the-discordance-of-ras-mutations-in-blood-and-tissue-sidedness-and-anatomical-metastasis-as-factors-of
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/interim-safety-analysis-of-the-phase-iib-study-of-ramucirumab-in-combination-with-tas102-vs.-tas102-monotherapy-in-metastatic-colorectal-cancer-th
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ib-ii-study-of-ibrutinib-ibr-in-combination-with-cetuximab-cetux-in-patients-pts-with-previously-treated-metastatic-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-iii-randomized-trial-comparing-short-term-infusion-of-oxaliplatin-and-capecitabine-xelox30-with-chronomodulated-xelox30-in-patients-with
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/evaluation-of-conversion-therapy-in-patients-undergoing-secondary-resection-of-metastases-in-curative-intent-within-the-fire-3-aio-krk-0306-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/camrelizumab-combined-with-apatinib-in-the-treatment-of-patients-with-advanced-gastric-cancer-and-colorectal-cancer-one-arm-exploratory-clinical-t
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/first-line-chemotherapy-with-raltitrexed-in-metastatic-colorectal-cancer-an-ageo-multicentre-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prodige-25-ffcd-11-01-folfa-a-randomized-phase-ii-trial-evaluating-aflibercept-associated-with-lv5fu2-regimen-as-first-line-treatment-of-non-res
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-evidence-rwe-on-the-clinical-outcomes-in-1st-line-chemotherapy-ct-for-fit-and-vulnerable-patients-pts-with-metastatic-colorectal-c
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-data-rwd-survival-analysis-of-first-line-1l-metastatic-colorectal-cancer-mcrc-patients-pts-with-braf-v600-and-non-v600-kras-g12
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/long-term-survival-with-regorafenib-reality-real-life-in-italy-trial-a-giscad-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/predictive-factor-of-cardiotoxicity-in-fluoropyrimidine-treated-colorectal-cancer-patients-interim-analysis-of-the-prospective-observational-check
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/randomized-phase-ii-study-comparing-pathological-responses-of-resected-colorectal-cancer-metastases-crcm-after-bevacizumab-bev-with-folfox-or-f
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-impact-of-late-line-treatment-on-overall-survival-os-from-the-initiation-of-first-line-chemotherapy-ct-for-patients-pts-with-metastatic-c
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/novel-somatic-genetic-variants-as-predictors-of-resistance-to-egfr-targeted-therapies-in-metastatic-colorectal-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ib-dose-escalation-study-of-binimetinib-plus-mfolfiri-in-patients-with-metastatic-ras-mutated-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/quality-of-life-and-survival-of-metastatic-colorectal-cancer-patients-treated-with-trifluridine-tipiracil-qualitas
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparative-study-of-metronomic-capecitabine-and-oxaliplatin-versus-classic-xelox-in-egyptian-patients-with-metastatic-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-meta-analysis-of-efficacy-and-safety-of-cetuximab-with-biweekly-vs.-weekly-dosing
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tumor-response-to-irinotecan-is-associated-with-il-10-expression-level-in-metastatic-colorectal-cancer-results-from-mcrc-biomarker-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/1st-line-panitumumab-plus-folfiri-or-folfox-for-patients-with-ras-wildtype-metastatic-colorectal-cancer-in-germany-interim-results-of-the-non-inte
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ph-i-ib-trial-of-fruquintinib-fru-in-patients-pts-with-advanced-solid-tumors-preliminary-results-of-the-dose-expansion-exp-cohort-in
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/effect-of-ras-amplification-rasa-on-outcomes-to-egfr-monoclonal-antibody-therapy-egfrmab-in-metastatic-colorectal-cancer-mcrc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/update-analysis-of-phase-ii-study-of-oxaliplatin-based-regimen-in-relapsed-colorectal-cancer-patients-treated-with-oxaliplatin-based-adjuvant-chemo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-time-pcr-based-assessment-of-ras-braf-mutations-in-the-plasma-of-metastatic-colorectal-cancer-mcrc-patients-a-single-institution-experience
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/treatment-trends-and-clinical-outcomes-of-left-sided-ras-raf-wild-type-metastatic-colorectal-cancer-in-the-united-states
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-prognostic-role-of-tumour-inflammation-markers-in-patients-pts-with-colorectal-cancer-crc-treated-with-trifluridine-tipiuracil-hydrochlorid
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pharmacokinetic-analysis-of-nuc-3373-with-and-without-leucovorin-in-patients-with-previously-treated-metastatic-colorectal-cancer-nutide-302-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/single-nucleotide-polymorphism-snp-analysis-identifies-potential-prognostic-and-predictive-biomarker-in-patients-pts-with-metastatic-colorectal
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/folfoxiri-versus-folfox-or-folfiri-with-targeted-therapy-in-patients-with-mutant-braf-metastatic-colorectal-cancer-a-systematic-review-and-meta-an
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/panib-20139173-randomized-multicentre-phase-ii-trial-comparing-fluorouracil-leucovorin-and-oxaliplatin-folfox-plus-panitumumab-versus-folfox-p
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-and-safety-of-anlotinib-combined-with-capeox-in-first-line-treatment-of-patients-with-ras-and-braf-wild-type-unresectable-metastatic-color
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/anti-tumor-mechanisms-of-rigosertib-in-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/identification-and-validation-of-a-new-prognostic-score-in-metastatic-colorectal-cancer-mcrc-gemcad-score
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/whole-genome-sequencing-of-metastatic-crc-reveals-footprints-from-the-past-and-present-with-future-clinical-relevance
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/plk1-expression-and-kras-mutations-in-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-and-predictive-role-of-consensus-molecular-subtypes-cms-determined-by-immunohistochemistry-in-metastatic-colorectal-cancer-mcrc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/diffusion-kurtosis-imaging-signature-in-predicting-the-chemotherapeutic-response-of-colorectal-liver-metastases-the-result-of-the-fdzl-mrinclm-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/mutational-profiling-allows-the-stratification-of-metastatic-colorectal-cancer-patients-with-poor-prognosis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genomically-matched-therapy-in-refractory-crc-according-to-escat
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ras-mutation-clearance-in-patients-with-metastatic-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-chromatin-region-ocr-based-model-predicts-advanced-adenoma-in-plasma-cell-free-dna-whole-genome-bisulfite-sequencing-data
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comprehensive-genomic-and-clinical-analysis-of-adolescents-and-young-adults-with-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/different-gene-mutation-of-colorectal-cancer-was-tightly-associated-with-various-types-of-tumor-immune-microenvironment
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/identification-of-proteome-and-secretome-signatures-in-primary-colorectal-cancer-associated-fibroblasts
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-autophagy-depended-pxr-regulation-in-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/practices-and-expectations-on-the-use-of-circulating-tumor-dna-in-colorectal-cancer-patients-a-bi-national-ageo-aiom-gercor-ffcd-french-survey
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/link-between-podxl-and-the-egfr-axis-in-metastatic-colorectal-cancer-and-in-vitro-implications-for-improved-treatment-stratification
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genetic-polymorphism-profile-associated-with-cetuximab-efficiency-in-colorectal-cancer-patients-from-kazakhstan
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/use-of-patient-derived-tumour-organoids-to-identify-acquired-treatment-resistance-and-determine-optimal-post-progression-combinations-in-metastatic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patient-derived-organoids-as-a-tool-for-modelling-localized-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/somatic-mosaic-model-of-colorectal-cancer-for-translational-immune-cancer-research
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/metastatic-colorectal-cancer-derived-organoids-recapitulate-genomic-profile-and-treatment-response-of-the-original-tumor
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neoadjuvant-nivolumab-in-early-stage-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-multicenter-large-retrospective-database-on-the-personalization-of-stereotactic-ablative-radiotherapy-for-lung-metastases-from-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pembrolizumab-pembro-plus-mfolfox7-or-folfiri-in-patients-pts-with-metastatic-colorectal-cancer-mcrc-updated-results-from-keynote-651-cohort
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/lack-of-liver-metastases-identifies-a-group-of-mss-metastatic-colorectal-cancer-with-potential-benefit-from-pd-1-pd-l1-targeting
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/factors-associated-with-colorectal-cancer-in-patients-18-to-50-years-old-in-the-united-states
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/investigating-the-potential-relationship-between-kmt2c-kmt2d-mutations-and-immune-checkpoint-inhibitor-ici-in-colorectal-cancer-crc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/differences-in-tumor-immune-microenvironment-and-clinical-outcomes-between-right-and-left-colon-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/heterogeneity-in-the-immune-inflamed-biomarkers-of-mss-and-msi-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/local-lymphatic-reaction-in-colorectal-cancer-the-relationship-to-patient-survival-systemic-inflammatory-markers-msi-and-kras-mutations-to-tumour
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/spatial-immunology-in-colorectal-liver-metastases
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nivolumab-alone-or-with-ipilimumab-for-mismatch-repair-deficient-metastatic-colorectal-cancer-a-united-kingdom-multicentre-analysis-of-patient-o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-screening-and-consensus-based-on-practices-and-evidence-scope-survey-treatment-goals-and-practice-patterns-in-third-and-fourth-line-metasta
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/primary-tumour-location-impacts-oncological-outcome-of-patients-with-resected-colorectal-liver-metastases
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prediction-of-mortality-in-metastatic-colorectal-cancer-in-a-real-life-population-based-on-treatment-modality-and-accompanying-clinical-parameters
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/relation-of-metastasis-localization-survival-outcome-and-treatment-modality-in-metastatic-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/central-nervous-system-recurrence-in-her2-positive-metastatic-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/evaluating-colorectal-cancer-treatment-patterns-by-stage-in-european-cancer-registries
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-different-epidemiological-trend-in-brazilian-early-onset-colorectal-cancer-eocrc-real-world-data-from-a-reference-cancer-center
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/young-adult-colorectal-cancer-in-southwestern-ireland-2015-2019
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-survival-outcomes-of-asian-metastatic-colorectal-cancer-patients-undergoing-hepatectomy-from-the-asianmcrcregistry
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/external-validity-of-the-arcad-nomogram-in-a-real-life-population-of-older-patients-with-unresectable-advanced-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prospective-evaluation-of-the-g8-screening-tool-for-predicting-survival-in-elderly-patients-with-colon-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/updated-analysis-of-outcomes-of-elderly-patients-with-resectable-liver-metastases-from-colorectal-cancer-crlm-single-center-experience
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/modeling-the-long-term-effectiveness-of-colonoscopy-screening-by-a-discrete-event-simulation-model-calibrated-with-german-screening-registry-data
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/outcomes-of-patients-with-metastatic-anal-cancer-according-to-hiv-infection-a-multicenter-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/early-stage-squamous-cell-carcinoma-of-the-anal-canal-results-of-curative-intent-therapy-in-a-multicenter-retrospective-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/treatment-outcome-and-prognostic-factors-after-chemoradiotherapy-for-anal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patterns-of-care-and-outcomes-in-carcinoma-of-unknown-primary-a-seer-medicare-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-multicenter-study-to-evaluate-the-impact-of-circulating-tumor-dna-guided-therapy-bespoke-in-patients-with-stage-ii-and-iii-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/circulating-tumor-dna-guided-adjuvant-chemotherapy-in-stage-ii-colon-cancer-according-the-trials-within-cohorts-design-the-medocc-create-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prodige-71-bevamaint-a-randomized-phase-iii-study-comparing-maintenance-treatment-with-fluoropyrimidine-bevacizumab-versus-fluoropyrimidine-af
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/mountaineer-open-label-phase-ii-study-of-tucatinib-combined-with-trastuzumab-for-her2-positive-metastatic-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/vemurafenib-in-non-melanoma-v600-and-non-v600-braf-mutated-cancers-results-of-the-acse-basket-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patient-reported-outcomes-pros-from-patients-pts-with-ntrk-fusion-positive-ntrk-fp-solid-tumours-receiving-entrectinib-in-the-global-phase-ii
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/entrectinib-in-patients-with-italic-ros1-italic-fusion-positive-non-small-cell-lung-cancer-nsclc-or-italic-ntrk-italic-fusion-positive-soli
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/derazantinib-dzb-an-oral-fibroblast-growth-factor-receptor-inhibitor-fgfri-shows-promising-activity-in-pdx-tumour-models-with-aberrations-in
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/growth-modulation-index-gmi-of-larotrectinib-versus-prior-systemic-treatments-for-trk-fusion-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/entrectinib-in-ntrk-fusion-positive-nsclc-updated-integrated-analysis-of-startrk-2-startrk-1-and-alka-372-001
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-i-study-of-the-irreversible-fgfr-inhibitor-i-futibatinib-fbn-tas-120-in-japanese-patients-pts-with-advanced-adv-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/preclinical-profile-of-epi-7386-a-second-generation-n-terminal-domain-androgen-receptor-inhibitor-for-the-treatment-of-prostate-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/innovative-medicine-in-rare-cancer-perceived-value-of-adaptive-trials-and-surrogate-endpoints-for-clinical-decisions
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/rucaparib-sacituzumab-govitecan-sg-initial-data-from-the-phase-ib-ii-seastar-study-nct03992131
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/molecular-pre-screening-using-comprehensive-gene-panels-offered-by-clinical-trials-ct
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/identification-of-ret-rearrangement-in-12888-chinese-lung-cancer-patients-by-next-generation-sequencing-ngs
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/preclinical-characterization-of-cpl304110-as-a-potential-selective-inhibitor-of-fibroblast-growth-factors-1-2-3-in-solid-cancers
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-i-study-of-lurbinectedin-in-japanese-patients-with-pretreated-advanced-tumours-final-results
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-efficacy-of-long-term-exposure-lte-to-tislelizumab-in-chinese-patients-with-advanced-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/activity-of-trastuzumab-and-pertuzumab-hp-in-patients-with-non-breast-gastroesophgeal-her2-amplified-tumours-results-of-the-nci-match-trial-eay
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/selinexor-in-combination-with-carboplatin-and-paclitaxel-in-patients-with-advanced-or-metastatic-solid-tumours-results-of-an-open-label-single-ce
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/metronomic-oral-vinorelbine-mov-combined-with-tremelimumab-t-durvalumab-d-in-advanced-solid-tumours-ast-dose-finding-results
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/initial-clinical-experience-of-lucitanib-nivolumab-in-advanced-metastatic-solid-tumours-data-from-the-phase-ib-ii-lio-1-study-co-3810-101-nct0
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/binimetinib-pemetrexed-pem-and-cisplatin-cis-followed-by-maintenance-of-binimetinib-and-pem-in-patients-with-advanced-non-small-cell-lung-can
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-i-study-of-rebastinib-and-carboplatin-in-patients-with-metastatic-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ib-study-of-cc-90011-plus-etoposide-and-cisplatin-ep-in-patients-with-first-line-extensive-stage-es-small-cell-lung-cancer-sclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-efficacy-of-debio-1143-an-antagonist-of-inhibitor-of-apoptosis-proteins-iaps-in-combination-with-nivolumab-in-a-phase-ib-ii-trial-in
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ib-study-of-ribociclib-r-trametinib-t-in-patients-pts-with-metastatic-advanced-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/target-engagement-and-clinical-safety-of-cb-103-a-first-in-class-small-molecule-inhibitor-of-the-notch-transcription-complex
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/first-in-class-cd13-targeted-tissue-factor-ttf-ngr-in-patients-with-recurrent-or-refractory-malignant-tumours-safety-and-pharmacokinetic-results-o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/updated-results-of-a-phase-i-study-of-felezonexor-sl-801-a-novel-xpo-1-reversible-inhibitor-in-patients-with-relapsed-refractory-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/selinexor-in-combination-with-topotecan-in-patients-with-advanced-or-metastatic-solid-tumours-results-of-an-open-label-single-center-multi-arm-p
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-multicenter-open-label-dose-escalation-first-in-man-study-of-metap2-inhibitor-m8891-in-patients-with-advanced-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exposure-response-analyses-of-dabrafenib-and-trametinib-in-melanoma-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-i-dose-escalation-study-of-the-dual-pi3k-mtorc1-2-inhibitor-gedatolisib-pf-05212384-in-combination-with-paclitaxel-p-and-carboplatin-c
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/intratumoral-injection-of-allogeneic-pro-inflammatory-dendritic-cells-ilixadencel-in-combination-with-anti-ctla-4-treatment-induce-complete-tumou
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-first-in-human-phase-i-study-of-the-axl-inhibitor-ds-1205c-in-combination-with-gefitinib-in-subjects-with-egfr-mutant-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/preclinical-evaluation-of-fap-2286-a-peptide-targeted-radionuclide-therapy-ptrt-to-fibroblast-activation-protein-alpha-fap
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/limited-efficacy-of-immunotherapy-combination-regimens-in-patients-with-unselected-cold-tumours-enrolled-in-early-clinical-trials
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-of-immunotherapy-it-after-prior-immune-checkpoint-inhibitors-icis-exposure
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tld-1-a-novel-liposomal-doxorubicin-in-patients-pts-with-advanced-solid-tumours-dose-escalation-part-of-a-multicenter-open-label-phase-i-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/updated-results-of-phase-i-study-of-senaparib-imp4297-in-australian-patients-with-advanced-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-synergistic-anticancer-effect-of-plag-on-the-pd-1-immune-checkpoint-inhibitor-in-the-llc-1-murine-lung-carcinoma-syngeneic-model
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/updated-analysis-of-phase-i-dose-escalation-and-dose-cohort-expansion-studies-of-senaparib-imp4297-in-chinese-patients-with-advanced-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/interim-analysis-of-a-phase-ii-study-of-shr-1210-combined-with-neoadjuvant-chemoradiation-in-patients-with-locally-advanced-proximal-stomach-adenoc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/morab-109-a-site-specific-eribulin-conjugated-adc-targeting-human-mesothelin
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/at1412-a-patient-derived-cd9-antibody-promotes-tumour-immune-infiltration-and-induces-tumour-rejection
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/vhio-immune-gene-expression-profiling-vigex-panel-a-tool-to-explore-tumour-immune-microenvironment
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/preclinical-development-of-at1412-a-patient-derived-cd9-antibody-that-does-not-induce-thrombosis-for-treatment-of-precursor-b-all
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/effect-of-infusion-rate-premedication-and-prophylactic-peg-filgrastim-treatment-on-the-safety-of-the-liposomal-formulation-of-eribulin-e7389-lf
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tepotinib-exposure-response-analyses-of-safety-and-efficacy-in-patients-with-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/trends-in-patient-reported-outcome-pro-use-in-early-phase-oncology-trials
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/bidirectional-chemotherapy-for-initially-unresectable-malignant-peritoneal-mesothelioma-proof-of-concept-of-a-new-conversion-strategy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/toxicity-and-antitumor-activity-of-novel-agents-in-elderly-cancer-patients-in-phase-i-studies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/analysis-and-adherence-to-the-asco-recommendations-for-research-biopsies-and-archival-tissue-requirements-in-clinical-trials-conducted-at-institut
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-impact-of-sarcopenia-in-patients-enrolled-in-early-phase-cancer-trials
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-double-blind-randomized-parallel-group-study-to-demonstrate-the-equivalent-pharmacokinetic-properties-of-a-single-intravenous-dose-hd201-a-tra
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/distress-and-perceived-information-among-patients-in-phase-i-trials-and-their-relatives-a-prospective-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-predictive-score-of-antitumour-activity-of-novel-agents-in-cancer-patients-treated-in-early-phase-studies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/longitudinal-description-of-clinical-trials-for-the-development-of-cyclin-dependent-kinases-inhibitors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-drug-rediscovery-protocol-drup-results-of-the-first-500-treated-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/abdominal-events-in-targeted-therapies-report-from-the-drug-rediscovery-protocol-drup
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-i-first-in-human-study-of-abbv-151-as-monotherapy-or-in-combination-with-budigalimab-in-patients-with-locally-advanced-or-metastatic-solid-tu
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ib-study-on-a-trpv6-inhibitor-sorc13-in-patients-with-advanced-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-i-ib-dose-escalation-study-of-intravenously-administered-sb-11285-alone-and-in-combination-with-nivolumab-in-patients-with-advanced-solid-t
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/bt8009-100-phase-i-ii-study-of-the-safety-pharmacokinetics-preliminary-clinical-activity-of-bt8009-in-patients-with-nectin-4-expressing-advance
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-first-in-human-study-of-nuc-7738-a-3-da-phosphoramidate-in-patients-with-advanced-solid-tumours-nutide-701
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-first-in-human-study-of-nov1601-chc2014-small-molecule-inhibitor-of-trk-family-proteins-in-adult-patients-with-solid-organ-malignancies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/first-in-human-phase-i-study-of-a-novel-oral-wee1-inhibitor-debio-0123-in-combination-with-carboplatin-in-patients-with-advanced-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ii-open-label-study-of-erdafitinib-in-adult-and-adolescent-patients-pts-with-advanced-solid-tumours-harboring-fibroblast-growth-factor-rec
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/on-trk-a-non-interventional-study-of-larotrectinib-in-patients-with-trk-fusion-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/targeting-anti-cancer-drug-resistance-in-gastro-intestinal-cancer-inhibition-of-the-srpk1-kinase-and-degradation-of-the-abcg2-drug-efflux-pump
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/novel-mirna-based-assay-for-gep-nens-management
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-value-of-early-total-free-and-bound-to-lipoprotein-fractions-plasma-mitotane-measurements-in-advanced-adrenocortical-carcinoma-at-the-t
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/metnet-a-phase-ii-trial-of-metformin-in-patients-with-well-differentiated-neuroendocrine-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/maintenance-versus-discontinuation-of-androgen-deprivation-therapy-during-docetaxel-administration-with-a-continuous-or-an-intermittent-schedule-in
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pembrolizumab-pembro-plus-docetaxel-and-prednisone-in-patients-with-abiraterone-acetate-abi-or-enzalutamide-enza-pretreated-metastatic-castr
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pembrolizumab-pembro-plus-olaparib-in-patients-pts-with-docetaxel-pretreated-metastatic-castration-resistant-prostate-cancer-mcrpc-keynote-3
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exploring-the-impact-of-treatment-switching-on-the-interim-overall-survival-os-results-of-the-profound-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/keynote-199-phase-ii-study-of-pembrolizumab-plus-enzalutamide-for-enzalutamide-resistant-metastatic-castration-resistant-prostate-cancer-mcrpc-c
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pembrolizumab-pembro-plus-enzalutamide-enza-in-patients-with-abiraterone-acetate-abi-pretreated-metastatic-castration-resistant-prostate-canc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tolerability-of-olaparib-ola-in-patients-pts-with-metastatic-castration-resistant-prostate-cancer-mcrpc-and-homologous-recombination-repair
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cabazitaxel-treatment-in-patients-with-metastatic-castration-resistant-prostate-cancer-mcrpc-in-daily-practice-interim-analysis-of-the-non-inter
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-evidence-rwe-for-patients-pts-with-metastatic-castration-resistant-prostate-cancer-mcrpc-treated-with-cabazitaxel-cbz-compariso
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/treatment-in-card-eligible-metastatic-castration-resistant-prostate-cancer-mcrpc-patients-according-to-the-status-of-germline-hrr-mutations-caba
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neutrophil-lymphocyte-ratio-nlr-as-a-prognostic-and-predictive-biomarker-in-patients-with-metastatic-castration-resistant-prostate-cancer-mcrpc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/apalutamide-for-non-metastatic-castration-resistant-prostate-cancer-nmcrpc-a-comparison-of-real-life-experience-from-an-international-named-pati
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/darolutamide-d-enzalutamide-e-and-apalutamide-a-the-risk-of-adverse-events-aes-in-patients-with-non-metastatic-castration-resistant-prost
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/health-related-quality-of-life-hrqol-at-final-analysis-of-the-spartan-study-of-apalutamide-apa-vs-placebo-pbo-in-patients-pts-with-non-meta
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tolerability-and-treatment-response-to-darolutamide-daro-in-patients-with-non-metastatic-castration-resistant-prostate-cancer-nmcrpc-in-the-pha
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-metastatic-lymph-node-burden-on-survival-in-patients-with-mhspc-from-the-docetaxel-comparison-of-the-stampede-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/arches-the-role-of-androgen-deprivation-therapy-adt-with-enzalutamide-enza-or-placebo-pbo-in-metastatic-hormone-sensitive-prostate-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-study-of-sustained-androgen-signaling-dependence-in-metastatic-castrate-resistant-prostate-cancer-mcrpc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-prognostic-value-of-the-baseline-neutrophil-to-lymphocyte-ratio-nlr-in-patients-with-metastatic-castration-resistant-prostate-cancer-mcrpc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/meningeal-metastases-mm-in-patients-with-metastatic-castration-resistant-prostate-cancer-mcrpc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/223ra-in-asymptomatic-patients-pts-with-metastatic-castration-resistant-prostate-cancer-mcrpc-who-progressed-to-first-line-abiraterone-acetate
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/quality-of-life-and-survival-in-elderly-metastatic-castration-resistant-prostate-cancer-mcrpc-patients-pts-treated-with-docetaxel
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-patterns-of-genomic-testing-in-patients-pts-with-metastatic-castration-resistant-prostate-cancer-mcrpc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/role-of-free-testosterone-serum-levels-during-salvage-chemotherapy-with-carboplatin-plus-weekly-docetaxel-in-patients-with-docetaxel-refractory-me
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/evaluating-biomarkers-in-metastatic-castration-resistant-prostate-cancer-mcrpc-patients-pts-treated-with-enzalutamide-enza-psa-circulating
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/brca2-status-and-intraductal-idc-and-cribriform-crib-histologic-variants-partners-in-prostate-cancer-pc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prediction-of-brca2-mutations-in-prostate-cancer-patients-according-early-onset-metastatic-phenotypes-or-family-history-of-breast-ovary-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prostate-cancer-metastatic-profiles-correlate-with-molecular-alterations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-implications-of-intraductal-carcinoma-of-the-prostate-sub-patterns-in-metastatic-castration-resistant-prostate-cancer-patients-treated-wit
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/abiraterone-and-dexamethasone-in-castration-resistant-prostate-cancer-biological-response-after-switch-or-rechallenge
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/abiraterone-acetate-in-men-with-metastatic-castration-resistant-prostate-cancer-and-no-prior-chemotherapy-a-double-arm-multiple-centre-phase-iii
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparing-the-predictive-value-of-exosome-circulating-tumor-cells-and-tumor-tissue-in-detecting-ar-v7-among-metastatic-castration-resistant-prost
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-abiraterone-acetate-plus-prednisone-aap-in-patients-with-castration-sensitive-prostate-cancer-mcspc-and-visceral-metastases-subgroup
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparison-of-current-systemic-combination-therapies-for-metastatic-hormone-sensitive-prostate-cancer-and-selection-of-candidates-for-optimal-treat
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/features-of-molecular-profile-of-prostate-cancer-after-neoadjuvant-treatment
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-treatment-tx-patterns-in-patients-pts-with-metastatic-castration-resistant-prostate-cancer-mcrpc-and-homologous-recombination-repa
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-significance-of-docetaxel-d-plus-androgen-deprivation-therapy-adt-in-patients-p-with-metastatic-castration-sensitive-prostate-canc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/divergent-results-between-advanced-prostate-cancer-consensus-conference-apccc-panelist-p-and-global-non-panelist-np-survey-respondents
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/mutation-landscape-of-genes-involved-in-dna-damage-repair-pathway-among-chinese-patients-with-prostate-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-a-mutation-in-hsd3b1-gene-on-the-effectiveness-of-androgenic-deprivation-treatment-in-prostate-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/rucaparib-population-pharmacokinetics-ppk-and-exposure-response-er-analyses-in-patients-pts-with-metastatic-castration-resistant-prostate-can
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sequencing-after-taxane-in-patients-with-metastatic-castration-resistant-prostate-cancer-mcrpc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-treatment-tx-patterns-of-metastatic-castration-resistant-prostate-cancer-mcrpc-patients-pts-in-the-us
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genomic-genetic-testing-gt-patterns-for-patients-with-metastatic-castrate-resistant-prostate-cancer-mcrpc-interim-results-from-a-real-world-st
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sarcopenia-assessment-in-men-with-metastatic-castration-resistant-prostate-cancer-mcrpc-undergoing-radium-223-ra223-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-of-triptorelin-after-radical-prostatectomy-in-patients-with-high-risk-prostate-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-enzalutamide-on-patient-reported-fatigue-in-hormone-sensitive-prostate-cancer-hspc-or-castration-resistant-prostate-cancer-crpc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-role-of-docetaxel-induced-reduction-of-free-testosterone-serum-levels-in-metastatic-prostate-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-pretreatment-neutrophil-to-lymphocyte-ratio-nlr-and-platelet-to-lymphocyte-ratio-plr-on-overall-survival-os-in-patients-p-with-me
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-factors-that-are-prognostic-for-survival-outcomes-in-men-with-metastatic-castration-resistant-prostate-cancer-mcrpc-treated-with-radium-223
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/body-composition-and-clinical-outcomes-in-men-with-metastatic-castration-resistant-prostate-cancer-mcrpc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/linac-based-re-irradiation-for-locally-recurrent-prostate-cancer-after-first-course-radiotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prospective-assessment-of-ar-splice-variant-and-psma-detection-on-circulating-tumour-cells-of-mcrpc-patients-preliminary-results-of-primera-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/fracture-risk-in-men-with-metastatic-castration-resistant-prostate-cancer-mcrpc-treated-with-radium-223-ra-223
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/evaluation-of-cognitive-function-cogf-in-trials-testing-new-generation-hormonal-treatments-nght-in-patients-with-prostate-cancer-pc-a-system
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/assessing-bone-health-and-osteoporotic-risk-in-patients-requiring-anti-androgen-therapy-for-prostate-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/her2-expression-in-circulating-tumour-cells-is-associated-with-poor-outcomes-in-patients-with-metastatic-castration-resistant-prostate-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-role-of-nutritional-status-ns-for-health-related-quality-of-life-hrqol-in-men-with-advanced-prostate-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ii-study-of-enzalutamide-enz-with-dutasteride-dut-or-finasteride-fin-in-men-65-years-with-hormone-naive-systemic-prostate-cancer-h
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/metastasis-directed-stereotactic-body-radiotherapy-sbrt-guided-by-pet-ct-18f-choline-versus-pet-ct-68ga-psma-in-castration-sensitive-oligorecurre
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/treatment-patterns-of-metastatic-castration-sensitive-prostate-cancer-mcspc-a-real-world-evidence-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparative-efficacy-of-first-line-novel-anti-androgen-therapies-versus-docetaxel-in-metastatic-hormone-sensitive-prostate-cancer-mhspc-an-updat
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-and-immune-responses-to-immunotherapy-in-biochemically-recurrent-non-metastatic-castration-sensitive-prostate-cancer-bcrpc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-advance-a-phase-i-ii-open-label-non-randomised-safety-and-efficacy-study-of-the-viral-vectored-chadox1-mva-5t4-vtp-800-vaccine-in-c
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/correlation-between-castration-resistant-prostate-cancer-crpc-free-survival-crpc-fs-and-metastasis-free-survival-mfs-in-men-initiating-androg
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-real-effects-of-prostate-cancer-chemotherapy-results-of-the-euproms-prostate-patient-driven-quality-of-life-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/macrophage-composition-as-a-prognostic-indicator-of-time-to-progression-and-radiotherapy-response-in-prostate-adenocarcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/macrophage-composition-as-a-prognostic-indicator-of-time-to-progression-and-radiotherapy-response-in-prostate-adenocarcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/arc-6-a-phase-ib-ii-open-label-randomized-platform-study-evaluating-the-efficacy-and-safety-of-ab928-based-treatment-combinations-in-patients-wi
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genetic-information-to-inform-treatment-and-screening-gifts-study-for-prostate-cancer-characterizing-germline-dna-alterations-in-men-with-metast
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nrg-oncology-s-gu007-nadir-a-randomized-phase-ii-trial-of-niraparib-with-standard-combination-androgen-deprivation-therapy-adt-and-radiotherap
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-iii-randomized-double-blind-trial-of-nivolumab-or-placebo-combined-with-docetaxel-for-metastatic-castration-resistant-prostate-cancer-mc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-iii-randomized-study-of-enzalutamide-enza-plus-leuprolide-lhrha-enza-monotherapy-and-placebo-plus-lhrha-in-men-with-high-risk-nonmet
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/brca2men-an-international-multicentre-observational-and-ambispective-study-to-validate-the-predictive-value-of-germline-brca2-mutations-for-sele
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/lobster-long-term-better-than-short-term-adt-with-salvage-radiotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/dasl-hicap-darolutamide-augments-standard-therapy-for-localised-very-high-risk-cancer-of-the-prostate-anzup1801-.-a-randomised-phase-iii-double-b
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/oraculum-a-retrospective-observational-epidemiological-study-using-artificial-intelligence-and-natural-language-processing-in-electronic-health-re
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cabozantinib-c-in-combination-with-atezolizumab-a-in-non-clear-cell-renal-cell-carcinoma-nccrcc-results-from-cohort-10-of-the-cosmic-021-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ii-trial-of-lenvatinib-len-pembrolizumab-pembro-for-progressive-disease-after-pd-1-pd-l1-immune-checkpoint-inhibitor-ici-in-metastati
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nivolumab-ipilimumab-n-i-vs-sunitinib-s-for-first-line-treatment-of-advanced-renal-cell-carcinoma-arcc-in-checkmate-214-4-year-follow-up-a
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/primary-tumour-response-in-patients-treated-with-nivolumab-for-metastatic-renal-cell-carcinoma-mrcc-results-of-the-getug-afu-26-nivoren-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/treatment-free-survival-with-and-without-toxicity-after-immuno-oncology-vs-targeted-therapy-for-advanced-renal-cell-carcinoma-arcc-42-month-re
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/time-to-deterioration-in-quality-of-life-in-previously-untreated-patients-with-advanced-renal-cell-carcinoma-arcc-in-checkmate-214
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immune-checkpoint-therapy-ict-re-challenge-after-immune-related-adverse-events-iraes-in-genitourinary-cancers-guc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/optimizing-ipilimumab-in-metastatic-renal-cell-carcinoma-sakk-07-17-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparison-of-long-term-survival-and-cost-effectiveness-ce-of-first-line-1l-treatment-options-in-advanced-renal-cell-carcinoma-arcc-with-inte
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ii-study-of-patients-with-advanced-or-metastatic-renal-cell-carcinoma-mrcc-receiving-pazopanib-after-previous-checkpoint-inhibitor-treatment
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/correlative-serum-biomarker-analyses-lenvatinib-len-plus-pembrolizumab-pembro-in-a-phase-ib-ii-trial-in-advanced-renal-cell-carcinoma-rcc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/randomised-phase-ii-study-to-assess-the-efficacy-and-tolerability-of-sunitinib-by-dose-administration-regimen-in-anti-angiogenic-naive-patients-wit
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ipilimumab-and-nivolumab-compassionate-use-program-in-metastatic-renal-cell-carcinoma-patients-with-intermediate-or-poor-imdc-risk-score-the-large
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cabozantinib-in-elderly-patients-results-from-a-subanalysis-of-the-caboreal-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/response-to-systemic-therapy-in-fumarate-hydratase-fh-mutated-papillary-renal-cell-carcinoma-prcc-is-there-a-winner
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-prospective-phase-ii-study-of-gemcitabine-plus-platinum-in-combination-with-bevacizumab-for-metastatic-renal-medullary-and-collecting-duct-carcin
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/collecting-duct-and-renal-medullary-carcinoma-a-population-based-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-values-of-pd-l1-expression-and-cd8-infiltration-phenotype-in-metastatic-and-recurrent-renal-cell-carcinoma-an-exploratory-analysis-of-t
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cabozantinib-cabo-concentration-cmin-association-with-toxicity-tox-and-treatment-failure-in-metastatic-renal-cell-carcinoma-mrcc-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/primary-resistance-prr-versus-acquired-resistance-acr-to-immune-checkpoint-inhibitors-ici-in-first-line-metastatic-renal-cell-carcinoma-mrcc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/interim-analysis-of-cassiope-a-real-world-study-of-cabozantinib-for-the-treatment-of-advanced-renal-cell-carcinoma-arcc-after-vegf-targeted-ther
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-value-of-pd-l1-status-in-the-primary-lesion-as-a-risk-factor-for-developing-metastatic-disease-in-localized-renal-cell-carcinoma-a-subg
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-impact-of-proton-pump-inhibitors-on-pazopanib-exposure
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cabozantinib-in-non-clear-cell-metastatic-renal-cell-carcinoma-and-sarcomatoid-renal-cell-carcinoma-real-world-data-from-the-caboreal-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/quality-of-life-assessment-in-renal-cell-carcinoma-phase-ii-and-iii-clinical-trials-published-between-2010-and-2020
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/kidney-manifestations-in-patients-with-hereditary-leiomyomatosis-and-renal-cell-cancer-syndrome-lhrcc-in-spain
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/metastatic-renal-medullary-and-collecting-duct-carcinoma-in-the-era-of-antiangiogenic-and-immune-checkpoint-inhibitors-a-multicentric-retrospectiv
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/updated-data-on-patients-pts-with-metastatic-renal-cell-carcinoma-mrcc-treated-with-sorafenib-sor-vs-observation-obs-after-radical-metastas
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/synchronous-metastatic-renal-cell-carcinoma-mrcc-treated-with-nivolumab-and-ipilimumab-n-i-and-the-primary-tumour-pt-in-place
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/soluble-pd-1-pd-l1-pan-btn3as-btn3a1-and-btn2a1-as-predictive-biomarkers-of-nivolumab-response-in-patients-with-metastatic-clear-cell-renal-carc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-previous-nephrectomy-on-clinical-outcome-of-metastatic-renal-carcinoma-treated-with-immuno-oncology-a-real-world-study-on-behalf-of-meet
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-outcomes-stratified-by-charlson-comorbidity-index-cci-score-from-a-retrospective-study-of-patients-with-advanced-renal-cell-carcinoma-a
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/response-assessment-in-advanced-renal-cell-carcinoma-mrcc-patients-pts-treated-by-nivolumab-n-ipilimumab-i-ct-volumetric-measurement-ver
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/activation-of-the-wnt-signaling-pathway-correlates-with-innate-resistance-to-immune-checkpoint-therapies-in-clear-cell-renal-cell-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/activity-of-systemic-therapies-after-cabozantinib-cabo-in-patients-pts-with-metastatic-renal-cell-carcinoma-mrcc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/association-between-gene-expression-signatures-sigs-and-pembrolizumab-pembro-efficacy-in-patients-pts-with-advanced-urothelial-cancer-uc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patient-reported-outcomes-pros-from-javelin-bladder-100-avelumab-first-line-1l-maintenance-best-supportive-care-bsc-vs-bsc-alone-for-advan
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ev-201-long-term-results-of-enfortumab-vedotin-monotherapy-for-locally-advanced-or-metastatic-urothelial-cancer-previously-treated-with-platinum-a
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/association-of-tmb-with-efficacy-of-pembrolizumab-pembro-in-patients-pts-with-advanced-urothelial-cancer-uc-results-from-keynote-045-and-key
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-factors-related-to-post-platinum-atezolizumab-for-relapsed-metastatic-urothelial-cancer-muc-from-the-saul-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nivolumab-n-alone-or-in-combination-with-ipilimumab-i-in-patients-pts-with-platinum-pretreated-metastatic-urothelial-carcinoma-muc-extende
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/erdafitinib-erda-in-patients-pts-with-locally-advanced-or-metastatic-urothelial-carcinoma-muc-subgroup-analyses-of-long-term-efficacy-outcom
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/analysis-of-circulating-tumor-dna-ctdna-from-the-phase-ii-blc2001-trial-of-erdafitinib-in-locally-advanced-or-metastatic-urothelial-carcinoma-mu
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/updated-data-from-the-norse-trial-of-erdafitinib-erda-plus-cetrelimab-cet-in-patients-pts-with-metastatic-or-locally-advanced-urothelial-carc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/urine-tumor-dna-methylation-assay-enables-early-diagnosis-residual-detection-and-recurrence-monitoring-for-bladder-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ibrutinib-ibr-in-combination-with-paclitaxel-pac-has-activity-in-patients-pts-with-advanced-urothelial-carcinoma-auc-final-analysis-of-a-p
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparative-clinical-efficacy-of-neoadjuvant-nact-versus-adjuvant-chemotherapy-act-in-the-treatment-of-locally-advanced-penile-cancer-peca-a
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/molecular-subtyping-and-immune-gene-signatures-identify-a-subset-of-clinical-t1-high-grade-ct1-hg-and-ct2-bladder-urothelial-carcinoma-uc-as-ca
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/an-observational-study-of-outcomes-of-patients-pts-with-advanced-urothelial-carcinoma-uc-after-anti-programmed-death-ligand-1-pd-l-1-thera
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/assessment-of-prognostic-and-predictive-value-of-fgfr-alterations-fgfra-in-a-real-world-cohort-of-patients-pts-with-high-risk-pt1-non-muscle-in
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/towards-personalized-medicine-in-mibc-immunohistochemistry-based-taxonomical-classification-and-outcome-in-patients-treated-with-adjuvant-chemothe
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/platinum-based-adjuvant-chemotherapy-in-upper-tract-urothelial-carcinomas-utucs-a-change-of-paradigm-a-meta-analysis-of-aggregate-data
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-the-combination-of-durvalumab-medi4736-plus-olaparib-azd2281-administered-prior-to-surgery-in-the-molecular-profile-of-resectable-uro
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/molecular-profiling-of-post-pembrolizumab-muscle-invasive-bladder-cancer-mibc-reveals-unique-features-that-may-inspire-new-sequential-therapies-i
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-influence-of-multidisciplinary-team-meetings-on-treatment-decisions-in-muscle-invasive-bladder-cancer-a-nationwide-study-in-the-netherlands
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pre-clinical-and-clinical-studies-on-the-role-of-rbm3-in-muscle-invasive-bladder-cancer-longitudinal-expression-transcriptome-level-effects-and-m
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/predicting-survival-in-urothelial-cancer-patients-after-immunotherapy-using-real-world-data
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-effect-of-systemic-immune-inflammation-index-sii-in-987-patients-with-advanced-metastatic-urinary-tract-carcinoma-mutc-treated-with
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neutrophil-to-lymphocyte-ratio-nlr-and-systemic-inflammation-index-sii-as-prognostic-factors-in-advanced-urinary-tract-carcinoma-patients-treat
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-score-combining-systemic-inflammation-index-sii-and-pd-l1-ldh-in-advanced-urinary-tract-carcinoma-patients-treated-with-atezolizum
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/apobec-signatures-and-high-tumour-mutational-burden-as-predictors-of-clinical-outcomes-and-response-to-therapy-in-patients-with-urothelial-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-and-predictive-value-of-ribonucleotide-reductase-subunit-family-m1-m2-in-urothelial-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ib-ii-study-of-durvalumab-plus-guadecitabine-in-advanced-clear-cell-renal-cell-cancer-ccrcc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-of-enfortumab-vedotin-in-populations-of-interest-among-patients-with-advanced-urothelial-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cabozantinib-cabo-plus-durvalumab-durva-in-patients-pts-with-advanced-urothelial-carcinoma-uc-after-platinum-chemotherapy-safety-and-preli
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/adoption-of-immune-checkpoint-inhibitors-icis-in-bladder-cancer-findings-from-a-real-world-study-in-eu5
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/whole-blood-transcriptomic-profiling-to-predict-response-to-immunotherapy-in-metastatic-urothelial-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ii-trial-of-concurrent-nivolumab-in-urothelial-bladder-cancer-with-radiation-therapy-in-localized-locally-advanced-disease-for-chemotherapy-i
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/decrease-in-derived-neutrophil-to-lymphocyte-ratio-dnlr-related-to-immune-checkpoint-inhibitors-ici-benefit-in-patients-with-metastatic-urothel
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/concomitant-antibiotic-use-and-its-effect-on-immune-checkpoint-inhibitor-efficacy-in-patients-with-advanced-urothelial-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/validation-of-prognostic-scores-in-patients-with-metastatic-bladder-carcinoma-mbc-enrolled-in-early-phase-clinical-trials
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cancer-susceptibility-mutations-in-chinese-patients-with-urothelial-malignancies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-factors-in-patients-with-metastatic-urothelial-carcinoma-who-have-been-treated-with-atezolizumab
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-evidence-of-the-impact-of-prior-autoimmune-disease-on-immune-checkpoint-inhibitor-outcomes-in-patients-with-metastatic-urothelial-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-outcomes-in-patients-pts-with-metastatic-urothelial-carcinoma-muc-who-received-first-1l-or-second-line-2l-pd-1-and-pd-l1-inhibi
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/perioperative-multimodality-treatment-in-high-risk-node-positive-penile-cancer-a-single-institution-study-of-patients-treated-in-a-supraregional-c
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/thromboembolic-events-te-during-treatment-with-cisplatin-based-chemotherapy-cbct-in-metastatic-testicular-germ-cell-cancer-tc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ii-trial-of-paclitaxel-ifosfamid-and-cisplatin-in-patients-with-poor-prognosis-disseminated-non-seminomatous-germ-cell-tumors-with-unfavor
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/urachal-urac-and-non-urachal-nurac-adenocarcinomas-of-the-urinary-bladder-a-comparative-comprehensive-genomic-profiling-cgp-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/urachal-carcinoma-large-retrospective-multicentric-getug-afu-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-differential-gene-expression-signature-identifies-a-population-of-stage-i-testicular-non-seminomatous-germ-cell-tumours-nsgct-at-high-risk-of-r
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/palliative-chemotherapy-in-patients-with-advanced-nonseminomatous-germ-cell-tumors-ansgct
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/penile-cancer-in-older-men-a-seer-dataset-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-retrospective-review-of-the-survival-outcomes-of-patients-with-nonseminomatous-germ-cell-tumors-nsgcts-with-and-without-teratoma-in-the-primary
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/chek2-inactivating-germ-line-mutations-play-a-role-in-the-development-of-testicular-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/uk-practices-for-treatment-of-relapse-in-seminoma-testicular-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-iii-study-of-the-programmed-cell-death-protein-1-inhibitor-pf-06801591-plus-bacillus-calmette-guerin-for-non-muscle-invasive-bladder-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/trophy-u-01-cohort-3-sacituzumab-govitecan-sg-and-pembrolizumab-pembro-in-patients-pts-with-progression-or-recurrence-of-metastatic-urotheli
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/race-it-a-prospective-single-arm-multicenter-phase-ii-trial-to-assess-safety-and-efficacy-of-preoperative-radiation-therapy-before-radical-cyst
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/study-ev-302-a-3-arm-open-label-randomized-phase-iii-study-of-enfortumab-vedotin-plus-pembrolizumab-and-or-chemotherapy-versus-chemotherapy-alo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/proof-302-a-randomized-double-blind-placebo-controlled-phase-iii-trial-of-infigratinib-as-adjuvant-therapy-in-patients-with-invasive-urothelial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/meet-uro-12-a-randomized-phase-ii-trial-of-niraparib-versus-best-supportive-care-bsc-as-maintenance-treatment-in-patients-with-locally-advanced
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ii-study-of-cabozantinib-in-combination-with-atezolizumab-as-neoadjuvant-treatment-for-muscle-invasive-bladder-cancer-abate
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immune-tumor-microenvironment-tme-in-correlation-with-peripheral-blood-immune-biomarkers-as-prognostic-factor-in-metastatic-renal-cell-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pilot-study-of-cabozantinib-efficacy-safety-and-tolerability-in-metastatic-renal-carcinoma-in-aged-fragile-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cabopoint-a-phase-ii-study-of-second-line-cabozantinib-in-patients-with-metastatic-renal-cell-carcinoma-rcc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/response-to-olaparib-monotherapy-in-relapsed-ovarian-cancer-by-hrr-gene-mutational-status-and-hrd-scarring-analysis-results-from-the-randomized-ph
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/veliparib-with-carboplatin-and-paclitaxel-in-frontline-high-grade-serous-ovarian-cancer-hgsoc-efficacy-and-safety-of-paclitaxel-weekly-and-every
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-and-safety-of-niraparib-in-older-patients-pts-with-advanced-ovarian-cancer-oc-results-from-the-prima-engot-ov26-gog-3012-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ii-study-of-pamiparib-in-chinese-patients-pts-with-advanced-ovarian-cancer-aoc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/timing-of-adverse-events-during-maintenance-treatment-with-rucaparib-for-recurrent-ovarian-cancer-in-the-phase-iii-ariel3-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/extended-follow-up-of-a-real-world-cohort-of-patients-pts-with-brca-mutation-brcam-relapsed-epithelial-ovarian-cancer-eoc-receiving-olaparib
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-data-rwd-on-platinum-pt-outcomes-after-parp-inhibitors-parpi-progression-in-high-grade-serous-ovarian-cancer-hgsoc-patients-p
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/olaparib-maintenance-therapy-in-routine-clinical-practice-quality-of-life-interim-results-of-the-non-interventional-c-patrol-study-in-ovarian-canc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparative-efficacy-of-first-line-maintenance-parp-inhibitors-parpi-in-advanced-ovarian-cancer-oc-a-network-meta-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/first-real-life-data-on-olaparib-in-1st-line-1stl-maintenance-brca1-2-mutated-epithelial-ovarian-cancer-eoc-in-france-descriptive-analysis-of
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/expected-versus-observed-response-to-platinum-based-chemotherapy-after-poly-adp-ribose-polymerase-inhibitor-treatment-for-relapsed-ovarian-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/regorafenib-r-or-tamoxifen-t-for-platinum-sensitive-recurrent-ovarian-cancer-psroc-with-rising-ca125-and-no-evidence-of-clinical-or-radiologi
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/subanalysis-of-a-randomized-phase-iii-study-comparing-trabectedin-and-pld-vs-pld-alone-in-patients-with-recurrent-ovarian-cancer-roc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-of-platinum-based-chemotherapy-in-platinum-resistant-ovarian-cancer-a-systematic-review-with-pooled-analysis-of-outcomes
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/geico1601-rolando-trial-a-multicentric-single-arm-phase-ii-clinical-trial-to-evaluate-the-combination-of-olaparib-and-pegylated-liposomal-doxorubi
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/mirvetuximab-soravtansine-mirv-a-folate-receptor-alpha-fra-targeting-antibody-drug-conjugate-adc-in-combination-with-carboplatin-carbo-an
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ii-study-of-gemcitabine-cisplatin-and-bevacizumab-for-first-recurrent-and-refractory-ovarian-clear-cell-carcinoma-kcog-g1601-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-outcomes-of-advanced-recurrent-ovarian-clear-cell-carcinoma-in-a-multi-ethnic-asian-cohort-following-bevacizumab-and-immune-checkpoint-in
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-efficacy-of-xmt-1536-in-ovarian-cancer-a-subgroup-analysis-from-the-phase-i-expansion-study-of-xmt-1536-a-napi2b-antibody-drug-conjugate
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ii-trial-of-oncolytic-vaccinia-virus-primed-immunochemotherapy-in-platinum-resistant-refractory-ovarian-cancer-prroc-nct02759588
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/trioc-a-randomised-phase-ii-trial-to-examine-mva-5t4-vaccine-in-patients-with-relapsed-asymptomatic-epithelial-ovarian-fallopian-tube-or-primary-p
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ib-ii-study-of-rebastinib-and-paclitaxel-in-advanced-or-metastatic-platinum-resistant-ovarian-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/famitinib-malate-plus-camrelizumab-for-recurrent-platinum-resistant-ovarian-fallopian-tube-primary-peritoneal-cancer-and-advanced-cervical-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ii-study-of-anlotinib-plus-pemetrexed-for-platinum-resistant-epithelial-ovarian-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/carboplatin-induced-thrombocytopenia-in-ovarian-cancer-a-focus-on-predictive-factors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/association-of-gene-expression-signatures-and-tmb-with-response-to-pembrolizumab-pembro-in-patients-pts-with-recurrent-ovarian-cancer-roc-enr
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/kras-mutant-epithelial-ovarian-carcinomas-eoc-represent-distinct-genomic-genotypes
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-utility-of-monitoring-tp53-mutation-tp53m-circulating-tumour-dna-ctdna-in-patients-pts-with-high-grade-ovarian-carcinomas-hgoc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/drdscore-can-predict-platinum-resistance-in-advanced-high-grade-serous-ovarian-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-prognostic-value-of-chemosensitivity-estimated-by-the-modeled-ca-125-kelim-in-ovarian-cancer-patients-treated-with-neo-adjuvant-chemotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/features-and-clinical-outcomes-for-younger-women-with-epithelial-ovarian-cancer-eoc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/characterization-of-immunoreactivity-with-whole-slide-imaging-and-digital-analysis-in-high-grade-serous-ovarian-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genetic-factors-contributing-to-the-success-rate-of-patient-derived-xenograft-revealed-by-genomic-characterization-in-epithelial-ovarian-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pla2g7-paf-ah-as-protective-factor-and-potential-negative-regulator-of-the-wnt-signaling-pathway-in-brca1-mutant-ovarian-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exploring-the-correlation-between-axl-expression-and-gene-expression-molecular-subtyping-gems-in-high-grade-serous-ovarian-cancer-hgsoc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-germline-mutation-landscape-of-ddr-genes-in-chinese-patients-with-epithelial-ovarian-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-multicenter-clinical-registry-with-associated-biological-samples-of-gynecological-cancer-patients-pilot-study-of-the-spanish-ovarian-cancer-rese
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-novel-biomarker-panel-improves-ovarian-cancer-diagnosis-in-postmenopausal-woman-presenting-with-symptomatic-pelvic-masses
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/uptake-of-risk-reducing-bilateral-salpingo-oophorectomy-rrbso-in-brca1-brca2-carriers
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patient-reported-outcomes-pros-in-the-garnet-trial-in-patients-pts-with-advanced-or-recurrent-mismatch-repair-deficient-microsatelite-instabili
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/long-term-survival-outcomes-in-endometrial-cancer-patients-having-lymphadenectomy-sentinel-node-mapping-followed-by-backup-lymphadectomy-and-senti
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-treatment-modalities-on-quality-of-life-for-endometrial-cancer-patients-in-norway
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/redefining-prognosis-in-early-stage-high-grade-endometrial-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/limited-implementation-of-the-esmo-esgo-european-society-of-gynaecological-oncology-estro-european-society-for-radiotherapy-and-oncology-consen
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-role-of-cd3-cd4-cd8-and-foxp3-positive-populations-in-early-stage-endometrial-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-i-study-of-mirvetuximab-soravtansine-mirv-and-gemcitabine-g-in-pts-with-selected-fra-positive-solid-tumours-results-in-the-endometria
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ii-of-abtl0812-a-pro-autophagic-drug-in-combination-with-paclitaxel-and-carboplatin-p-c-as-first-line-treatment-in-advanced-recurrent-end
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ii-study-of-sintilimab-plus-anlotinib-for-chinese-patients-pts-with-persistent-recurrent-or-metastatic-cervical-cancer-cc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neoadjuvant-chemotherapy-followed-by-radical-surgery-versus-concurrent-chemoradiotherapy-in-patients-with-stage-iia-iiia-cervical-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patterns-of-recurrence-after-minimally-invasive-and-open-abdominal-radical-hysterectomy-for-cervical-cancer-a-propensity-matched-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-clinical-study-on-the-application-of-3d-printing-minimally-invasive-guided-template-in-brachytherapy-of-patients-with-locally-advanced-cervical-c
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-impact-of-hpv-ctdna-detection-during-chemoradiotherapy-for-cervix-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/potential-assessment-of-radiomic-pet-in-the-evaluation-of-cervical-cancer-treatment
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prevalence-of-self-reported-cognitive-impairment-among-cervical-cancer-survivors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparison-of-colposcopy-pap-smear-test-and-visual-inspection-with-acetic-acid-via-as-screening-tests-for-precancer-of-the-cervix-cin2-in-hig
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/in-vivo-persistence-of-iovance-tumour-infiltrating-lymphocytes-ln-145-in-cervical-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/programmed-death-ligand-1-pd-l-1-expression-in-cervical-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/performance-and-diagnostic-accuracy-of-human-papillomavirus-testing-on-urine-and-self-collected-vaginal-samples-in-a-referral-population
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-effect-of-surgical-techniques-on-sexuality-and-global-quality-of-life-qol-in-women-with-ovarian-germ-cell-ogct-and-sex-cord-stromal-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ii-study-of-bintrafusp-alfa-a-bifunctional-fusion-protein-targeting-tgf-v-and-pd-l1-in-platinum-experienced-advanced-cervical-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/randomized-open-label-phase-ii-trial-of-dostarlimab-tsr-042-as-maintenance-therapy-for-patients-with-high-risk-locally-advanced-cervical-cance
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-multi-centre-open-label-phase-ii-trial-of-the-combination-of-vb10.16-and-atezolizumab-in-patients-with-advanced-or-recurrent-non-resectable-hpv
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/innovatv-208-new-weekly-dosing-cohort-in-the-phase-ii-study-of-tisotumab-vedotin-in-platinum-resistant-ovarian-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/moonstone-gog-3032-a-phase-ii-open-label-single-arm-study-to-evaluate-the-efficacy-and-safety-of-niraparib-dostarlimab-in-patients-with-platin
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/attend-engot-en7-a-multicenter-phase-iii-double-blind-randomized-controlled-trial-of-atezolizumab-in-combination-with-paclitaxel-and-carboplatin-i
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/diffuse-large-b-cell-testicular-lymphomas-dlbcl-tl-survival-outcomes-over-20-years
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-i-study-results-of-the-type-ii-glycoengineered-humanized-anti-cd20-monoclonal-antibody-mil62-in-chinese-patients-with-relapsed-refractory-cd2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/survival-of-adult-burkitt-lymphoma-patients-treated-with-the-nhl-bfm-90-protocol-in-a-10-year-period-in-slovenia
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/analysis-of-dlbcl-genetic-databases-using-machine-learning
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/t-cell-lymphomas-tcl-real-world-experience-analysis-from-cancer-registry
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pharmacoeconomic-assessment-of-subcutaneous-retuximab-formulation-compared-to-intravenous-retuximab-in-nhl-and-cll-patients-a-single-institution-e
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-emerging-treatment-options-of-plasmablastic-lymphoma-analysis-of-173-individual-patients-outcomes
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/matching-adjusted-indirect-comparisons-maic-of-safety-between-single-agent-belantamab-mafodotin-versus-selinexor-plus-dexamethasone-in-relapsed-r
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/quality-of-life-and-response-to-treatment-with-ixazomib-lenalidomide-dexamethasone-ird-in-patients-with-relapsed-refractory-multiple-myeloma-rrm
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/combination-of-nivolumab-with-brentuximab-vedotin-in-therapy-of-relapsed-and-refractory-hodgkin-lymphoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-role-of-arginine-citrulline-cycle-disorders-in-the-liver-injury-pathogenesis-in-acute-myeloid-leukemia-patients-with-concomitant-obesity
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-and-safety-of-hhpg-19k-for-prophylaxis-of-chemotherapy-induced-neutropenia-in-patients-with-lymphoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/avelumab-anti-pd-l1-in-patients-with-platinum-refractory-ineligible-recurrent-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-r-m-scc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pembrolizumab-plus-docetaxel-for-the-treatment-of-recurrent-metastatic-head-and-neck-cancer-a-prospective-phase-i-ii-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/each-a-phase-ii-study-evaluating-the-safety-and-anti-tumour-activity-of-avelumab-and-cetuximab-in-recurrent-metastatic-squamous-cell-carcinomas
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immune-alterations-in-a-window-of-opportunity-for-durvalumab-medi4736-plus-metformin-trial-in-squamous-cell-carcinoma-of-the-head-and-neck-scchn
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sns-301-added-to-pembrolizumab-in-patients-pts-with-asph-advanced-squamous-cell-carcinoma-of-the-head-neck-scchn
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-of-2nd-line-treatment-with-chemotherapy-ct-or-immune-checkpoint-inhibitors-icis-for-patients-pts-with-a-prolonged-objective-response
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-data-in-the-era-of-immune-checkpoint-inhibitors-icis-cetuximab-containing-first-line-therapy-in-patients-with-recurrent-and-or-metast
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/initial-results-from-a-phase-ii-study-tacti-002-of-eftilagimod-alpha-soluble-lag-3-protein-and-pembrolizumab-as-2-sup-nd-sup-line-treatment-f
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-i-dose-expansion-part-ii-study-of-isu104-a-novel-anti-erbb3-monoclonal-antibody-alone-and-combination-with-cetuximab-cet-in-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/anlotinib-in-patients-with-recurrent-or-metastatic-nasopharyngeal-carcinoma-an-interim-analysis-of-a-phase-ii-clinical-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/weekly-paclitaxel-carboplatin-and-cetuximab-pcc-as-first-line-treatment-of-recurrent-and-or-metastatic-head-neck-squamous-cell-carcinoma-r-m
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/topical-steroid-versus-placebo-for-the-prevention-of-radiation-dermatitis-in-head-and-neck-cancer-patients-receiving-chemoradiotherapy-a-phase-iii
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-geriatric-assessment-on-the-management-of-older-head-and-neck-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-impact-of-patients-and-physicians-characteristics-on-surgery-decision-for-head-and-neck-cancer-results-of-a-national-survey
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparing-frailty-screening-tools-for-older-head-and-neck-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/diclofenac-versus-tramadol-for-mucositis-related-pain-in-head-and-neck-cancer-patients-undergoing-concurrent-chemoradiation-a-phase-iii-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/outcome-and-toxicity-in-older-patients-with-locoregionally-advanced-head-and-neck-cancer-relevance-of-an-oncogeriatric-approach
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/outcome-patterns-of-failure-and-toxicity-profile-following-adjuvant-intensity-modulated-radiotherapy-for-oral-cavity-squamous-cell-carcinomas
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nutritional-status-ns-as-a-strong-predictor-for-immunotherapy-it-outcome-in-recurrent-or-metastatic-r-m-head-and-neck-squamous-cell-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/evaluation-of-oral-nano-silymarin-formulation-efficacy-on-prevention-of-radiotherapy-induced-mucositis-a-randomized-double-blinded-placebo-contr
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/analysis-of-a-cohort-of-elderly-patients-p-with-head-and-neck-cancer-hnc-managed-within-a-multidisciplinary-head-and-neck-cancer-unit-hncu
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-and-safety-of-apatinib-combined-with-capecitabine-in-patients-with-advanced-nasopharyngeal-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genomic-characterization-reveals-potential-therapeutic-targets-in-nasopharyngeal-carcinoma-with-relapse
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-most-optimal-induction-chemotherapy-regimen-for-loco-regionally-advanced-nasopharyngeal-carcinoma-a-network-meta-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-prognostic-role-of-cop-nlr-score-combination-of-platelet-count-and-neutrophil-to-lymphocyte-ratio-in-locally-advanced-nasopharyngeal-cancer-p
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/association-of-epstein-barr-virus-infection-with-peripheral-immune-parameters-and-clinical-outcome-in-advanced-nasopharyngeal-carcinomas
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/germinal-immunogenetics-and-response-to-nivolumab-in-recurrent-metastatic-head-and-neck-squamous-cell-carcinoma-rm-hnscc-patients-pts-topnivo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/association-between-genetic-variants-and-cisplatin-nephrotoxicity-a-genome-wide-approach
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pre-treatment-characteristics-and-long-term-outcomes-of-recurrent-metastatic-head-and-neck-cancer-patients-treated-with-immune-checkpoint-inhibitors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-antibiotic-use-and-derived-neutrophil-to-lymphocyte-ratio-dnlr-in-patients-with-recurrent-metastatic-head-and-neck-squamous-cell-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-and-predictive-value-of-skeletal-muscle-mass-smm-in-squamous-cell-carcinoma-of-the-head-and-neck-scchn-in-patients-treated-with-immu
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-relationship-between-overall-survival-os-progression-free-survival-pfs-and-objective-response-rate-orr-in-immune-checkpoint-inhibitor-c
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neutrophil-to-lymphocyte-ratio-nlr-and-survival-in-recurrent-or-metastatic-head-and-neck-cancer-patients-treated-with-immunotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sarcopenia-as-predictive-factor-of-response-to-nivolumab-in-recurrent-metastatic-head-and-neck-rm-scchn-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/changes-in-levels-of-cytokines-and-interleukins-during-nivolumab-treatment-a-subgroup-analysis-of-the-nivactor-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/activation-of-the-wnt-signaling-pathway-correlates-with-innate-resistance-to-immune-checkpoint-therapies-in-head-and-neck-squamous-cell-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/combined-accuracy-of-computed-tomography-and-magnetic-resonance-imaging-in-detecting-level-wise-metastatic-neck-nodes-and-extracapsular-spread
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ameloblastoma-of-the-head-and-neck-hnamb-a-comprehensive-profiling-cgp-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/circulating-tumour-dna-as-a-biomarker-in-head-and-neck-squamous-cell-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/analysis-of-concurrent-chemo-radiation-using-weekly-cisplatin-in-locally-advanced-scchn-identification-of-prognostic-factors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-real-world-clinical-outcomes-and-prognostic-factors-in-japanese-patients-with-recurrent-or-metastatic-squamous-cell-carcinoma-of-head-and-neck-tr
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genomic-and-transcriptomic-profiling-in-head-and-neck-tumours-to-identify-treatment-options-the-winther-trial-experience
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immunotherapeutic-implications-of-mucin-1-16-expression-in-head-and-neck-squamous-cell-carcinoma-hnscc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-and-histological-prognostic-factors-of-recurrent-and-or-metastatic-salivary-gland-adenoid-cystic-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/gene-expression-profiling-to-improve-prognostic-characterization-of-olfactory-neuroblastoma-and-to-define-new-targetable-pathways
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/role-of-stat3-signal-transducer-and-activator-of-transcription-3-activation-and-its-regulation-by-ptprt-protein-receptor-tyrosine-phosphatase-ty
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/activation-of-the-wnt-pcp-signaling-pathway-is-an-adverse-prognostic-predictor-in-patients-with-low-grade-glioma-lgg
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/metastases-harbored-in-the-maxillofacial-region-a-retrospective-review-of-patient-and-tumour-characteristics
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neoadjuvant-nivolumab-n-plus-weekly-carboplatin-c-and-paclitaxel-p-outcomes-in-hpv-resectable-locally-advanced-head-and-neck-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparison-of-outcomes-of-weekly-paclitaxel-versus-weekly-cisplatin-in-oral-cavity-oropharyngeal-and-hypopharyngeal-cancer-patients-with-concurren
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/medinduction-phase-i-trial-evaluating-the-safety-of-durvalumab-in-combination-with-docetaxel-cisplatin-and-5-fu-dcf-as-induction-therapy-for-lo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-and-pathological-characteristics-of-orbital-tumours-in-patients-diagnosed-at-the-united-states
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ii-study-of-intratumoral-mk-1454-plus-pembrolizumab-compared-with-pembrolizumab-monotherapy-as-first-line-treatment-for-metastatic-or-unresec
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/leap-010-phase-iii-study-of-first-line-pembrolizumab-with-or-without-lenvatinib-in-patients-pts-with-recurrent-metastatic-r-m-head-and-neck-sq
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exploratory-phase-ib-iia-study-of-intratumorally-administered-tigilanol-tiglate-to-assess-safety-tolerability-and-tumour-response-in-patients-with
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ib-trial-of-abbv-368-tilsotolimod-in-combination-with-nab-paclitaxel-and-or-budigalimab-abbv-181-in-patients-with-recurrent-metastatic-he
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/spearhead-2-trial-design-a-phase-ii-pilot-trial-of-adp-a2m4-in-combination-with-pembrolizumab-in-patients-with-recurrent-or-metastatic-head-and-ne
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/role-of-microbiome-as-a-biomarker-in-locoregionally-advanced-oropharyngeal-squamous-cell-carcinoma-2-roma-la-opscc2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/durvalumab-with-cetuximab-and-radiotherapy-for-locally-advanced-squamous-cell-carcinoma-of-the-head-and-neck-a-phase-i-ii-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/poppy-a-phase-ii-trial-to-assess-the-efficacy-and-safety-profile-of-pembrolizumab-in-patients-with-performance-status-2-with-recurrent-or-metastat
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/voice-head-and-neck-cancer-patient-journey-s-health-literacy-needs-and-experience-patient-caregivers-and-healthcare-professionals-perspectives
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparison-of-donafenib-and-sorafenib-as-advanced-hepatocellular-carcinoma-first-line-treatments-subgroup-analysis-of-an-open-label-randomized-p
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/camrelizumab-c-in-combination-with-apatinib-a-in-patients-with-advanced-hepatocellular-carcinoma-rescue-an-open-label-multi-center-phase-i
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ii-study-of-camrelizumab-for-advanced-hepatocellular-carcinoma-two-year-outcomes-and-continued-treatment-beyond-recist-defined-progression
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sorafenib-plus-hepatic-arterial-infusion-chemotherapy-versus-sorafenib-alone-for-advanced-hepatocellular-carcinoma-with-major-portal-vein-tumor-thr
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-of-atezolizumab-atezo-bevacizumab-bev-after-disease-progression-with-atezo-monotherapy-in-patients-with-previously-untreated-unrese
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ib-study-of-the-pd-1-antagonist-cs1003-plus-lenvatinib-len-in-chinese-patients-pts-with-the-first-line-1l-unresectable-hepatocellular
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-analysis-of-the-run-in-phase-1st-and-2nd-cohort-of-the-immunib-trial-aio-hep-0218-ass-an-open-label-single-arm-phase-ii-study-evaluat
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/effects-of-combination-therapy-using-lenvatinib-and-anti-pd-1-antibody-on-liver-function-in-patients-with-advanced-hepatocellar-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/updated-results-of-a-phase-ib-study-of-regorafenib-reg-plus-pembrolizumab-pembro-for-first-line-treatment-of-advanced-hepatocellular-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sintilimab-plus-ibi305-as-first-line-treatment-for-advanced-hepatocellular-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/yttrium-90-glass-microspheres-in-the-treatment-of-early-and-advanced-hepatocellular-carcinoma-the-legacy-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nbtxr3-radiation-enhancing-hafnium-oxide-nanoparticles-rp2d-for-the-treatment-of-hcc-and-liver-metastases
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/stem-cell-like-subtypes-revealed-by-integrative-multi-omics-analysis-in-early-stage-hepatocellular-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ctnnb1-mutations-in-chinese-hcc-patients-and-immune-microenvironment-related-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/characterization-of-the-tumor-immune-microenvironment-in-hepatocellular-carcinoma-prognostic-value-of-m0-macrophage-high-subtype
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pd-l1-protein-expression-as-a-predictor-of-response-to-immune-checkpoint-inhibitor-ici-in-hepatocellular-carcinoma-hcc-a-meta-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-biomarkers-associated-with-hyperprogression-hp-to-immune-checkpoint-inhibitors-icis-in-chinese-hepatocellular-carcinoma-hcc-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-life-clinical-data-of-cabozantinib-for-unresectable-hepatocellular-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/trends-of-characteristics-treatment-and-prognosis-of-hepatocellular-carcinoma-in-japan-during-the-last-decade
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pd1midklrg1-tbethigh-effector-memory-t-in-the-peripheral-blood-correlates-with-tumor-response-to-combined-therapy-with-lenvatinib-and-anti-pd-1-ant
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/usefulness-of-hand-foot-skin-reaction-as-a-prognostic-marker-in-patients-with-hepatocellular-carcinoma-treated-with-sorafenib-close-cooperation-be
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/baseline-bl-liver-function-and-outcomes-in-patients-pts-with-unresectable-hepatocellular-carcinoma-hcc-in-keynote-240
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/modified-albumin-bilirubin-tnm-score-better-predictor-of-survival-in-patients-with-hepatocellular-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/response-rate-to-immune-checkpoint-inhibitors-in-patients-with-advanced-hepatocellular-carcinoma-a-systematic-review-with-quantitative-data-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pd-l1-tumor-mutational-burden-and-overall-survival-among-patients-undergoing-surgical-treatment-for-hepatocellular-carcinoma-prior-to-systemic-th
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cfdna-and-ctdna-variations-are-predictive-of-disease-progression-to-conventional-transarterial-chemoembolization-ctace-in-patients-with-hepatocel
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/imbrave150-management-of-adverse-events-of-special-interest-aesis-for-atezolizumab-atezo-and-bevacizumab-bev-in-unresectable-hcc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/regorafenib-in-patients-pts-with-unresectable-hepatocellular-carcinoma-uhcc-in-real-world-practice-in-asia-interim-results-from-the-observatio
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-experience-associated-with-caregiving-for-patients-with-intermediate-stage-hepatocellular-carcinoma-hcc-receiving-transcatheter-arterial-chem
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-dosing-of-regorafenib-reg-in-patients-pts-with-unresectable-hepatocellular-carcinoma-uhcc-interim-analysis-ia-of-the-observatio
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/analysis-of-tumor-location-related-oncologic-characteristics-of-hepatocellular-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ptpn13-inactivation-by-hepatitis-b-virus-x-regulates-metabolic-reprogramming-for-hepatocellular-carcinoma-progression
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/proof-a-multicenter-open-label-randomized-phase-iii-trial-of-infigratinib-vs-gemcitabine-cisplatin-in-patients-with-advanced-cholangiocarcino
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ramucirumab-in-patients-with-advanced-hepatocellular-carcinoma-and-elevated-alpha-fetoprotein-following-a-non-sorafenib-based-systemic-therapy-an
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/leap-012-trial-in-progress-pembrolizumab-plus-lenvatinib-and-transarterial-chemoembolization-tace-in-patients-with-intermediate-stage-hepatocell
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/keynote-937-trial-in-progress-adjuvant-pembrolizumab-in-patients-with-hepatocellular-carcinoma-hcc-and-complete-radiologic-response-after-surgic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/alter-h-004-a-phase-ii-study-of-anlotinib-combined-with-tace-as-adjuvant-therapy-in-hepatocellular-carcinoma-patients-at-high-risk-of-post-surgery
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-results-of-a-pilot-trial-of-gen-009-a-neoantigen-vaccine-containing-immunogenic-tumour-specific-neoantigens-in-combination-with-pd-1-inh
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/addition-of-dendritic-cell-vaccines-to-neoadjuvant-chemotherapy-in-her2-negative-breast-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/first-in-human-study-of-camidanlumab-tesirine-adct-301-cami-an-anti-cd25-targeted-therapy-in-patients-pts-with-advanced-solid-tumours-pharma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tilsotolimod-engages-the-tlr9-pathway-to-promote-antigen-presentation-and-type-i-ifn-signaling-in-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-data-from-stratum-d-of-the-phase-i-insight-platform-trial-evaluating-feasibility-of-imp321-lag-3ig-protein-eftilagimod-alpha-combined-wit
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-phase-i-insight-platform-trial-strata-a-and-b-evaluating-feasibility-of-intratumoral-and-intraperitoneal-imp321-soluble-lag-3-protein-eftila
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/camrelizumab-in-the-treatment-of-patients-with-local-advanced-metastatic-esophageal-squamous-cell-carcinoma-escc-a-multi-center-prospective-co
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/effect-of-gut-microbiota-on-immunotherapy-of-advanced-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patients-sex-and-pd-l1-expression-jointly-associated-with-overall-survival-benefits-of-immune-checkpoint-inhibitors-in-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patients-sex-and-pd-l1-expression-jointly-associated-with-overall-survival-benefits-of-immune-checkpoint-inhibitors-in-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-metastatic-location-on-immune-checkpoint-inhibitors-efficacy-in-patients-with-different-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/analysis-of-predictive-and-prognostic-soluble-biomarkers-in-advanced-non-small-cell-lung-cancer-nsclc-patients-treated-with-anti-pd1-pdl1
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-prognostic-role-of-drug-score-on-the-outcome-of-advanced-cancer-patients-treated-with-immune-checkpoint-inhibitors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/objective-response-rate-as-an-intermediate-surrogate-endpoint-to-predict-overall-survival-at-12-months
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/explore-the-efficacy-of-immune-checkpoint-inhibitors-in-non-small-cell-lung-cancer-patients-of-different-gender
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-review-of-meta-analyses-on-the-impact-of-antibiotics-on-the-efficacy-of-immune-checkpoint-inhibitors-and-cancer-patients-survival
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/predicting-response-to-checkpoint-inhibitors-using-complex-molecular-characteristic-and-immunoprofiling-in-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-prognostic-value-of-derived-neutrophil-to-lymphocyte-ratio-in-patients-treated-with-checkpoint-inhibitors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/outcomes-of-patients-with-solid-tumour-malignancies-treated-with-first-line-1l-immuno-oncology-io-agents-who-do-not-meet-eligibility-criteria-f
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/long-terms-efficacy-of-anti-pd-l-1-in-msi-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/should-i-stay-or-should-i-go-optimal-duration-for-antipd-l-1-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-and-safety-of-low-dose-immunotherapy-in-palliative-setting-of-advanced-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/does-immunotherapy-impact-the-outcomes-of-future-anti-tumour-therapies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-experience-of-tabelecleucel-in-patients-with-ebv-primary-pid-or-acquired-immunodeficiency-aid-associated-lymphoproliferative-disease
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genetic-modification-of-iovance-s-til-through-talen-mediated-knockout-of-pd-1-as-a-strategy-to-empower-til-therapy-for-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/iovance-generation-2-tumour-infiltrating-lymphocyte-til-product-is-reinvigorated-during-the-manufacturing-process
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/treatment-history-affects-bone-marrow-toxicity-after-conditioning-non-myeloablative-chemotherapy-in-adoptive-cell-therapy-in-non-melanoma-cancer-pa
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/updated-results-of-subcutaneous-sc-anti-programmed-cell-death-1-pd-1-receptor-antibody-pf-06801591-for-locally-advanced-or-metastatic-non-small
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/durvalumab-d-in-combination-with-chemoradiotherapy-crt-in-solid-tumours-phase-i-clover-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/preliminary-pharmacokinetics-pk-safety-and-efficacy-of-two-dosing-regimens-of-cs1003-anti-pd-1-in-solid-tumours-200-mg-every-3-week-q3w-and
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-single-centre-prospective-open-label-single-arm-trial-of-toripalimab-with-nab-paclitaxel-and-s-1-as-a-neoadjuvant-therapy-for-esophageal-squam
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nemio-a-randomized-phase-i-ii-trial-evaluating-efficacy-and-safety-of-dose-dense-mvac-ddmvac-durvalumab-tremelimumab-as-neoadjuvant-treatm
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/her2-xpat-a-novel-protease-activatable-pro-drug-t-cell-engager-tce-engineered-to-address-on-target-off-tumour-toxicity-and-provide-large-predi
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tcr-and-hla-analysis-of-patients-in-a-phase-i-iia-trial-of-a-therapeutic-cmv-vaccine-against-recurrent-glioblastoma-gbm
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/egfr-xpat-a-novel-pro-drug-t-cell-engager-tces-engineered-to-address-on-target-off-tumour-toxicity-and-an-orthogonal-approach-for-cancer-immuno
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/profiling-of-peripheral-t-cell-receptor-beta-chain-repertoire-in-non-small-cell-lung-cancer-nsclc-patients-treated-with-anti-pd1
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-of-a-novel-anti-ceacam1-monoclonal-antibody-and-ceacam1-up-regulation-in-tumour-infiltrating-lymphocytes-tils-of-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/adverse-events-reporting-in-phase-iii-oncology-clinical-trials-of-checkpoint-inhibitors-a-systematic-review
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/thyroid-toxicity-as-predictor-of-response-to-immunotherapy-in-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cardiac-related-deaths-in-immune-dependent-treatment-a-population-based-study-of-the-non-immunotherapy-vs-immunotherapy-era
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/rescue-chemotherapy-ct-after-immune-oncology-io-drugs-in-patients-pts-with-refractory-solid-tumours-a-propensity-score-ps-matched-cohort-s
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-multicenter-phase-ii-study-of-nivolumab-combined-with-ipilimumab-in-patients-with-pediatric-solid-tumours-in-adulthood-gethi021
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neutrophil-to-lymphocyte-ratio-predicts-survival-in-patients-with-cancer-of-unknown-primary
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sex-and-age-related-bias-in-estimating-tumour-mutation-burden-from-targeted-panel-sequencing-data
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/beyond-classical-surrogate-endpoints-in-trials-of-pd1-pd-l1-immune-checkpoint-inhibitors-ici-plus-chemotherapy-ct
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-i-first-in-human-multicenter-open-label-dose-escalation-study-of-iph5201-as-monotherapy-or-in-combination-with-durvalumab-oleclumab-i
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sgntgt-001-a-phase-i-study-of-sgn-tgt-an-effector-function-enhanced-monoclonal-antibody-mab-in-advanced-malignancies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/medi1191-a-novel-il-12-mrna-therapy-for-intratumoral-it-injection-for-advanced-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cosibelimab-an-anti-pd-l1-antibody-in-metastatic-cutaneous-squamous-cell-carcinoma-mcscc-preliminary-safety-and-efficacy-results-from-a-phase
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/health-related-quality-of-life-in-stage-iii-melanoma-patients-treated-with-neoadjuvant-ipilimumab-and-nivolumab-followed-by-index-lymph-node-excisi
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cemiplimab-for-advanced-cutaneous-squamous-cell-carcinoma-real-life-experience
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/time-to-clinically-meaningful-changes-in-pain-in-patients-with-advanced-cutaneous-squamous-cell-carcinoma-treated-with-cemiplimab-in-a-phase-ii-cli
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/performance-of-salamanca-s-refinement-of-the-ajcc8-for-t3-cutaneous-squamous-cell-carcinoma-cscc-versus-the-brigham-and-women-s-hospital-s-alter
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-features-of-the-tumour-microenvironment-and-the-tumour-budding-identify-prognostic-subgroups-in-high-risk-cutaneous-squamous-cell-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/demographics-prior-therapies-and-reasons-for-cemiplimab-treatment-prospective-cemiplimab-rwlc-survivorship-and-epidemiology-c.a.s.e.-study-in-p
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exosomal-microrna-in-serum-is-a-prognostic-factor-in-cutaneous-squamous-cell-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinicopathologic-risk-factors-for-large-cell-transformation-in-patients-with-sezary-syndrome
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/4-year-relapse-free-survival-rfs-overall-survival-os-and-long-term-toxicity-of-neo-adjuvant-ipilimumab-ipi-nivolumab-nivo-in-macroscopi
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neoadjuvant-cytoreductive-treatment-with-braf-mek-inhibition-of-prior-unresectable-regionally-advanced-melanoma-to-allow-complete-surgical-resectio
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/restricted-mean-survival-time-rmst-and-cure-rate-modeling-in-estimating-survival-benefit-with-adjuvant-dabrafenib-d-plus-trametinib-t-treatme
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/near-real-time-intraoperative-melanoma-diagnosis-using-deep-neural-networks
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-benefit-in-brafv600-mutation-positive-melanoma-defined-by-programmed-death-ligand-1-pd-l1-and-or-lactate-dehydrogenase-ldh-status-exp
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/long-term-survival-of-real-world-advanced-melanoma-patients-treated-with-targeted-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nivolumab-nivo-monotherapy-or-combination-therapy-with-ipilimumab-nivo-ipi-in-advanced-melanoma-patients-with-brain-metastases-real-world-evid
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/estimating-long-term-survivorship-in-patients-with-advanced-melanoma-treated-with-immune-checkpoint-inhibitors-analyses-from-the-phase-iii-checkma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/international-experience-of-ipilimumab-and-nivolumab-in-patients-with-advanced-melanoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-outcomes-to-checkpoint-inhibitors-in-nras-mutated-metastatic-melanoma-mm-compared-with-wild-type-braf-nras-an-italian-melanoma-intergro
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-rw-sequencing-outcomes-with-immunotherapy-and-targeted-therapy-tt-in-braf-metastatic-melanoma-the-noble-study-series
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/chinese-subgroup-results-from-an-open-label-phase-iia-study-of-dabrafenib-plus-trametinib-in-asian-patients-with-advanced-braf-v600-mutant-melanom
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-of-salvage-therapies-after-failure-of-anti-pd-1-monotherapy-for-advanced-melanoma-in-an-asian-population-a-multi-institutional-historical
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/suboptimal-real-world-rw-outcomes-for-braf-metastatic-melanoma-mm-patients-in-2l-therapy-the-noble-study-series
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/intralesional-therapy-with-talimogene-laherparepvec-for-stage-iiib-ivm1a-melanoma-is-able-to-achieve-a-high-rate-of-complete-and-durable-responses
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/mortality-prediction-in-real-world-advanced-melanoma-patients-treated-by-anti-pd1-within-melbase-a-french-multicentric-prospective-cohort
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-real-world-study-of-vemurafenib-plus-anti-pd-1-antibody-in-chinese-patients-with-advanced-braf-v600-mutant-melanoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/association-between-hospital-stays-with-infection-and-overall-survival-in-patients-treated-with-ipilimumab-analysis-of-the-french-nationwide-exhau
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-clinical-outcomes-with-pembrolizumab-pembro-for-treatment-of-advanced-melanoma-evidence-from-the-united-states-community-oncology-set
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/retrospective-analysis-of-safety-in-elderly-braf-v600-mutation-positive-advanced-melanoma-patients-treated-with-dabrafenib-d-and-trametinib-t-a
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immunotherapy-in-octogenarian-and-nonagenarian-metastatic-melanoma-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/targeted-treatment-and-immunotherapy-in-older-patients-with-advanced-melanoma-a-single-institution-real-life-experience
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/post-approval-trials-versus-patient-registries-comparability-of-advanced-melanoma-patients-with-brain-metastases
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/factors-predicting-overall-survival-os-and-progression-free-survival-pfs-in-real-life-classification-and-regression-tree-analysis-of-a-5-year
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-analysis-of-dabrafenib-plus-trametinib-in-patients-with-brafv600-mutated-melanoma-brain-metastases
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ib-study-of-rose-bengal-disodium-and-anti-pd-1-in-metastatic-cutaneous-melanoma-initial-results-in-patients-refractory-to-checkpoint-blockade
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ib-study-to-evaluate-the-safety-of-selinexor-sel-in-combination-with-pembrolizumab-pem-in-patients-with-advanced-malignancies-the-the-m
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ib-study-of-rose-bengal-disodium-and-anti-pd-1-in-metastatic-cutaneous-melanoma-results-in-patients-naive-to-immune-checkpoint-blockade
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prediction-of-clinical-outcome-by-soluble-immune-checkpoints-and-t-cell-subsets-in-patients-treated-with-immune-checkpoint-blockers-for-metastasize
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/correlation-of-braf-mutation-status-in-circulating-tumour-dna-ctdna-with-tumour-biopsy-and-clinical-outcomes-in-columbus
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/germline-variation-in-pdcd1-is-associated-with-survival-in-metastatic-melanoma-after-anti-pd-1-monotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/copy-number-alterations-in-9q-are-linked-to-prognosis-in-cutaneous-melanoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/braf-and-mek-inhibition-in-cdkn2a-germline-carriers-and-braf-mutant-melanoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/c-reactive-protein-as-biomarker-for-immune-related-adverse-events-in-melanoma-patients-treated-with-immune-checkpoint-inhibitors-in-the-adjuvant-se
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/dna-damage-repair-mutation-burden-ddrmb-was-significantly-associated-with-tmb-and-predicted-prognosis-of-immunotherapy-in-melanoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/skin-photoaging-around-the-site-of-occurrence-of-primary-melanoma-as-a-clinical-predictive-biomarker-of-response-to-pd-1-inhibitors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/braf-codon-600-mutations-in-patients-diagnosed-with-melanoma-in-the-uk-an-audit-to-assess-variation-in-mutation-frequency-methods-between-clinic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/plasma-proteomics-in-patients-with-metastatic-cutaneous-melanoma-treated-with-targeted-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/feasibility-of-linking-the-uk-100-000-genomes-project-and-real-world-evidence-databases-for-a-melanoma-patient-population
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/incidence-and-time-course-of-adverse-events-aes-with-atezolizumab-a-in-combination-with-vemurafenib-v-and-cobimetinib-c-in-the-phase-iii-im
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/delayed-immune-related-adverse-events-iraes-on-anti-pd1-based-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/long-term-safety-profile-of-pembrolizumab-monotherapy-and-relationship-with-clinical-outcome-a-pooled-analysis-of-patients-with-advanced-melanoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-digital-companion-for-patients-with-braf-mutant-advanced-melanoma-treated-with-targeted-therapies-tavie-skin-app
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/excite-an-analysis-of-the-metastatic-melanoma-patient-experience-in-the-advent-of-novel-therapies-using-health-related-social-media
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/treatment-of-metastatic-uveal-melanoma-mum-through-genomic-profiling
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nivolumab-and-ipilimumab-n-i-is-active-in-patients-pts-with-metastatic-uveal-melanoma-mum-with-extra-hepatic-only-involvement-pooled-analysi
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-predictors-of-therapeutic-benefit-from-anti-pd1-immune-checkpoint-inhibitors-ici-in-patients-pts-with-metastatic-uveal-melanoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/metabolic-activity-of-liver-metastases-may-predict-survival-in-patients-with-metastatic-uveal-melanoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/rh-endostatin-combined-with-chemotherapy-and-interferon-in-the-treatment-of-oral-mucosal-melanoma-without-clinical-cervical-lymph-node-metastasis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/primary-ipilimumab-nivolumab-immunotherapy-followed-by-adjuvant-nivolumab-in-locally-advanced-or-oligometastatic-melanoma-preliminary-results
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/multiple-primary-melanoma-incidence-trends-over-five-decades-a-nationwide-population-based-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/validation-of-a-model-combining-clinicopathologic-risk-factors-and-a-gene-expression-profile-to-identify-primary-melanoma-patients-who-can-safely-f
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/long-term-outcomes-of-stage-iib-iv-melanoma-patients-nationwide-data-from-norway
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/trends-in-melanoma-mortality-in-brazil-a-20-year-registry-based-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/influence-of-dietary-and-physical-exercise-habits-on-the-melanoma-risk-a-case-control-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ii-open-label-study-to-investigate-the-efficacy-and-safety-of-domatinostat-in-combination-with-avelumab-in-patients-with-advanced-unresect
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-randomized-prospective-multicenter-study-to-assess-the-impact-of-early-detection-of-asymptomatic-brain-metastases-mets-vs-standard-follow-up
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pan-tumour-study-checkmate-8tt-for-long-term-follow-up-of-cancer-survivors-who-have-participated-in-trials-investigating-nivolumab
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-value-of-mirna-profiling-in-neuroendocrine-neoplasias-nens-from-lung-and-gastroenteropancreatic-gep-origin
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/lanreotide-as-maintenance-therapy-after-first-line-treatment-in-patients-with-non-resectable-duodeno-pancreatic-neuroendocrine-tumours-nets-an-i
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/subgroup-analysis-by-ki-67-and-primary-tumour-origins-of-the-randomized-placebo-controlled-phase-iii-study-of-surufatinib-in-advanced-well-differe
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/silvelul-score-an-original-or-modified-immunohistochemical-score-ips-or-mips-in-patients-pts-with-pancreatic-neuroendocrine-tumours-pannet-t
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/survey-of-challenges-in-access-to-diagnostics-and-treatment-for-neuroendocrine-tumour-net-patients-scan-healthcare-quality-evaluation
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/first-line-fluoropyrimidine-and-oxaliplatin-chemotherapy-in-gastro-entero-pancreatic-grade-3-well-differentiated-neuroendocrine-tumours-net-g3
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-prognostic-role-of-dll3-expression-in-high-grade-gastroenteropancreatic-neuroendocrine-neoplasms
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genetic-characteristics-of-neuroendocrine-tumours-at-different-anatomical-sites
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/extra-pulmonary-neuroendocrine-carcinomas-a-single-center-retrospective-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/high-pre-operative-fasting-blood-glucose-levels-predict-a-poor-prognosis-in-non-diabetic-pancreatic-neuroendocrine-neoplasm-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/resunet-getne-2016-01-a-phase-ii-study-to-evaluate-the-efficacy-and-safety-of-the-rechallenge-with-sunitinib-in-g1-g2-pancreatic-neuroendocrine
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/temozolomide-alone-or-combined-with-capecitabine-for-the-treatment-of-metastatic-neuroendocrine-neoplasia-a-real-world-data-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/expression-and-clinical-significance-of-pd-l1-in-small-cell-carcinoma-of-the-esophagus
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-and-toxicity-of-chemotherapy-with-carboplatin-and-etoposide-in-elderly-patients-with-extrapulmonary-neuroendocrine-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-and-toxicity-of-chemotherapy-with-carboplatin-and-etoposide-in-elderly-patients-with-extrapulmonary-neuroendocrine-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/therapeutic-sequences-in-advanced-grade-1-2-pancreatic-neuroendocriene-tumours-pnet
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/single-institution-real-life-experience-of-177lu-dotatate-treatment-in-progressive-well-differentiated-gepnets
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-data-on-neuroendocrine-neoplasms-nens-preliminary-results-of-an-observational-study-by-the-hellenic-society-of-medical-oncology-hesmo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/baseline-neutrophil-lymphocyte-ratio-and-its-variations-after-adjuvant-radiotherapy-predict-clinical-survival-outcomes-in-locally-advanced-merkel-c
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sequential-prrt-and-sirt-evaluation-of-safety-toxicity-and-best-sequence-treatment-in-liver-dominant-gepnets
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-single-center-retrospective-analysis-of-patients-with-advanced-g3-neuroendocrine-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/18f-fdg-pet-ct-and-long-term-response-to-everolimus-in-advanced-neuroendocrine-neoplasia
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-temozolomide-tem-and-capecitabine-cap-dose-reductions-in-toxicity-and-efficacy-in-patients-pts-with-neuroendocrine-neoplasms-nens
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/characterization-of-the-gastroenteropancreatic-neuroendocrine-tumour-patient-journey
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nice-nec-a-phase-ii-study-of-platinum-doublet-chemotherapy-in-combination-with-nivolumab-as-first-line-treatment-in-subjects-with-unresectable-lo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/automated-t1-2-staging-of-lung-cancer-patients-using-deep-learning
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cun-bae-vs-bmi-as-a-breast-cancer-risk-predictor
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/breast-cancer-induces-a-tolerogenic-signalling-pathway-profile-in-cd4-lymphocytes-from-a-subset-of-primary-breast-cancer-patients-characterized-b
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-validity-of-foundationone-liquid-cdx-f1l-cdx-assay-as-an-aid-in-selecting-patients-for-treatment-with-entrectinib
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/identification-and-validation-of-circulating-tumour-dna-methylation-markers-for-lung-nodule-stratification
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-value-of-detecting-resistance-through-liquid-biopsy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/identification-of-targetable-alterations-using-ngs-based-liquid-biopsy-in-nsclc-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/changes-in-the-concentration-of-egfr-mutated-egfr-m-plasma-dna-in-the-first-hours-of-tki-therapy-allow-the-prediction-of-tumour-response-in-pati
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/digital-droplet-pcr-based-detection-of-tp53-mutations-in-circulating-dna-for-the-disease-monitoring-in-patients-with-hereditary-ovarian-or-breast-c
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/identification-of-patient-specific-immune-therapy-treatment-sensitivity-by-ex-vivo-testing
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tyrosine-kinase-activity-profiling-as-a-predictive-biomarker-for-clinical-benefit-to-immune-checkpoint-inhibition-in-advanced-melanoma-and-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-role-of-a-mini-tumour-mutational-burden-tmb-score-generated-with-a-customized-ngs-panel-to-predict-benefit-from-immunotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/identification-of-a-gene-signature-closely-related-to-immunosuppressive-tumour-microenvironment-predicting-prognosis-of-patients-in-egfr-mutant-lun
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-implication-of-clinical-decision-support-system-cdss-for-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/expression-of-cholinesterase-is-associated-with-prognosis-and-response-to-chemotherapy-in-advanced-gastric-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/facilitate-a-real-world-multicentre-prospective-study-investigating-the-utility-of-a-rapid-fully-automated-rt-pcr-assay-vs-reference-methods-rm
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/computing-hrd-score-by-a-capture-based-ngs-panel-reveal-its-prevalence-in-chinese-breast-ovarian-prostate-and-pancreatic-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neurotrophin-tyrosine-receptor-kinase-ntrk-partners-identified-by-next-generation-sequencing-in-chinese-patients-with-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/eit-pacman-study-results-oncosignal-signaling-pathway-analysis-using-ffpe-compatible-tests-identifies-actionable-cancer-targets-in-a-variety-of-ca
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-new-whole-genome-based-parpi-profiler-_alice-demonstrates-unprecedented-efficiency-in-patient-selection-for-parpi-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/discovery-and-validation-of-novel-dna-methylation-markers-for-thyroid-nodule-diagnostics-in-plasma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/early-detection-of-pancreatic-ductal-adenocarcinoma-pdac-using-methylation-signatures-in-circulating-tumour-dna
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exosomes-cargo-analysis-as-an-approach-to-identify-new-biomarkers-in-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/next-generation-sequencing-of-metastatic-prostate-cancer-targetable-alternations-in-dna-damage-repair-genes-and-beyond
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-circulating-exosomal-mirna-based-risk-score-as-a-predictive-biomarker-of-relapse-in-early-stage-non-small-cell-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/breathomics-enose-technology-as-a-non-invasive-inexpensive-point-of-care-predictive-test-to-detect-early-stage-lung-cancer-in-never-or-former-lig
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-outcome-and-toxicity-of-adjuvant-chemotherapy-in-non-small-cell-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ai-powered-prediction-of-2-year-relapse-free-survival-in-operable-nsclc-patients-using-peritumoral-radiomic-features-according-to-tumour-size-in-ch
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/proposals-for-revision-of-n-descriptors-in-the-forthcoming-edition-of-tnm-staging-for-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/surgically-resected-superior-sulcus-ss-non-small-cell-lung-cancer-nsclc-after-induction-chemo-c-and-radiotherapy-r-a-focus-on-the-immune
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/spontaneous-ventilation-video-assisted-thoracoscopic-surgery-for-geriatric-patients-with-non-small-cell-lung-cancer-a-propensity-score-matching-an
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genetic-alterations-in-swi-snf-chromatin-remodeling-complex-in-lung-adenocarcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/potential-modifiable-risk-factors-and-lung-cancer-a-mendelian-randomization-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-prognostic-value-of-textural-features-of-primary-tumour-and-systemic-inflammation-markers-in-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/curative-treatment-in-egfr-mt-nsclc-stage-iii-by-induction-tki-chemotherapy-combination-feasibility-and-outcome-in-7-cases
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comprehensive-molecular-characterization-of-chinese-patients-with-early-stage-multiple-primary-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/integrated-analysis-of-gene-expression-and-chromosomal-aberrations-to-determine-the-global-patterns-of-dna-methylation-heterogeneity-in-the-tracerx
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exploring-the-utility-of-tp53-mutations-as-prognostic-markers-in-patients-with-non-small-cell-lung-cancer-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/risk-of-cancer-in-patients-with-behcet-s-disease-a-mendelian-randomization-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/significant-impact-of-preoperative-smoking-period-on-postoperative-prognosis-in-patients-with-surgically-resected-non-small-cell-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/an-exploratory-study-of-a-pd-1-inhibitor-for-high-risk-multiple-ground-glass-nodules-mggns-in-synchronous-stage-i-non-small-cell-lung-cancer-pati
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/epidemiology-of-female-lung-cancer-in-tertiary-level-hospitals-in-bangladesh
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/symptom-monitoring-with-patient-reported-outcomes-using-a-web-application-among-lung-cancer-patients-in-the-netherlands-sympro-lung
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/perioperative-pembrolizumab-platinum-based-chemotherapy-for-resectable-locally-advanced-non-small-cell-lung-cancer-the-phase-iii-keynote-671-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/quality-of-life-with-adjuvant-gefitinib-versus-vinorelbine-plus-cisplatin-in-patients-with-completely-resected-stage-ii-iiia-n1-n2-egfr-mutant-no
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-impact-of-the-controlling-nutritional-status-conut-score-in-patients-with-stage-iii-non-small-cell-lung-cancer-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-monitoring-of-adjuvant-2-weekly-durvalumab-for-patients-with-stage-iii-nsclc-implications-for-a-4-weekly-regimen-during-the-covid-19-pandem
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/characteristics-of-the-first-615-patients-enrolled-in-pacific-r-a-study-of-the-first-real-world-data-on-unresectable-stage-iii-nsclc-patients-trea
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pathologic-response-as-early-endpoint-for-survival-following-neoadjuvant-therapy-neo-at-in-resectable-non-small-cell-lung-cancer-rnsclc-system
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/durvalumab-after-definitive-radiochemotherapy-rct-in-locally-advanced-unresectable-nsclc-real-world-data-on-survival-and-safety-from-the-german
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-role-of-surgery-for-clinical-and-pathological-n2-lung-cancer-with-interstitial-pneumonia
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/hybrid-capture-based-assays-in-primary-diagnostics-of-nsclc-patients-results-from-the-neolung-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/uptake-of-durvalumab-in-the-management-of-stage-iii-nsclc-the-real-world-application-of-pacific
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immune-checkpoint-inhibition-with-chemoradiotherapy-crt-in-stage-iii-non-small-cell-lung-cancer-a-systematic-review-of-current-evidence-and-meta
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pd-l1-expression-and-survival-in-stage-iii-unresectable-non-small-cell-lung-cancer-patients-in-denmark
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-holistic-perspective-on-plasma-proteome-changes-associated-with-response-to-anti-pd-1-treatment-in-nsclc-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exploring-quantitative-biomarkers-from-different-tumour-volumes-for-radiomics-in-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/construction-of-immune-related-and-prognostic-lncrna-clusters-and-identification-of-their-immune-and-genomic-alterations-characteristics-in-lung-ad
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-relevance-of-immune-factors-beyond-cd8-t-cells-and-mutation-status-of-egfr-and-alk-in-patients-with-non-small-cell-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/radical-radiotherapy-rt-and-chemoradiotherapy-crt-in-non-small-cell-lung-cancer-nsclc-outcomes-from-a-regional-cancer-network
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/checkmate-73l-a-phase-iii-study-comparing-nivolumab-nivo-plus-concurrent-chemoradiotherapy-ccrt-followed-by-nivo-ipilimumab-ipi-versus-ccr
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-iii-study-of-pembrolizumab-pembro-with-concurrent-chemoradiation-therapy-ccrt-followed-by-pembro-with-or-without-olaparib-ola-vs-ccrt-f
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/randomized-open-label-phase-iii-study-of-pembrolizumab-pembro-vs-docetaxel-doce-in-patients-pts-with-previously-treated-nsclc-with-pd-l1-tum
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tislelizumab-chemotherapy-vs-chemotherapy-alone-as-first-line-treatment-for-locally-advanced-metastatic-nonsquamous-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/updated-analysis-of-tislelizumab-plus-chemotherapy-vs-chemotherapy-alone-as-first-line-treatment-of-advanced-squamous-non-small-cell-lung-cancer-s
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impower150-a-post-hoc-analysis-of-efficacy-outcomes-in-patients-with-kras-stk11-and-keap1-mutations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/initial-results-from-a-phase-ii-study-tacti-002-of-eftilagimod-alpha-soluble-lag-3-protein-and-pembrolizumab-in-patients-with-pd-l1-unselected
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-of-camrelizumab-shr-1210-plus-apatinib-as-second-line-treatment-for-advanced-squamous-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/jasper-efficacy-and-safety-of-first-line-1l-niraparib-plus-a-programmed-death-receptor-1-inhibitor-pd-1i-in-patients-with-advanced-non-small-c
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/empower-lung-4-phase-ii-randomized-open-label-high-dose-or-standard-dose-cemiplimab-alone-plus-ipilimumab-in-the-second-line-treatment-of-advanc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/imscin001-phase-ib-dose-finding-study-of-subcutaneous-atezolizumab-in-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/4-year-survival-in-randomised-phase-ii-poplar-and-phase-iii-oak-studies-of-atezolizumab-atezo-vs-docetaxel-doc-in-pre-treated-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/three-year-follow-up-of-bintrafusp-alfa-a-bifunctional-fusion-protein-targeting-tgf-v-and-pd-l1-for-second-line-2l-treatment-of-non-small-cell
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/durvalumab-d-compared-to-maintenance-chemotherapy-soc-in-patients-pts-with-metastatic-non-small-cell-lung-cancer-nsclc-results-from-the-ra
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/first-line-1l-nivolumab-nivo-plus-ipilimumab-ipi-in-asian-patients-pts-with-advanced-non-small-cell-lung-cancer-ansclc-in-checkmate-227
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/extended-follow-up-of-durvast-trial-a-phase-ii-study-evaluating-durvalumab-treatment-in-hiv-1-infected-patients-with-solid-tumours-by-the-spanish
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nivolumab-treatment-in-advanced-non-small-cell-lung-cancer-ansclc-real-world-3-year-outcomes-within-overall-and-special-populations-the-univoc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/an-exosomal-mirna-signature-as-predictor-of-benefit-from-immune-checkpoint-inhibitors-in-non-small-cell-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/hyperprogressive-disease-hpd-upon-first-line-pd-1-pd-l1-inhibitors-ici-as-single-agent-or-in-combination-with-platinum-based-chemotherapy-in-no
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-kras-mutations-and-subtypes-on-efficacy-of-immune-checkpoint-inhibitors-ici-in-non-small-cell-lung-cancer-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/analysis-of-arid1a-and-arid1b-as-potential-biomarkers-for-nsclc-immunotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-prognostic-impact-of-tissue-tumour-mutational-burden-tmb-in-the-first-line-treatment-of-advanced-non-oncogene-addicted-non-small-cell-lung-ca
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/trial-based-costs-of-all-cause-adverse-events-in-first-line-therapy-for-advanced-non-small-cell-lung-cancer-findings-from-checkmate-227
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tepotinib-in-patients-pts-with-advanced-nsclc-with-met-exon-14-metex14-skipping-overall-efficacy-results-from-vision-cohort-a
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/met-inhibitor-capmatinib-plus-egfr-tyrosine-kinase-inhibitor-nazartinib-for-egfr-mutant-non-small-cell-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/capmatinib-in-patients-with-metex14-mutated-advanced-non-small-cell-lung-cancer-who-received-prior-immunotherapy-the-phase-ii-geometry-mono-1-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/activity-of-tepotinib-in-brain-metastases-bm-preclinical-models-and-clinical-data-from-patients-pts-with-met-exon-14-metex14-skipping-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-and-safety-of-entrectinib-in-locally-advanced-metastatic-italic-ros1-italic-fusion-positive-nsclc-an-updated-integrated-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-of-entrectinib-in-patients-with-italic-ntrk-italic-or-italic-ros1-italic-fusion-positive-nsclc-with-cns-metastases-at-baseline
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-and-safety-of-larotrectinib-in-patients-with-tropomyosin-receptor-kinase-trk-fusion-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-and-safety-with-selpercatinib-by-last-prior-systemic-therapy-received-in-patients-pts-with-ret-fusion-non-small-cell-lung-cancer-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/hypersensitivity-reactions-hr-to-selpercatinib-in-ret-fusion-non-small-cell-lung-cancer-nsclc-patients-pts-following-immune-checkpoint-inhib
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exploratory-patient-reported-outcomes-pros-among-patients-with-ret-fusion-non-small-cell-lung-cancer-nsclc-in-libretto-001-a-phase-i-ii-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impower150-updated-efficacy-analysis-in-patients-with-egfr-mutations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/relay-erlotinib-plus-ramucirumab-or-placebo-in-untreated-egfr-mutated-metastatic-nsclc-outcomes-by-egfr-mutation-type
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/osimertinib-vs-comparator-egfr-tki-as-first-line-treatment-for-egfr-mutated-egfrm-advanced-nsclc-flaura-china-study-overall-survival-os
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/blu-945-a-highly-potent-and-selective-4th-generation-egfr-tki-for-the-treatment-of-egfr-t790m-c797s-resistant-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/relay-ramucirumab-plus-erlotinib-ram-erl-versus-placebo-plus-erlotinib-p-erl-in-untreated-egfr-mutated-metastatic-non-small-cell-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-treatment-patterns-clinical-outcomes-and-egfr-t790m-testing-practices-in-patients-with-egfrm-advanced-nsclc-and-1l-egfr-tki-therapy-a
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/intracranial-efficacy-of-brigatinib-brg-vs-crizotinib-crz-updated-results-from-the-alta-1l-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/blood-first-assay-screening-trial-bfast-in-patients-pts-with-1l-nsclc-alk-cohort-updated-biomarker-analyses
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/lorlatinib-in-patients-with-alk-nsclc-treated-beyond-initial-disease-progression
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/lorlatinib-for-advanced-alk-non-small-cell-lung-cancer-nsclc-efficacy-and-safety-data-from-ifct-1803-lorlatu-expanded-access-program-eap-cohort
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/brigatinib-brg-vs-crizotinib-crz-in-asian-vs-non-asian-patients-pts-update-from-alta-1l
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/health-related-quality-of-life-hrqol-in-a-phase-iii-study-of-first-line-brigatinib-brg-vs-crizotinib-crz-in-nsclc-updated-results-from-alta-1l
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/platin-pemetrexed-with-or-without-bevacizumab-with-upfront-versus-at-progression-brain-radiotherapy-in-advanced-non-squamous-non-small-cell-lung
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/blood-based-genomic-profiling-of-advanced-non-small-cell-lung-cancer-ansclc-patients-pts-from-blood-first-assay-screening-trial-bfast-and-com
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/effect-of-current-treatment-evolution-in-advanced-nsclc-on-overall-survival-in-the-real-world
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/arc-4-efficacy-and-safety-of-ab928-plus-carboplatin-pemetrexed-and-a-pd-1-antibody-in-participants-with-metastatic-non-small-cell-lung-cancer-mn
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/vinmetatezo-phase-ii-trial-of-metronomic-oral-vinorelbine-mov-with-atezolizumab-atz-for-recurrent-stage-iv-nsclc-gfpc-04-18
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/first-line-1l-nivolumab-nivo-ipilimumab-ipi-chemotherapy-chemo-in-asian-patients-pts-with-advanced-non-small-cell-lung-cancer-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/chemotherapy-followed-by-immunotherapy-compared-to-reverse-sequence-in-nsclc-with-pd-l1-low-expression-pfs2-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-iii-leap-006-safety-run-in-part-1-1l-pembrolizumab-pembro-chemotherapy-chemo-with-lenvatinib-len-for-metastatic-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/blood-based-proteomic-biomarkers-for-predicting-response-to-immunotherapy-in-non-small-cell-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ib-ii-open-label-randomised-evaluation-of-atezolizumab-atezo-cpi-444-vs-docetaxel-as-second-third-line-therapy-in-morpheus-nsclc-non-sm
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/trial-based-costs-of-all-cause-adverse-events-in-first-line-therapy-for-advanced-non-small-cell-lung-cancer-findings-from-checkmate-9la
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/survival-quality-of-life-qol-and-geriatric-outcomes-of-elderly-patients-pt-with-advanced-non-small-cell-lung-cancer-nsclc-treated-with-pemb
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/association-between-soluble-pd-l1-and-prognosis-of-non-small-cell-lung-cancer-nsclc-patients-treated-with-immunotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/interdependence-of-kras-and-tp53-mutations-in-predicting-benefit-from-immune-checkpoint-inhibitor-ici-in-non-squamous-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-body-mass-index-bmi-in-non-small-cell-lung-cancer-patients-treated-with-anti-pd-1-immunotherapy-io-a-retrospective-cohort-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/advanced-lung-cancer-inflammation-index-ali-score-as-a-biomarker-of-immunotherapy-efficacy-in-patients-with-advanced-non-small-cell-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-treatment-patterns-and-immunotherapy-io-sequencing-based-on-pd-l1-tps-in-european-patients-with-metastatic-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/natural-killer-cell-activity-as-a-prognostic-biomarker-in-non-small-cell-lung-cancer-patients-treated-with-check-point-inhibitors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pembrolizumab-as-a-monotherapy-p-or-in-combination-with-platinum-based-chemotherapy-pct-in-advanced-non-small-cell-lung-cancer-ansclc-with-pd
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/long-term-survival-and-health-related-quality-of-life-in-patients-treated-with-nivolumab-for-advanced-non-small-cell-lung-cancer-a-wide-prospectiv
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/liver-metastasis-but-not-bone-metastasis-impact-overall-survival-of-advanced-non-small-cell-lung-cancer-nsclc-treated-by-nivolumab-gfpc-04-2016
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/benchmarking-the-efficacy-and-safety-of-pembrolizumab-plus-chemotherapy-to-pembrolizumab-monotherapy-a-consecutive-analysis-of-nsclc-patients-with
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-outcomes-of-pembrolizumab-plus-chemotherapy-in-non-squamous-metastatic-nsclc-patients-aged-75-years-or-older-at-us-oncology-practices
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immune-checkpoint-inhibitors-in-advanced-nsclc-patients-with-poor-performance-status-the-role-of-clinical-pathological-variables-and-inflammatory
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/discontinuation-of-icis-above-18-months-of-treatment-in-real-life-patients-with-nsclc-a-multicentric-retrospective-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/correlation-between-development-and-grade-of-immune-related-toxicities-and-outcomes-during-treatment-with-immune-checkpoint-inhibitors-in-non-small
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-value-of-baseline-and-dynamic-change-value-of-ctc-in-advanced-nsclc-patients-treated-with-immune-checkpoint-inhibitor-based-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-influence-of-polypharmacy-on-outcome-in-real-life-non-small-cell-lung-cancer-nsclc-patients-treated-with-immunotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-word-experience-with-first-line-immunotherapy-in-advanced-non-small-cell-lung-cancer-patients-in-a-danish-nationwide-cohort
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/anti-tumour-efficacy-of-cetuximab-plus-avelumab-in-nsclc-through-induction-of-adcc-final-data-from-cave-lung-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patients-with-egfr-exon-20-insertion-mutation-non-small-cell-lung-cancer-benefit-from-pemetrexed-based-chemotherapy-a-multicenter-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-clincial-utility-of-circulating-free-dna-cfdna-analysis-in-non-small-cell-lung-cancer-nsclc-in-the-united-kingdom
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/molecular-characteristics-and-response-to-immunotherapy-in-chinese-nsclc-patients-with-her2-alterations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinicopathological-characteristics-and-treatment-patterns-observed-in-real-world-care-in-patients-with-advanced-non-small-cell-lung-cancer-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-treatment-patterns-and-outcomes-in-patients-pts-with-advanced-alk-non-small-cell-lung-cancer-nsclc-in-europe
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/afatinib-in-asian-and-non-asian-patients-pts-with-egfr-mutation-positive-egfrm-nsclc-harboring-uncommon-mutations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/anlotinib-combined-with-icotinib-provides-a-promising-first-line-treatment-option-for-egfr-positive-nsclc-patients-harboring-concomitant-mutations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/correlating-osimertinib-and-erlotinib-pharmacokinetics-with-efficacy-and-toxicity-in-egfr-mutated-nsclc-patients-start-tki-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-impact-of-tp53-mutations-on-egfr-mt-nsclc-iv-patients-treated-with-3rd-generation-tki-on-second-line-or-further-line-therapy-real-world-data
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/preliminary-safety-and-activity-of-cln-081-in-nsclc-with-egfr-exon-20-insertion-mutations-ins20
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparison-of-clinical-outcomes-of-patients-with-metdex14-nsclc-treated-with-first-line-capmatinib-in-the-geometry-mono-1-study-with-those-of-a-coh
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/health-related-quality-of-life-hrqol-in-patients-pts-with-nsclc-harboring-met-exon-14-skipping-metex14-treated-with-tepotinib
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-and-safety-of-ceritinib-450-mg-fed-vs-750-mg-fasted-in-asian-patients-pts-with-alk-non-small-cell-lung-cancer-nsclc-in-the-ascend-8-t
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/lorlatinib-for-advanced-ros1-non-small-cell-lung-cancer-nsclc-efficacy-and-safety-data-from-ifct-1803-lorlatu-expanded-access-program-eap-cohort
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-treatment-outcomes-with-brigatinib-in-patients-with-pretreated-alk-metastatic-non-small-cell-lung-cancer-mnsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-impact-of-brca-mutation-status-on-nsclc-disease-course-and-response-to-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/circulating-tumour-ct-dna-next-generation-sequencing-ngs-in-advanced-non-small-cell-lung-cancer-mnsclc-a-uk-single-institution-experience
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-utility-of-circulating-tumour-ct-dna-next-generation-sequencing-ngs-for-target-identification-in-diagnostic-and-acquired-resistance-se
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/detection-of-egfr-t790m-in-egfr-activating-mutation-positive-advanced-non-small-cell-lung-cancer-nsclc-comparison-between-two-assays-on-circulat
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/value-of-rebiopsy-in-advanced-epidermal-growth-factor-receptor-mutated-non-small-cell-lung-cancer-real-world-data
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/disease-monitoring-and-tki-resistance-mutations-of-egfr-mutation-positive-nsclc-patients-via-circulating-tumour-dna
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/outcomes-of-treated-patients-with-egfr-mutated-advanced-or-metastatic-non-small-cell-lung-cancer-harboring-exon-19-deletions-or-l858r-substitution
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-and-toxicity-of-combined-inhibition-of-egfr-and-vegfr-in-advanced-non-small-cell-lung-cancer-patients-harboring-activating-egfr-mutations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-characteristics-of-advanced-nsclc-patients-with-phosphatidylinositol-4-5-bisphosphate-3-kinase-catalytic-subunit-alpha-pik3ca-mutations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/identification-of-epidermal-growth-factor-receptor-egfr-fusions-in-a-large-chinese-lung-cancer-population
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/determination-of-alk-rearrangements-in-non-small-cell-lung-cancer-clinical-and-economic-impact-of-current-practice-in-spain
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-and-real-world-outcomes-in-patients-with-epidermal-growth-factor-receptor-egfr-exon-20-insertions-in-non-small-cell-lung-cancer-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-treatment-patterns-of-patients-with-locally-advanced-metastatic-egfrm-nsclc-in-belgium-reveal
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/treatment-and-outcome-of-a-real-world-cohort-of-patients-with-advanced-non-squamous-nsclc-and-kras-mutations-with-a-special-focus-on-kras-g12c
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-prospective-phase-ii-trial-of-low-dose-afatinib-monotherapy-for-patients-with-egfr-mutation-positive-non-small-cell-lung-cancer-torg1632
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-and-safety-of-apatinib-plus-egfr-tki-in-advanced-non-small-cell-lung-cancer-with-egfr-tki-resistance-date-updated
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/treatment-duration-and-adherence-in-alk-non-small-cell-lung-cancer-patients-treated-with-brigatinib-following-prior-alk-tki-therapy-in-the-us
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/lorlatinib-in-pretreated-alk-ros1-positive-non-small-cell-lung-cancer-nsclc-results-from-the-german-early-access-program
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/egfr-t790m-ctdna-abundance-and-tp53-co-mutation-by-next-generation-sequencing-predicted-clinical-outcomes-of-osimertinib-in-non-small-cell-lung-can
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pd-l1-expression-as-a-predictive-biomarker-for-chemotherapy-response-in-metastatic-non-small-cell-lung-cancer-mnsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/randomized-phase-ii-trial-of-pemetrexed-with-or-without-bevacizumab-maintenance-after-cisplatin-pemetrexed-and-bevacizumab-in-advanced-non-squamou
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-and-safety-of-nintedanib-docetaxel-in-lung-adenocarcinoma-patients-pts-after-failure-of-previous-immune-checkpoint-inhibitor-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/difference-in-nephrotoxicity-caused-by-cisplatin-after-a-short-or-long-hydration-scheme-in-non-small-cell-lung-cancer-a-retrospective-cohort-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/docetaxel-nindetanib-as-efficient-treatment-option-after-failure-of-immune-checkpoint-inhibition-real-world-evidence
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/predicting-chemotherapy-toxicity-in-elderly-patients-with-advanced-non-small-cell-lung-cancer-a-prospective-multicenter-study-of-the-national-hosp
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/anlotinib-combination-with-docetaxol-for-patients-with-previously-treated-advanced-non-small-cell-lung-cancer-a-phase-ii-single-arm-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exploratory-analyses-of-efficacy-from-a-phase-iii-study-comparing-sb8-a-proposed-bevacizumab-biosimilar-and-reference-bevacizumab-in-patients-wit
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/is-30-day-mortality-after-systemic-anticancer-therapy-in-lung-cancer-in-the-era-of-varied-treatments-still-relevant
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-rw-clinical-outcomes-of-patients-with-metastatic-non-small-cell-lung-cancer-mnsclc-in-the-united-kingdom
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/description-of-the-clinical-characteristics-and-survival-in-patients-with-metastatic-nsclc-in-the-spanish-population-an-analysis-of-the-thoracic-t
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/spatial-statistics-based-modeling-for-predicting-treatment-response-in-non-small-cell-lung-cancer-nsclc-patients-using-h-e-pathology-images
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/automating-access-to-real-world-evidence
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/lung-cancer-in-adolescents-and-young-adults-aya-in-asia-tumour-characteristics-and-molecular-profiles
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-factors-for-survival-in-patients-with-metastatic-lung-adenocarcinoma-analysis-of-the-seer-database
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/analysis-of-drug-induced-rna-expression-changes-in-nsclc-patient-derived-explants-as-a-potential-tool-for-personalized-therapy-choice
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/anlotinib-combined-with-whole-brain-radiation-therapy-wbrt-for-advanced-non-small-cell-lung-cancer-with-multiple-brain-metastases-an-open-label
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ib-study-of-lxh254-ltt462-in-patients-with-kras-or-braf-mutant-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/poziotinib-in-advanced-nsclc-with-egfr-or-her2-exon-20-insertion-mutation-initial-results-from-a-single-site-expanded-access-program
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ifct-1602-chiva2-phase-ii-trial-nivolumab-in-previously-treated-hiv-patients-with-advanced-non-small-cell-lung-cancer-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-adding-viagenpumatucel-l-to-nivolumab-in-non-small-cell-lung-cancer-nsclc-patients-with-low-levels-of-tumour-infiltrating-lymphocytes
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-iii-confirmatory-efficacy-and-safety-study-of-proposed-bevacizumab-biosimilar-myl-1402o-compared-with-avastin-in-the-first-line-treatment
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/risk-of-sars-cov2-related-mortality-in-non-small-cell-lung-cancer-patients-treated-with-first-line-immune-oncology-alone-or-in-combination-with-che
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/brigatinib-in-patients-with-alk-positive-advanced-non-small-cell-lung-cancer-pretreated-with-sequential-alk-inhibitors-a-multicentric-real-world-s
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/deep-learning-model-to-predict-clinical-outcomes-in-patients-with-advanced-non-small-cell-lung-cancer-treated-with-immune-checkpoint-inhibitors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/who-will-maintain-as-long-term-responders-more-than-3-years-with-first-or-second-generation-egfr-tki-among-egfr-mutant-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/development-and-validation-of-a-host-dependent-pdl1-independent-biomarker-to-predict-6-month-progression-free-survival-in-metastatic-non-small-ce
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/high-incidence-of-treatment-related-adverse-events-after-combination-egfr-tyrosine-kinase-inhibitor-and-immune-checkpoint-inhibitors-in-egfr-mutate
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-life-progression-pd-pattern-of-egfr-mutant-advanced-non-small-cell-lung-cancer-ansclc-patients-pts-receiving-systemic-therapy-after-firs
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-efficacy-of-dostarlimab-in-patients-pts-with-recurrent-advanced-non-small-cell-lung-cancer-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/vibostolimab-an-anti-tigit-antibody-as-monotherapy-and-in-combination-with-pembrolizumab-in-anti-pd-1-pd-l1-refractory-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/osimertinib-plus-platinum-pemetrexed-in-newly-diagnosed-egfr-mutation-egfrm-positive-advanced-nsclc-safety-run-in-results-from-the-flaura2-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/egfr-mutation-testing-and-tki-treatment-patterns-in-locally-advanced-or-metastatic-nsclc-in-norway-a-nationwide-cohort-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/epidermal-growth-factor-receptor-mutation-egfrm-testing-in-advanced-non-small-cell-lung-cancer-ansclc-in-a-real-world-setting
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immune-microenvironment-could-be-responsible-for-response-to-immune-checkpoint-inhibitors-among-nsclc-patients-with-various-egfr-mutation-types
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/survival-of-patients-with-non-small-cell-lung-cancer-and-exon-20-insertion-mutation-from-the-czech-republic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/external-quality-assessment-of-immunohistochemistry-in-situ-hybridization-and-rna-dna-sequencing-for-ros1-testing-reveals-high-concordance-for-all
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/lymphocyte-subsets-predict-clinical-outcomes-of-advanced-non-small-cell-lung-cancer-patients-treated-with-platinum-based-chemotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-landscape-of-ros1-fusion-in-patients-with-non-small-cell-lung-cancer-in-china
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparing-different-methods-of-fgfr1-aberrations-analysis-in-squamous-cell-lung-cancer-sqclc-targeted-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-efficacy-of-vibostolimab-an-anti-tigit-antibody-plus-pembrolizumab-in-patients-with-anti-pd-1-pd-l1-naive-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/gfpc-06-2018-a-multicenter-non-randomized-phase-ii-study-evaluating-platinum-pemetrexed-atezolizumab-bevacizumab-for-patients-with-stage-iiib
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/mobocertinib-tak-788-as-first-line-treatment-vs-platinum-based-chemotherapy-ct-for-nsclc-with-egfr-exon-20-insertions-exon20ins
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/libretto-431-selpercatinib-in-treatment-tx-naive-patients-with-ret-fusion-positive-ret-non-small-cell-lung-cancer-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/evaluating-telisotuzumab-vedotin-in-combination-with-osimertinib-in-patients-with-advanced-non-small-cell-lung-cancer-a-phase-i-ib-study-cohort
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/insight-2-tepotinib-osimertinib-in-patients-pts-with-egfr-mutant-nsclc-having-acquired-resistance-to-first-line-osimertinib-due-to-met-amplifi
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/codebreak-200-a-phase-iii-multicenter-study-of-sotorasib-amg-510-a-kras-g12c-inhibitor-versus-docetaxel-in-patients-with-previously-treated-a
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immunotherapy-chemotherapy-and-stereotactic-radiotherapy-to-metastases-followed-by-definitive-surgery-or-radiotherapy-to-the-primary-tumour-in-p
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/randomized-placebo-controlled-phase-iii-study-of-1l-pembrolizumab-pembro-plus-carboplatin-taxane-followed-by-pembro-with-or-without-maintenance
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-i-ii-trial-of-radium-223-ra-223-in-combination-with-pembrolizumab-in-patients-pts-with-stage-iv-non-small-cell-lung-cancer-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/arc-7-a-phase-ii-study-to-evaluate-the-safety-and-efficacy-of-zimberelimab-alone-ab154-in-combination-with-zimberelimab-and-ab154-in-combination
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/gender-differences-in-treatment-characteristics-and-outcomes-of-esophagogastric-cancer-surgery-data-from-the-dutch-upper-gi-cancer-audit
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ii-study-of-neoadjuvant-concurrent-chemoradiotherapy-with-apatinib-for-her-2-negative-siewert-type-ii-and-iii-adenocarcinoma-of-esophagogas
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/apatinib-combined-with-docetaxel-in-second-line-treatment-of-advanced-gastric-cancer-a-prospective-clinical-study-data-updated
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ii-trial-of-perioperative-mdcf-avelumab-in-locally-advanced-gastroesophageal-adenocarcinoma-safety-efficacy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patient-reported-outcome-pro-results-from-agitg-doctor-a-randomised-phase-ii-trial-of-tailored-neoadjuvant-therapy-for-resectable-oesophageal-ad
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/study-on-the-safety-and-efficacy-of-apatinib-combined-with-concurrent-chemoradiotherapy-in-the-treatment-of-non-operative-oesophageal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-and-safety-of-large-field-postoperative-radiotherapy-using-3d-radiation-technique-for-locally-advanced-thoracic-esophageal-squamous-cell-c
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-on-work-productivity-in-unresectable-locally-advanced-or-metastatic-gastric-cancer-gastroesophageal-junction-cancer-and-esophageal-adenocar
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-prospective-multicenter-non-randomized-controlled-trial-of-apatinib-plus-perioperative-chemotherapy-with-flot-protocol-and-surgery-for-the-tre
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/survival-of-t1a-of-gastric-signet-ring-cell-carcinoma-for-guidance-of-safe-endoscopic-treatment-analysis-of-collaborative-stage-data-of-korean-cen
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparison-of-perioperative-chemotherapy-versus-postoperative-chemoradiation-therapy-for-operable-stomach-cancer-a-western-canadian-province-exper
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-outcome-of-neoadjuvant-flot-chemotherapy-in-east-sussex-uk-a-comparison-study-to-flot4
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/can-fdg-pet-predict-early-disease-relapse-in-patients-receiving-peri-operative-flot-for-localised-oesophago-gastric-adenocarcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ii-study-to-evaluate-feasibility-and-safety-of-oral-nutritional-supplementation-with-high-density-liquid-diet-after-total-gastrectomy-for-pat
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-efficacy-of-flot-regimen-neoadjuvant-treatment-in-polish-population-interim-analysis-of-prospective-biomarker-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/outcomes-of-neoadjuvant-chemoradiation-ncrt-surgery-and-definitive-crt-dcrt-in-a-single-institution-using-the-cross-trial-regimen-in-esopha
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/association-of-tmb-using-the-foundation-medicine-companion-diagnostic-f1cdx-with-efficacy-of-first-line-pembrolizumab-pembro-or-pembro-plus-che
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/modified-folfox-versus-modified-folfox-plus-nivolumab-and-ipilimumab-in-patients-with-previously-untreated-advanced-or-metastatic-adenocarcinoma-of
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-nivolumab-safety-data-from-650-patients-with-unresectable-advanced-or-recurrent-gastric-cancer-that-had-progressed-after-cancer-chemothe
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cs1001-an-anti-pd-l1-antibody-combined-with-standard-of-care-soc-chemotherapy-for-first-line-1l-advanced-gc-gej-and-escc-preliminary-results
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/initial-safety-and-efficacy-findings-with-bavituximab-plus-pembrolizumab-in-patients-with-advanced-gastric-or-gastroesophageal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/s-1-maintenance-therapy-in-non-asian-patients-with-advanced-her-2-negative-esophagogastric-adenocarcinoma-first-results-of-the-international-mat
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/paclitaxel-and-cisplatin-combined-with-anlotinib-as-first-line-regimen-for-advanced-esophageal-squamous-cell-carcinoma-escc-a-single-arm-multic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/hospital-volume-and-beyond-first-line-palliative-systemic-treatment-administration-in-metastatic-esophagogastric-adenocarcinoma-a-population-based
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-and-safety-analysis-of-modified-biweekly-sox-regimen-in-the-first-line-treatment-of-advanced-gastric-adenocarcinoma-or-esophagogastric-jun
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparative-response-evaluation-of-cisplatin-capecitabine-with-cisplatin-5-fluorouracil-in-advanced-gastric-carcinoma-a-quasi-experimental-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-i-study-of-apatinib-plus-pof-paclitaxel-plus-folfox-in-patients-pts-with-treatment-naive-advanced-gastric-cancer-tnagc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-efficacy-of-vactosertib-a-tgf-vr1-kinase-inhibitor-in-combination-with-paclitaxel-in-patients-with-metastatic-gastric-adenocarcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/parafirigast-paclitaxel-ramucirumab-versus-folfiri-as-second-line-chemotherapy-of-metastatic-gastric-cancer-an-ageo-multicenter-comparative-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-single-arm-open-label-prospective-multicenter-study-of-apatinib-combined-with-chemotherapy-as-second-line-therapy-in-patients-with-advanced-ga
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/retrospective-comparative-analysis-of-s-1-and-oxaliplatin-or-cisplatin-as-first-line-therapy-in-metastatic-gastric-cancer-in-a-european-population
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-survival-in-advanced-gastro-oesophageal-adenocarcinoma-with-best-supportive-care
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-treatment-patterns-of-unresectable-advanced-or-synchronous-metastatic-esophageal-squamous-cell-cancer-in-a-western-population
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/albumin-as-a-simple-criterion-to-reduce-early-mortality-em-in-gastric-cancer-gc-trials
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-sites-of-metastatic-dissemination-on-survival-in-advanced-gastroesophageal-adenocarcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sex-differences-in-treatment-and-survival-of-patients-with-unresectable-or-metastatic-esophagogastric-cancer-a-population-based-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-impact-of-clinical-and-laboratory-nutritional-markers-in-resectable-gastroesophageal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-relevance-of-weight-loss-during-a-perioperative-chemotherapy-for-locally-advanced-gastric-cancer-gc-and-tumours-of-the-gastroesophagea
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/asian-ethnicity-related-differences-among-patients-with-metastatic-gastroesophageal-junction-gej-and-gastric-adenocarcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-nationwide-population-based-study-comparing-treatment-patterns-and-outcomes-in-synchronous-versus-metachronous-metastatic-esophageal-and-gastric
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-implications-of-neutrophil-to-lymphocyte-ratio-and-mdsc-kinetics-in-gastric-cancer-patients-treated-with-ramucirumab-plus-paclitaxel
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-development-and-verification-of-nomogram-to-predict-the-survival-prognosis-of-patients-with-esophageal-squamous-cell-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/characteristics-and-prognosis-of-gastric-cancer-gc-in-adolescents-and-young-adults-aya-in-singapore
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-humanistic-burden-reported-by-patients-with-unresectable-locally-advanced-or-metastatic-adv-met-gastric-cancer-gc-gastroesophageal-junctio
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/urban-rural-differences-in-outcomes-of-patients-with-advanced-gastroesophageal-cancers
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/3d-patient-derived-gastric-cancer-organoids-as-a-tool-for-functional-precision-medicine-for-gastric-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/association-among-blood-transfusion-post-operative-infectious-complications-and-cancer-specific-survival-in-patients-with-stage-ii-iii-gastric-ca
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/parameters-of-complete-blood-count-might-predict-the-prognosis-of-patients-with-advanced-gastric-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immune-inflammatory-indexes-and-bmi-as-predictors-of-outcome-and-treatment-response-in-advanced-gastric-cancer-receiving-ramucirumab-containing-sec
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/negative-impact-of-intraoperative-blood-loss-on-long-term-outcome-after-curative-gastrectomy-for-ct3-4a-gastric-cancer-exploratory-analysis-of-jc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nutritional-index-for-immune-checkpoint-inhibitors-ici-nutrici-for-patients-pts-with-metastatic-gastro-oesophageal-junction-goj-gastric-can
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-clinical-value-of-prognostic-nutritional-index-in-esophagogastric-junctional-adenocarcinoma-patients-with-anastomotic-leakage-after-surgery
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/flvcr1-predicts-poor-prognosis-and-promotes-malignant-phenotype-in-esophageal-squamous-cell-carcinoma-via-upregulating-cse1l
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinicopathological-and-genomic-characteristics-of-dna-mismatch-repair-deficient-dmmr-and-microsatellite-instability-high-msi-h-resected-gastri
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/m2-macrophages-could-promote-an-immunosuppressive-phenotype-in-a-prospective-cohort-of-advanced-gastric-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/expression-of-erbb2-and-pd1-mrna-in-advanced-gastric-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comprehensive-molecular-profiling-and-identification-of-prognostic-factors-in-patients-with-resectable-esophageal-squamous-cell-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tumor-volume-dynamic-change-during-radiotherapy-as-a-potential-prognostic-factor-for-short-term-effect-in-patients-with-esophageal-squamous-cell-ca
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-baseline-pi3kca-expression-on-outcomes-with-first-line-eox-or-eox-plus-aspirin-in-advanced-gastric-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/response-prediction-using-nanostring-ncounter-technology-and-ngs-panel-sequencing-in-neoadjuvant-chemotherapy-in-patients-with-esophagogastric-aden
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-impact-of-ct-based-body-composition-parameters-on-survival-outcomes-in-western-patients-pts-with-resected-gastric-and-gastroesophageal-juncti
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-impact-of-thyroid-hormone-status-in-resectable-gastroesophageal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-prognostic-biomarker-study-in-patients-who-underwent-surgery-or-received-chemoradiotherapy-for-clinical-stage-i-esophageal-squamous-cell-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/liquid-biopsy-forecasted-disease-progression-and-indicated-therapeutic-improvement-for-gastric-cancer-patients-receiving-her2-targeted-regimen
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/evaluation-of-circulating-tumor-cells-in-esophageal-carcinoma-patients-who-received-chemotherapy-or-neoadjuvant-chemotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/bespoke-circulating-tumor-dna-assay-for-the-detection-of-minimal-residual-disease-in-esophageal-adenocarcinoma-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/investigation-of-dna-damage-repair-mutations-and-correlation-with-immunogenic-biomarker-in-chinese-esophageal-squamous-cell-carcinoma-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/an-integrated-analysis-of-gene-expression-profile-and-chromosomal-aberrations-highlighted-the-oxidative-stress-role-in-anti-her2-drug-resistant-gas
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/updated-safety-data-of-the-dante-trial-perioperative-atezolizumab-in-combination-with-flot-versus-flot-alone-in-patients-with-resectable-esophagog
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/folfiri-plus-ramucirumab-versus-paclitaxel-plus-ramucirumab-as-second-line-therapy-for-patients-with-advanced-or-metastatic-gastroesophageal-adenoc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-i-study-evaluating-safety-and-tolerability-of-amg-910-a-half-life-extended-bispecific-t-cell-engager-targeting-claudin-18.2-cldn18.2-in-ga
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/reaction-a-phase-ib-pilot-study-of-nivolumab-or-nivolumab-in-combination-with-relatlimab-after-targeted-radiation-in-patients-with-advanced-esoph
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-multi-center-randomized-open-label-phase-iii-study-of-sintilimab-ramucirumab-as-1st-line-treatment-for-advanced-gastric-or-gastroesophageal
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/folfiri-plus-ramucirumab-versus-paclitaxel-plus-ramucirumab-for-taxane-pretreated-patients-with-advanced-or-metastatic-adenocarcinoma-of-the-stomac
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ib-ii-multicenter-open-label-dose-escalation-and-dose-expansion-study-evaluating-trastuzumab-deruxtecan-t-dxd-ds-8201-monotherapy-and
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/changes-in-the-tumour-immune-microenvironment-in-oesophageal-squamous-cell-carcinoma-patients-receiving-different-neoadjuvant-therapies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/paclitaxel-ramucirumab-versus-paclitaxel-alone-in-patients-with-squamous-cell-carcinoma-of-the-esophagus-refractory-or-intolerant-to-combination
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-prospective-study-of-apatinib-in-combination-with-neoadjuvant-concurrent-chemoradiotherapy-for-locally-advanced-esophageal-squamous-cell-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-predictive-value-of-2-d-myocardial-strain-for-epirubicin-induced-cardiotoxicity
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-retrospective-study-of-angiotensin-converting-enzyme-inhibitors-or-beta-blockers-to-prevent-trastuzumab-induced-cardiotoxicity
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-efficacy-and-patients-satisfaction-of-initial-peripherally-inserted-central-catheters-compared-with-usual-intravenous-access-in-terminall
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-differential-diagnosis-of-cachexia-and-refractory-cachexia-and-appropriate-nutritional-support-for-cachexia-on-survival-in-terminal-cance
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/effects-and-feasibility-of-home-parenteral-nutrition-hpn-in-cancer-patients-with-or-without-migrant-background
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-real-world-study-of-pyrotinib-in-patients-with-her-2-positive-mutations-tumors-excluding-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/therapeutic-de-escalation-and-decision-making-in-early-breast-cancer-a-radiotherapy-option-grid-developed-and-implemented-in-france
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/palliative-care-unit-pcu-at-home-impact-on-emergency-room-visits-and-the-number-of-hospital-admissions-in-cancer-patients-at-the-end-of-life-in
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patient-reported-outcomes-of-early-integration-palliative-care-in-quality-of-life-and-symptom-burden-in-advanced-lung-cancer-a-randomized-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/aggressiveness-and-economic-impact-of-advanced-cancer-treatment-near-the-end-of-life
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-implementation-of-serious-illness-care-program-sicp-in-cancer-care
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/integration-of-the-palliative-care-team-with-oncologic-care-in-a-tertiary-cancer-center-in-brazil-perception-of-patients-and-healthcare-profession
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/survey-on-knowledge-and-attitudes-of-emergency-medicine-physicians-towards-practice-scope-and-integration-of-palliative-medicine-services-in-the-e
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/survey-on-knowledge-and-attitudes-of-emergency-medicine-physicians-towards-practice-scope-and-integration-of-palliative-medicine-services-in-the-e2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/effect-of-molecular-targeting-agents-and-immune-checkpoint-inhibitors-use-near-the-end-of-life-patients-with-advanced-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/polypharmacy-and-therapeutic-futility-in-patients-near-the-end-of-life
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/effect-of-end-of-life-care-questionnaire-on-participant-mood-level
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/mindfulness-and-buddhist-practices-among-buddhist-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sleep-disorders-among-tunisian-cancer-patients-prevalence-and-potential-risk-factors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/first-and-second-line-palliative-systemic-treatment-outcomes-in-a-real-world-metastatic-pancreatic-cancer-cohort
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/assessing-clinical-benefit-of-olaparib-maintenance-treatment-in-subgroups-of-patients-with-germline-brca-mutation-gbrcam-and-metastatic-pancreati
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-i-trial-of-the-first-in-class-agent-cend-1-in-combination-with-gemcitabine-and-nab-paclitaxel-in-patients-with-metastatic-pancreatic-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/first-line-1l-liposomal-irinotecan-5-fluorouracil-leucovorin-5-fu-lv-oxaliplatin-ox-in-patients-with-locally-advanced-or-metastatic-pancr
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/gemcitabine-nab-paclitaxel-versus-modified-folfirinox-for-palliative-first-line-treatment-of-advanced-pancreatic-cancer-a-propensity-score-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/folfirinox-relative-dose-intensity-rdi-and-disease-control-in-advanced-pancreatic-cancer-patients-apc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nab-paclitaxel-plus-s1-with-or-without-sintilimab-in-metastatic-pancreatic-ductal-adenocarcinoma-a-single-center-retrospective-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-life-data-from-the-platform-for-outcome-quality-of-life-and-translational-research-on-pancreatic-cancer-paragon
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/multivariable-analysis-of-real-world-clinical-outcomes-associated-with-dose-reductions-drs-for-patients-pts-with-metastatic-pancreatic-ductal-a
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/paclitaxel-based-intraperitoneal-chemotherapy-for-gastric-and-pancreatic-cancer-with-peritoneal-metastases-achieves-higher-conversion-surgery-rate
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/chemotherapy-vs-best-supportive-care-in-octogenarian-and-older-stage-iv-pancreatic-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-i-ii-study-with-cxcl12-inhibitor-nox-a12-and-pembrolizumab-in-patients-with-microsatellite-stable-metastatic-colorectal-or-pancreatic-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/deleterious-germline-mutations-in-patients-with-pancreatic-ductal-adenocarcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/signature-protein-biomarkers-in-serum-for-diagnosis-of-pancreatic-ductal-adenocarcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comprehensive-molecular-profiling-of-pancreatic-ductal-adenocarcinoma-in-chinese-population
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-genomic-features-of-chinese-pancreatic-adenocarcinoma-and-the-implications-for-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/untargeted-metabolomics-to-identify-novel-biomarkers-of-pancreatic-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-relevance-of-somatic-and-germline-alterations-in-patients-with-pancreatic-ductal-adenocarcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/use-of-pharmacokinetic-parameters-of-preoperative-5-fu-as-a-prognostic-factor-in-resected-pancreatic-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/dna-damage-repair-ddr-gene-mutations-mut-are-predictors-of-response-to-platinum-based-chemotherapy-in-advanced-pancreatic-cancer-pc-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-role-of-tumoral-dna-damage-repair-protein-expression-in-patients-with-resectable-pancreatic-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/project-survival-R-high-fidelity-longitudinal-phenotypic-and-multi-omic-characterization-of-pancreatic-ductal-adenocarcinoma-pdac-for-biomarker-d
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/favourable-prognostic-significance-of-membranous-v-catenin-expression-and-negative-prognostic-significance-of-cytoplasmic-v-catenin-expression-in-p
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/molecular-alterations-ma-with-potential-therapeutic-implications-in-kras-wild-type-wt-pancreatic-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/combination-therapy-of-low-molecular-weight-heparins-chemotherapy-and-immunotherapy-induce-antitumor-activity-in-pancreatic-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/validation-of-response-and-survival-biomarkers-in-a-phase-ii-trial-of-bpm-31510-iv-in-advanced-refractory-pancreatic-ductal-adenocarcinoma-pdac
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patterns-of-venous-and-arterial-thromboembolism-in-patients-with-advanced-pancreatic-cancer-treated-with-palliative-first-line-chemotherapy-of-gemc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/incidence-of-and-risk-factors-for-venous-thromboembolism-in-patients-with-pancreatic-ductal-adenocarcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/can-thromboprophylaxis-impact-pfs-in-patients-with-advanced-pancreatic-cancer-intermediate-results-of-pact-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-treatment-patterns-and-effectiveness-of-liposomal-irinotecan-in-a-napoli1-based-regimen-among-patients-with-metastatic-pancreatic-ductal
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/extended-pancreatectomy-in-patients-with-pancreatic-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-and-epidemiological-characteristics-of-pancreatic-acinar-cell-carcinoma-a-study-from-the-united-states
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-and-epidemiological-characteristics-of-pancreatic-acinar-cell-carcinoma-a-study-from-the-united-states
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/chemotherapy-related-changes-of-peripheral-blood-lymphocytes-in-advanced-and-metastatic-pdac
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sarcopenia-and-sarcopenic-obesity-in-pancreatic-ductal-adenocarcinoma-pdac-patients-undergoing-surgery-after-neoadjuvant-therapy-nat-prevalenc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/anemia-and-iron-deficiency-id-in-association-with-tissue-iron-regulators-hepcidin-ferroportin-and-zip14-expression-in-patients-with-pancreatic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/observational-prospective-study-of-italian-guidelines-application-for-patients-with-pancreatic-ductal-adenocarcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/early-clinical-trials-in-patients-with-pancreatic-cancer-assessment-of-factors-limiting-eligibility-and-effectiveness
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-pathway-implications-and-real-world-characteristics-and-outcomes-for-patients-with-metastatic-pancreatic-ductal-adenocarcinoma-mpdac-tre
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-outcome-after-perioperative-treatment-on-locally-advanced-and-borderline-pancreatic-cancer-experience-of-a-single-academic-center
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prodige-65-ucgi-36-gempax-a-unicancer-phase-iii-randomized-study-evaluating-gemcitabine-and-paclitaxel-versus-gemcitabine-alone-after-folfiri
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-iii-trial-of-tumor-treating-fields-with-nab-paclitaxel-and-gemcitabine-for-front-line-treatment-of-locally-advanced-pancreatic-adenocarcino
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/integrating-patients-quality-of-life-qol-into-clinical-practice-a-delphi-method-based-consensus-among-french-physicians-managing-lung-cancer-pa
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-emotional-impact-of-covid-19-outbreak-on-cancer-out-patients-and-their-caregivers-impressions-from-the-heart-of-the-italian-pandemic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/chemotherapy-in-the-covid-19-era-the-patient-s-perception
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/psychological-impact-of-the-covid-19-pandemic-on-health-care-workers-in-oncology-in-tunisia
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/anxiety-and-depression-in-cancer-patients-during-the-covid-19-pandemic-a-single-centre-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-cognitive-affective-social-and-environmental-drivers-of-inappropriate-ovarian-cancer-screening-a-survey-of-women-and-their-clinicians-using
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/psychological-burden-in-mothers-of-children-with-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/marital-status-and-sexual-health-in-breast-cancer-survivors-a-cross-sectional-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/depression-and-anxiety-in-testicular-cancer-survivors-in-india
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/covid-19-and-hospitalised-cancer-patients-now-it-s-time-for-patients-to-talk
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/burnout-among-oncology-professionals-in-the-middle-east-and-north-africa-mena
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/fear-of-cancer-recurrence-among-young-adult-cancer-survivors-exploring-long-term-contributing-factors-in-a-large-population-based-cohort
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/whole-exome-sequencing-evolution-of-indications-and-cost-to-inform-public-health-policy-decision-making
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prices-and-price-developments-of-cancer-drugs-in-the-us-and-europe
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/harmonising-patient-access-programmes
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/connecting-primary-care-with-oncology-through-the-implementation-a-cancer-fast-track-program-reducing-time-from-initial-symptoms-to-diagnosis-and
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/could-population-based-cancer-registries-contribute-to-breast-cancer-screening-assessment
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/lung-cancer-screening-a-systematic-review
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/assessment-of-breast-cancer-awareness-screening-campaigns-by-analysing-stages-trends-of-lebanese-female-patients-a-retrospective-study-2012-2017
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/what-do-carers-know-a-study-evaluating-breast-cancer-knowledge-among-carers-of-breast-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/estimated-years-of-potential-life-lost-due-to-absence-of-pembrolizumab-in-sus
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/low-dose-pembrolizumab-is-effective-in-the-treatment-of-advanced-non-small-cell-lung-cancer-nsclc-with-reduced-cost
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/estimated-years-of-potential-life-lost-from-lack-of-access-to-crizotinib-nsclc-alk
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/can-we-reduce-the-acquisition-cost-of-car-t-cell-therapies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/aggregated-analysis-of-treatment-and-survival-outcome-of-all-metastatic-renal-cell-carcinoma-patients-treated-from-2014-to-2018-in-the-veneto-regio
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/number-of-untimely-deaths-prevented-with-alk-inhibitors-in-brazilian-patients-with-advanced-non-small-cell-lung-cancer-with-alk-driver-mutations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/developing-a-readiness-assessment-framework-for-radioligand-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-impact-of-absolute-neutrophil-count-on-clinical-trial-participation-in-the-united-states
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/publication-rate-and-characteristics-of-cancer-clinical-trials-in-india
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cancer-care-in-croatia-comparison-with-surrounding-countries-can-we-do-better
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/undergraduate-education-in-medical-oncology-lags-behind-in-greek-universities
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/healthcare-resource-utilization-hcru-and-costs-in-patients-pts-with-advanced-cancer-treated-with-immune-checkpoint-inhibitors-icis-who-experi
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-evidence-data-rwed-of-financial-toxicity-ft-in-cancer-patients-pts-receiving-immunotherapy-drugs-iot
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/an-estimate-of-the-2-year-oncology-workload-generated-by-each-new-patient-a-real-world-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/lgbtq-cancer-patients-are-uk-oncologists-being-supported-to-develop-essential-knowledge-attitudes-and-behaviours-to-provide-quality-care
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/crowdfunding-for-anticancer-therapies-an-analysis-of-non-us-gofundme-pages
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-a-clinical-pharmacist-with-oncology-specialty-training-on-clinical-humanistic-and-economic-outcomes-in-an-oncology-setup
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prevalence-and-impact-of-hiv-infection-on-mortality-rate-and-overall-survival-of-cancer-patients-in-a-haitian-cancer-clinic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/when-research-becomes-social-not-only-fake-news
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-efficacy-comparison-of-avapritinib-versus-other-tyrosine-kinase-inhibitors-tkis-in-gastrointestinal-stromal-tumours-gist-with-pdgfra-d
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/predictive-factors-of-the-efficacy-of-dose-escalation-in-patients-with-advanced-gastrointestinal-stromal-tumor-gist-who-progressed-on-imatinib-40
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/regorafenib-is-associated-with-increased-skeletal-muscle-loss-in-gastrointestinal-stromal-tumor
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/explorative-model-of-imatinib-resistant-wild-type-gist-and-potential-immunotherapy-strategies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-efficacy-of-continuous-circulatory-hyperthermic-intraperitoneal-chemotherapy-c-hipec-following-cytoreductive-surgery-for-metastatic-gastroint
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-and-pathologic-prognostic-factors-for-residual-lesion-surgery-following-disease-control-with-standard-dose-imatinib-im-in-patients-pts
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/metasyn-patterns-of-care-and-outcomes-of-387-metastatic-synovial-sarcoma-real-life-data-from-the-french-sarcoma-group-gsf-geto
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-adjuvant-chemotherapy-in-early-stage-uterine-leiomyosarcoma-a-systematic-review-and-updated-meta-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/are-all-leiomyosarcomas-created-equal-clinical-characteristics-and-experience-of-a-single-reference-centre
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/integrated-safety-analysis-of-tazemetostat-taz-800-mg-bid-in-adult-patients-pts-with-hematologic-and-solid-tumors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pegylated-liposomal-doxorubicin-pld-as-first-line-treatment-in-aids-related-kaposi-s-sarcoma-aids-ks-a-single-institution-retrospective-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/bone-and-soft-tissue-sarcoma-in-brazil-estimating-the-epidemiological-landscape-via-a-computerized-data-capture-tool
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/treatment-results-of-patients-diagnosed-with-rare-types-of-bone-sarcomas
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/demographics-and-outcomes-of-non-metastatic-ewing-s-sarcoma-es-from-a-low-middle-income-country-lmic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/dynamic-changes-in-quality-of-life-and-q-twist-analysis-for-ewing-sarcoma-patients-following-anlotinib-and-irinotecan-a-combination-of-phase-ib-an
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-data-on-cabozantinib-in-advanced-osteosarcoma-and-ewing-sarcoma-a-study-of-the-hellenic-group-of-sarcoma-and-rare-cancers
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/apatinib-for-treatment-of-inoperable-metastatic-or-locally-advanced-chondrosarcoma-what-we-can-learn-about-the-biological-behavior-of-chondrosarco
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/evaluation-of-baseline-neutrophil-to-lymphocyte-nlr-platelet-to-lymphocyte-plr-and-lymphocyte-to-monocyte-ratios-lmr-as-prognostic-factors-i
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/response-rate-and-time-to-progression-after-first-line-chemotherapy-with-cisplatin-and-adriamycin-in-patients-with-metastatic-osteosarcoma-at-prese
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/outcomes-of-multidisciplinary-treatment-of-fibromatosis-retrospective-analysis-from-a-reference-center
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/desmoid-type-fibromatosis-in-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pegylated-liposomal-doxorubicin-as-first-line-treatment-in-patients-with-advanced-soft-tissue-sarcoma-a-single-center-retrospective-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-prospective-single-arm-phase-ii-study-of-pegylated-liposome-doxorubincin-combined-with-ifosfamide-as-first-line-treatment-for-patients-with-adva
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genomic-profiling-of-chinese-sarcoma-patients-and-exploration-of-biomarkers-for-immunotherapy-a-retrospective-analysis-of-over-600-samples
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/analysis-of-predictive-biomarkers-for-immune-checkpoint-inhibitor-therapy-in-several-subtypes-of-sarcomas
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immune-signature-and-molecular-profiling-of-epithelioid-hemangioendothelioma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/anti-angiogenic-therapy-induced-pneumothorax-aip-is-associated-with-long-lasting-response-and-survival-benefit-for-paediatric-and-young-adult-sar
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pazopanib-treatment-outcome-in-advanced-soft-tissue-sarcoma-real-world-data
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-landscape-of-ntrk-fusions-in-chinese-sarcoma-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ai-based-grading-approach-identifies-fnclcc-grade-3-soft-tissue-sarcomas
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-promising-role-of-the-extracellular-matrix-in-the-activity-of-trabectedin-in-soft-tissue-sarcoma-a-prospective-study-on-a-ups-and-l-sarcoma-pa
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-role-of-regional-lymph-node-metastases-in-soft-tissue-sarcomas
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/outcomes-and-prognostic-factors-in-localized-soft-tissue-sarcoma-prospective-observational-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/local-recurrence-and-5-year-survival-control-of-primary-localized-sarcoma-of-the-soft-tissues-of-the-extremities-and-body
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/association-between-occupational-exposures-and-sarcoma-incidence-and-mortality-systematic-review-and-meta-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ii-single-arm-study-of-avelumab-in-combination-with-axitinib-in-patients-with-unresectable-metastatic-gastrointestinal-stromal-tumor-after
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-factors-in-pediatric-rhabdomyosarcoma-a-20-year-single-institution-experience
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-multicenter-open-label-randomized-phase-ii-study-to-compare-the-efficacy-and-safety-of-lenvatinib-in-combination-with-ifosfamide-and-etoposide
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-non-randomized-open-label-phase-ii-trial-evaluating-efficacy-and-feasibility-of-combined-treatment-with-trabectedin-and-nivolumab-in-patients-wi
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/international-multicentric-evaluation-of-breast-cancer-patients-satisfaction-and-experience-with-oncology-telemedicine-visits-tv-during-the-covi
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/activity-of-lurbinectedin-in-second-line-sclc-patients-candidates-for-platinum-re-challenge
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ib-expansion-study-of-adavosertib-plus-olaparib-in-patients-with-extensive-stage-or-relapsed-small-cell-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/small-cell-lung-cancer-sclc-extensive-stage-es-in-spain-efficacy-of-treatments-data-from-the-thoracic-tumours-registry-ttr-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/effect-of-anlotinib-in-advanced-small-cell-lung-cancer-patients-with-pleural-metastases-pleural-effusion-a-subgroup-analysis-from-a-randomized-do
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/persistent-sex-differences-in-lung-cancer-mortality-between-2001-and-2017-in-the-us-and-eu
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/fewer-liver-and-lymph-node-metastases-may-contribute-to-survival-benefits-for-patients-with-c-sclc-compared-with-sclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-utility-of-ctdna-and-ctcs-for-genomic-profiling-and-monitoring-chemotherapy-response-in-patients-with-small-cell-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/effect-of-anlotinib-in-advanced-small-cell-lung-cancer-sclc-patients-with-liver-metastases-a-subgroup-analysis-from-a-randomized-double-blind-p
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/french-real-world-study-on-patient-characteristics-and-treatment-strategies-in-first-line-of-extensive-stage-small-cell-lung-cancer-es-sclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/resilient-part-1-pharmacokinetics-of-second-line-2l-liposomal-irinotecan-in-patients-with-small-cell-lung-cancer-sclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/extensive-stage-es-small-cell-lung-cancer-sclc-in-spain-a-review-of-demographic-epidemiological-and-clinical-data-from-the-thoracic-tumors-re
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/anlotinib-combined-with-etoposide-as-maintenance-treatment-in-extensive-stage-small-cell-lung-cancer-es-sclc-a-single-arm-prospective-phase-ii
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/treatment-patterns-and-survival-for-small-cell-lung-cancer-patients-a-nationwide-danish-register-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-and-safety-analysis-of-ep-ec-regimen-combined-with-first-line-anlotinib-hydrochloride-in-the-treatment-of-extensive-small-cell-lung-canc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/carboplatin-paclitaxel-cp-chemotheraphy-as-salvage-treatment-for-small-cell-lung-cancer-sclc-a-real-world-evidence-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immune-checkpoint-inhibitor-plus-chemotherapy-versus-chemotherapy-alone-as-first-line-for-extensive-stage-small-cell-lung-cancer-a-meta-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/concordance-between-treatment-naive-tissue-and-circulating-tumour-dna-ctdna-in-late-stage-non-small-cell-lung-cancer-nsclc-and-small-cell-lung
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-efficacy-of-anlotinib-combined-with-etoposide-and-platinum-based-regimens-in-the-first-line-treatment-of-extensive-stage-small-cell-lung
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/serum-identification-of-myc-amplification-in-small-cell-lung-cancer-patients-using-droplet-digital-pcr
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-efficacy-of-cisplatin-cis-combined-with-sintilimab-sin-and-niraparib-nir-in-advanced-solid-tumours-a-phase-ib-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-efficacy-of-apatinib-plus-topotecan-as-laterline-therapy-for-advanced-small-cell-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/apatinib-combined-with-irinotecan-in-the-treatment-of-small-cell-lung-cancer-a-phase-ii-single-arm-prospective-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/final-safety-and-efficacy-data-from-clepsidra-trial-in-2l-ed-sclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-data-on-442-patients-p-with-small-cell-lung-cancer-sclc-treated-in-the-last-ten-years-at-vall-d-hebron-hospital
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/atezolizumab-atz-in-combination-with-carboplatin-cb-and-etoposide-eto-in-the-treatment-of-patients-with-previously-untreated-extensive-stage
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/determinants-of-new-onset-cardiovascular-disease-cvd-in-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/taxane-related-skin-toxicity-analysis-of-an-in-vivo-and-3d-in-vitro-model-study-of-the-impact-of-paclitaxel-on-skin
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-multicentre-analysis-of-toxicity-in-6-weekly-vs-3-weekly-pembrolizumab-dosing
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-iron-deficiency-management-on-quality-of-life-in-cancer-patients-a-prospective-cohort-study-camara-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/characterization-of-thrombosis-risk-in-patients-with-cancer-preliminary-results
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/incidence-risk-factors-and-clinical-outcome-of-venous-and-arterial-thromboembolism-in-patients-treated-with-immune-checkpoint-inhibitors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prevention-and-prophylaxis-thromboprophylaxis-act-of-cancer-associated-thrombosis-cat-in-high-risk-oncology-patients-act4cat
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/thrombosis-incidence-in-cancer-patients-treated-with-antiangiogenic-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/evaluation-of-oral-hemorrhage-following-dental-extractions-in-patients-receiving-bevacizumab
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/effect-of-serum-albumin-globulin-ratio-in-combination-with-mascc-and-cisne-risk-score-on-febrile-neutropenia-mortality
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/are-patient-reported-symptoms-and-concerns-affected-by-body-mass-index-bmi-and-weight-loss-wl-in-patients-with-cancer-cachexia
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/association-of-body-composition-measured-by-bioelectrical-impedance-analysis-and-hematologic-adverse-events-in-early-stage-breast-cancer-patients-r
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/role-of-body-composition-bc-in-advanced-non-small-cell-lung-cancer-nsclc-patients-receiving-first-line-pembrolizumab-pembro
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nutritional-status-assessment-in-patients-followed-for-head-and-neck-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/role-of-grip-strength-the-short-physical-performance-battery-in-prediction-of-chemotherapy-related-outcomes-in-older-adults-with-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/febrile-neutropenia-outside-of-clinical-trials-in-intermediate-risk-patients-receiving-chemotherapy-a-mascc-neutropenia-infection-and-myelosuppre
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/effect-of-serum-uric-acid-ua-level-and-mascc-risk-score-on-febrile-neutropenia-mortality
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/bacteraemia-in-cancer-patients-an-adverse-prognostic-factor-and-the-relationship-with-chemotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/febrile-neutropenia-fn-primary-prophylaxis-1o-prlx-with-platinum-and-etoposide-p-e-chemotherapy-cht-regimens-some-action-needed
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/do-irinotecan-iri-dose-reductions-driven-by-ugt1a1-28-genotyping-prevent-iri-related-severe-neutropenia-a-real-world-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/modification-of-systemic-anti-cancer-therapy-sact-and-weight-loss-a-population-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-diabetes-mellitus-in-cancer-patients-treated-by-chemotherapy-a-real-life-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/predicting-the-onset-of-immune-related-adverse-events-iraes-in-immune-checkpoint-inhibitor-ici-therapies-using-a-machine-learning-ml-model-tr
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-medication-reconciliation-for-patients-enrolled-in-oncology-early-phases-clinical-trials-a-drug-drug-interactions-retrospective-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/electro-acupuncture-for-quality-of-life-in-gastric-cancer-patients-undergoing-adjuvant-chemotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/effectiveness-of-normal-saline-solution-in-maintaining-the-permeability-of-totally-implantable-venous-catheters-in-adult-cancer-patients-experienc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/octogenarians-treated-for-lung-cancer-and-thoracic-cancers
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ib-international-dose-escalation-study-to-evaluate-the-safety-pharmacokinetics-pk-and-efficacy-of-st-617-a-dithiolethione-for-the-atten
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-longitudinal-study-investigating-lifestyle-modification-during-and-after-breast-cancer-treatment
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/managing-hypersensitivity-reactions-in-ovarian-malignancy-can-we-re-challenge-successfully
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immune-related-endocrine-dysfunction-in-chinese-a-single-tertiary-centre-experience
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-effectiveness-of-palliative-chemotherapy-ctx-for-patients-pts-with-malignant-bowel-obstruction-mbo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-added-value-of-the-h2-blocker-ranitidine-in-premedication-regimens-during-paclitaxel-treatment
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/chronic-cannabis-used-by-patients-with-advanced-cancer-during-immunotherapy-initiation-clinical-outcomes-and-endocannabinoid-levels-evaluation
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-evidence-of-quality-of-life-effects-qol-of-the-antiemetic-nepa-final-data-in-patients-receiving-oxaliplatin-based-chemotherapy-within
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-randomized-controlled-trial-to-evaluate-the-effect-of-reduced-dose-olanzapine-on-nausea-vomiting-and-addition-of-aprepitant-on-vomiting-in-patien
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/music-therapy-can-reduce-both-anxiety-and-chemotherapy-related-nausea-and-vomiting-in-patients-with-early-stage-colorectal-cancer-treated-with-adju
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-relevance-of-pancreatic-enzyme-replacement-therapy-pert-in-patients-affected-by-advanced-pancreatic-ductal-adenocarcinoma-pdac-undergo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/oncology-dedicated-emergency-department-patient-delineation-and-utility-of-care-a-retrospective-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/role-of-depression-and-quality-of-life-qol-status-as-predictors-of-hospital-length-of-stay-hlos-and-overall-survival-os-in-hospitalized-oncol
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/identifying-the-competence-of-the-medical-workers-and-the-method-of-managing-severe-side-effects-in-the-management-of-chemotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-and-feasibility-of-a-realistic-designed-geriatric-assessment-rdga-in-an-outpatient-brazilian-oncology-unit
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/influence-of-comprehensive-geriatric-assessment-on-therapeutic-decision-in-elderly-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/geriatric-assessment-tools-and-preliminary-patient-reported-outcomes-in-a-cohort-of-elderly-patients-treated-with-1.5t-mr-guided-abdominal-pelvic-sbrt
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-systemic-treatment-versus-best-supportive-care-on-survival-in-patients-older-than-80-years-with-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prospective-cohort-study-on-efficacy-of-topical-capsaicin-as-treatment-of-chemotherapy-induced-peripheral-neuropathy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/chemotherapy-induced-peripheral-neuropathy-in-long-term-hodgkin-s-lymphoma-survivors-compared-to-controls
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/quality-of-life-and-pain-in-patients-with-metastatic-bone-disease-from-solid-tumors-treated-with-bone-targeted-agents-a-real-world-cross-sectional
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/preliminary-quality-of-life-and-safety-results-of-naloxegol-for-patients-with-cancer-pain-diagnosed-with-opioid-induced-constipation.-nacasy-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-and-safety-of-naloxegol-in-patients-with-cancer-with-opioid-induced-constipation-with-laxative-inadequate-response-a-long-term-real-worl
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pain-in-cancer-the-patient-experience-in-spain
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/response-of-post-curative-survivors-suffering-from-fatigue-to-a-multimodal-inpatient-cancer-rehabilitation-program
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/overcoming-barriers-in-opioid-induced-constipation-management
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pain-in-oncology-prevalence-and-characterization
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cancer-related-fatigue-are-we-evaluating-it
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-infections-and-antibiotic-therapy-in-a-cohort-of-patients-with-advanced-solid-cancers-who-receive-immune-checkpoints-inhibitors.-an-obser
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/voluntary-assisted-dying-in-victoria-australia-a-case-series
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-combination-model-of-electronic-patient-reported-outcomes-epros-and-lab-measurements-in-prediction-of-immune-related-adverse-events-iraes-and
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/fatigue-changes-according-to-systemic-therapy-type-in-patients-with-advanced-solid-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/health-related-quality-of-life-hrqol-assessment-for-patients-with-advanced-renal-cell-carcinoma-arcc-treated-with-a-tyrosine-kinase-inhibitor
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/assessing-financial-toxicity-in-tunisian-cancer-patients-using-the-comprehensive-score-for-financial-toxicity-cost
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/two-thousand-consecutive-parallel-evaluations-of-karnofsky-and-ecog-performance-status-looking-for-a-correct-comparison
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/deterioration-of-sexual-health-of-cancer-survivors-5-years-after-diagnosis-french-national-cohort-vican
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sexual-functioning-in-women-with-solid-malignancies-often-neglected-but-an-essential-hardship
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/fertility-rates-in-spanish-young-breast-cancer-patients-ybcp
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patient-nurse-and-physician-preferences-final-results-of-the-convenience-study-evaluating-pegfilgrastim-prophylaxis-via-pre-filled-syringe-or-on
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/discrete-choice-experiment-to-estimate-physicians-preferences-in-terms-of-g-csf-use-for-febrile-neutropenia-primary-and-secondary-prophylaxis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/quantifying-quality-of-informed-consent-ic-in-patients-enrolled-in-phase-i-ph-i-oncology-clinical-trials-with-a-validated-instrument-quic-part
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-consistency-of-mutation-profiles-between-treatment-naive-circulating-tumor-dna-and-tumor-tissue-mutations-in-a-multi-cancer-monitoring-cohort
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/hepatitis-screening-in-oncology-patients-planned-to-receive-systemic-anti-cancer-therapy-sact
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/information-access-and-use-a-grounded-theory-of-how-patients-and-their-friends-and-family-use-information-to-navigate-the-cancer-journey
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/vitamin-e-in-the-treatment-of-chemotherapy-and-radiation-induced-mucositis-a-meta-analysis-of-randomized-controlled-trials
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/surgical-treatment-of-bone-metastasi-experience-in-the-general-university-hospital-of-valencia
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/one-year-experience-at-the-catalan-institute-of-oncology-ico-drug-desensitisation-centre-ddc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/hypersensitivity-reaction-to-chemotherapy-and-monoclonal-antibodies.-outcomes-of-97-desensitisation-in-24-patients-a-single-hospital-experience
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/final-results-from-a-prospective-study-examining-exhaled-breath-alcohol-levels-following-weekly-paclitaxel-chemotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/germline-and-somatic-mutational-landscape-in-a-cohort-of-malignant-pleural-mesothelioma-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ii-trial-of-first-line-combination-chemotherapy-with-cisplatin-pemetrexed-and-nivolumab-for-unresectable-malignant-pleural-mesothelioma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/autoimmune-diseases-in-centrally-reviewed-thymic-epithelial-tumours-tet
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/rames-trial-a-multicentre-double-blind-randomized-phase-ii-study-on-gemcitabine-plus-ramucirumab-versus-gemcitabine-alone-as-second-line-treatm
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immunomodulatory-role-of-multi-agent-therapy-in-thymic-epithelial-tumours-and-severe-immunological-dysregulation
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/association-of-high-intensity-statins-with-clinical-outcome-in-malignant-pleural-mesothelioma-and-advanced-non-small-cell-lung-cancer-patients-trea
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immunotherapy-for-malignant-pleural-mesothelioma-a-french-retrospective-real-life-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-implications-of-distinct-immunoprofiles-in-patients-with-thymic-epithelial-tumours-and-autoimmunity
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/bap1-and-mir-31-combination-predicts-outcome-in-epithelioid-malignant-pleural-mesothelioma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/lung-cancer-risk-in-solid-organ-transplant-recipients-a-meta-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/application-of-anti-pd1-drugs-before-or-during-thoracic-radiotherapy-increases-the-incidence-of-radiation-pneumonia-compared-to-the-application-aft
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/fgfr1-4-mutations-are-associated-with-immunotherapy-outcomes-in-patients-with-non-small-cell-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/treatment-patterns-and-outcomes-in-malignant-pleural-mesothelioma-mpm-in-england-a-nationwide-cas-registry-analysis-from-the-i-o-optimise-initia
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/outcomes-of-systemic-therapy-after-first-line-therapy-in-patients-p-with-malignant-pleural-mesothelioma-mpm
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/characteristics-and-real-world-outcomes-of-young-lung-cancer-patients-age-45-years-treated-in-a-uk-specialist-centre
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nicita-nivolumab-with-chemotherapy-in-pleural-mesothelioma-after-surgery
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-lenvatinib-pembrolizumab-combination-induces-long-lasting-and-complete-responses-in-patients-with-metastatic-anaplastic-or-poorly-differentiate
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/larotrectinib-treatment-of-advanced-trk-fusion-thyroid-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pembrolizumab-salvage-add-on-therapy-in-patients-with-radioiodine-refractory-rair-progressive-differentiated-thyroid-cancer-dtc-progressing-on
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/final-analysis-of-riftos-mki-a-global-non-interventional-study-assessing-the-use-of-multikinase-inhibitors-mkis-for-the-treatment-of-patients-w
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nintedanib-bibf1120-after-first-line-therapy-in-progressive-medullary-thyroid-cancer-a-multicenter-eortc-prospective-randomized-double-blind-pha
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/anlotinib-in-medullary-thyroid-carcinoma-a-subanalysis-based-on-alter01031-study-for-patients-with-high-prognostic-risk
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-impact-of-18f-fdg-pet-ct-in-differentiated-thyroid-cancer-with-bone-metastasis-a-french-tuthyref-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exploratory-patient-reported-outcomes-among-patients-with-ret-mutant-medullary-thyroid-cancer-in-libretto-001-a-phase-i-ii-trial-of-selpercatinib
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/assessment-of-the-efficacy-and-safety-of-lenvatinib-for-the-treatment-of-radioiodine-refractory-differentiated-thyroid-cancer-in-real-life-practice
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/diagnostic-demographics-of-radioiodine-refractory-differentiated-thyroid-cancer-rr-dtc-and-usage-patterns-of-local-and-systemic-therapies-erudit
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/dna-methylation-signature-for-prediction-of-metastasis-and-response-to-multikinase-inhibitors-of-differentiated-thyroid-carcinoma-dtc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pd-l1-expression-in-medullary-thyroid-carcinoma-and-its-relevance-with-clinicopathological-findings
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/libretto-531-selpercatinib-in-patients-with-treatment-tx-naive-ret-mutant-medullary-thyroid-cancer-mtc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/research-and-contextual-inquiry-on-information-and-communication-technologies-point-of-care-systems-for-cancer-follow-up
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ai-driven-big-data-analytics-for-effective-response-of-cancer-therapy-aibert-drug-discovery-and-development-platform
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/mis-selection-of-non-malignant-lesions-as-target-lesions-misclassification-of-recist-1.1-and-early-termination-of-promising-drugs
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ern-genturis-guidelines-for-the-li-fraumeni-and-heritable-tp53-related-cancer-syndromes
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/profiling-of-circulating-tumour-dna-for-treatment-selection-in-patients-with-advanced-and-refractory-carcinoma-a-prospective-two-stage-phase-ii-i
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/potential-role-of-longitudinal-plasma-next-generation-sequencing-ngs-in-advanced-non-small-cell-lung-cancer-ansclc-patients-pts-experiencing
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/calibration-can-early-changes-in-circulating-tumour-dna-ctdna-predict-durable-tumour-responses-in-patients-pts-with-advanced-esophageal-adenoc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/il6-pre-treatment-promotes-chemosensitivity-by-eliminating-quiescent-cancer-stem-cells
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tert-associated-dna-polymerases-genes-link-cd8-t-cells-to-improve-immunotherapy-response-rate
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/distribution-of-anti-pd1-pdl1-autoantibodies-in-multiple-cancer-types-and-potential-biomarker-role-for-anti-pd1-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/hyperglycemia-increased-nivolumab-induced-cardiotoxicity-enhanced-immunoresistance-of-er-pr-her2-breast-cancer-cells-modulating-growth-facto
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/dysregulation-of-immune-checkpoint-proteins-in-newly-diagnosed-early-breast-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/single-cell-analysis-reveals-that-cd8-t-cell-clone-size-determines-response-to-immune-checkpoint-blockade
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immune-suppressive-tumour-microenvironment-and-inferior-survival-of-pik3cg-or-pik3cd-high-expression-group-in-tcga-pan-cancer-cohort
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/characterising-the-peripheral-myeloid-response-to-immune-checkpoint-blockade
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/translate-activation-of-immune-response-in-refractory-patients-to-standard-treatment
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/niraparib-and-irinotecan-combination-in-atm-mutated-colorectal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/gender-and-molecular-aspects-of-targeted-therapy-recommendations-for-therapy-refractory-solid-tumours-data-from-the-real-world-precision-medicine
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comprehensive-profiling-of-mdm2-amplified-gastrointestinal-gi-cancers
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-pan-cancer-analysis-of-double-pik3ca-mutations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/survival-benefits-of-larotrectinib-in-an-integrated-dataset-of-patients-with-trk-fusion-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/survival-benefits-of-larotrectinib-in-an-integrated-dataset-of-patients-with-trk-fusion-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/evaluation-of-a-digital-treatment-assignment-system-on-whole-exome-sequencing-data-of-pediatric-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/reflex-screening-of-somatic-brca1-2-identifies-pathogenic-mutations-in-non-ovarian-and-breast-cancers
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-landscape-of-targetable-rearrangements-in-chinese-patients-with-gastrointestinal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/differential-induction-of-gene-expression-may-explain-differences-in-reported-adverse-event-profiles-between-the-fgfr-inhibitors-derazantinib-and-e
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-landscape-of-ptprt-mutations-and-correlation-with-tmb-in-chinese-solid-tumour-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genomic-characteristics-of-dna-damage-repair-deficiency-in-chinese-pancreatic-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-pan-cancer-study-of-gnaq-gna11-mutations-in-chinese-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genomic-characteristics-of-homologous-recombination-in-prostate-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/detection-of-brca1-2-mutations-using-next-generation-sequencing-in-asian-patients-with-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/improved-sensitivity-of-integrative-dna-and-rna-ngs-assay-on-fusion-detection
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comprehensive-analysis-of-a-microvascular-invasion-related-cerna-network-reveals-a-potential-prognostic-lncrnas-signature-involved-in-hepatocellula
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-clinical-effect-of-concurrent-oncogenic-gene-mutations-in-braf-p.-v600e-mutated-nsclc-treated-with-dabrafenib-and-trametinib
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-sglt2-inhibitor-dapagliflozin-enhanced-anticancer-activities-and-exerts-cardioprotective-effects-against-doxorubicin-and-trastuzumab-toxicity-t
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-multivariate-logistic-regression-model-for-detection-of-upper-tract-urinary-carcinoma-in-patients-with-hematuria
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neuroendocrine-ne-expression-profiling-in-non-castrate-tumours-is-associated-with-poor-therapy-benefit-and-adverse-clinical-outcome-in-metastatic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/circular-rna-is-associated-with-enzalutamide-resistant-prostate-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/membranous-vimentin-vim-expression-as-a-possible-surrogate-of-cell-surface-vimentin-in-prostate-cancer-pca
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/medigrid-a-novel-interface-for-real-time-collection-and-analysis-of-real-world-clinical-data
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/artificial-intelligence-based-tool-to-generate-directional-integrative-treatment-reports-for-cancer-patients-ziopar-zenonco.io-integrative-oncolo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-multi-national-study-of-treatment-resistance-following-anti-cancer-therapy-translate
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/relb-silencing-reversed-tamoxifen-resistance-by-regulating-gpx4-and-ferroptosis-in-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/fibroblasts-derived-matrices-confer-resistance-to-oxaliplatin-and-cetuximab-in-a-snail-dependent-way-in-crc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/metronomic-combination-of-5-fluorouracil-plus-vinorelbine-limits-endothelial-and-triple-negative-breast-cancer-cells-proliferation-and-migration-an
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tumour-infiltrating-lymphocytes-in-early-breast-cancer-high-levels-of-cd3-cd8-cells-and-immunoscore-R-are-associated-with-pathological-cr-and-time
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-correlation-between-the-amount-of-surface-receptors-tim-3-and-pd-1-and-cytotoxic-activity-in-patients-with-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/mdm2-amplification-and-hyperprogression-following-treatment-with-immune-checkpoint-inhibitors-in-advanced-non-small-cell-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/discordant-genomic-correlates-of-pd-l1-expression-in-lung-adenocarcinoma-among-multiple-cohorts-using-dissimilar-pd-l1-testing-techniques
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pd-l1-sp263-staining-of-fine-needle-aspirate-ffpe-samples-in-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/down-regulation-of-interleukin-related-genes-scgb1a1-and-il36a-serve-as-the-mechanism-of-tmb-low-leading-to-poor-immunotherapy-efficacy-on-stomach
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/relationship-of-t-cells-and-macrophages-in-the-tumour-microenvironment-across-multiple-tumour-indications
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/detection-of-pik3ca-mutations-in-plasma-samples-at-peruvian-cancer-institute
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/significance-of-erg-status-on-neural-microenvironment-in-prostate-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/integrative-molecular-and-genomic-analyses-of-trophoblast-reveal-grb7-pgap3-stard3-and-psmd3-may-orchestrate-the-lethal-her2-pathway-signaling-in
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-tumour-immune-contexture-and-theranostic-markers-expression-in-patients-with-gastric-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-significance-of-cannabinoid-receptor-cb2-expression-in-non-small-cell-lung-cancer-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-significance-of-ephrin-receptor-eph-b1-b2-b4-and-b6-expression-in-thymic-epithelial-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-akt-kinase-lancl2-functions-as-a-key-driver-in-egfr-mutant-lung-adenocarcinoma-tumorigenesis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/non-stem-like-tumour-cells-with-emt-features-exhibit-more-intravasation-potency
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/heterogeneity-of-circulating-tumour-cells-with-emt-features-in-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-egfr-testing-in-patients-with-advanced-egfrm-nsclc-in-belgium-reveal
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/adenoid-cystic-carcinomas-acc-of-the-trachea-salivary-gland-breast-a-comparative-comprehensive-genomic-profiling-cgp-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genomic-alterations-of-keap1-nfe2l2-cul3-k-n-c-in-chinese-lung-cancer-patients-pts
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/molecular-diagnostic-of-brca-mutations-for-parp-inhibitors-based-therapy-short-time-to-results-using-somatic-first-procedure-in-ovarian-and-brea
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exome-sequencing-of-germ-line-dna-from-young-onset-and-or-alk-fusion-positive-lung-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-significance-of-structural-variations-in-atm-brca1-brca2-and-rad51c-for-chinese-patients-with-solid-tumour
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-evidence-on-use-of-tumour-mutation-burden-in-a-pan-tumour-population
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tumour-mutational-burden-tmb-level-and-clinical-outcomes-in-a-real-world-pan-tumour-population
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-effect-of-the-use-of-complex-molecular-profiling-in-advanced-solid-organ-tumours-on-clinical-decision-turkey-molecular-profiling-in-advanced-c
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/gastric-cancer-in-brca1-germ-line-mutation-carriers-results-of-endoscopic-screening-and-molecular-analysis-of-tumour-tissues
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/mutational-profile-and-tumour-mutational-burden-in-li-fraumeni-syndrome-associated-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-impact-of-pathological-response-pr-on-adjuvant-chemotherapy-ac-decisions-and-patient-outcomes-in-gastrointestinal-cancers-gic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/double-immunofluorescent-dif-staining-of-cancer-stem-cells-csc-markers-in-prostate-cancer-pca
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/gastric-cancer-derived-exosomal-lncrna-pcgem1-promotes-invasion-and-metastasis-by-inducing-vascular-angiogenesis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/rebimmune-trial-a-prospective-study-of-rebiopsy-at-progression-during-immunotherapy-in-advanced-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-civil-service-enters-oncology-an-italian-reality
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-roadmap-of-oncology-nursing-specialisation-in-spain
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/new-blended-learning-module-for-breast-care-nurses-in-switzerland
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/duty-to-recontact-patients-previously-tested-with-negative-results-in-a-hereditary-cancer-syndrome-center
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/improved-staff-ergonomics-and-time-efficiency-using-surface-guided-radiotherapy-for-prostate-setup
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/digi-do-a-digital-information-tool-to-support-patients-with-breast-cancer-before-during-and-after-start-of-radiotherapy-treatment
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/leadership-in-support-of-interprofessional-collaboration-in-the-fican-west-cancer-centre
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/advocacy-working-group-eons-accreditation-for-cancer-units
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/descriptive-study-of-the-skill-level-of-palliative-care-nurses-with-end-of-life-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/coping-strategies-and-functional-status-among-patients-with-advanced-cancer-in-indonesia
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/predictors-of-distinct-prognostic-awareness-transition-patterns-over-cancer-patients-last-6-months
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/promoting-acceptance-and-execution-of-advanced-directives-a-retrospective-review-in-a-regional-hospice-center-in-hong-kong
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/healthcare-professionals-perception-about-end-of-life-conversations-an-observational-cross-sectional-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/occupational-risks-of-health-care-personnel-administering-antineoplastic-drugs.-results-of-the-large-scale-monitoring-in-czech-and-slovak-hospitals
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/increased-patient-and-occupational-safety-for-home-infusion-of-cytotoxic-and-other-hazardous-drugs
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/self-management-interventions-can-promote-health-related-quality-of-life-after-primary-treatment-for-early-stage-breast-cancer-but-to-what-extent
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/effects-of-music-therapy-on-anxiety-and-depression-in-cancer-patients-undergoing-chemotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/women-s-coping-strategies-during-the-first-three-months-of-adjuvant-endocrine-therapy-for-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/monitoring-immuno-oncologically-treated-patients-in-cancer-nursing-a-collaborative-project
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/implementing-a-nursing-symptom-self-management-intervention-the-symptom-navi-program
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/depression-and-its-impact-on-quality-of-life-in-lung-cancer-patients-with-comorbid-diabetes-type-2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-effect-of-type-2-diabetes-on-health-related-quality-of-life-in-colon-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-use-of-the-edmonton-symptom-assessment-scale-in-advanced-lung-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nurse-and-pharmacist-delivered-gynaecology-telephone-clinic-maintenance-therapies-patient-and-staff-survey
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/effect-of-self-care-teaching-module-on-radiation-induced-acute-side-effects-and-clinical-outcomes-for-head-and-neck-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/thrombosis-in-cancer-patients-related-to-central-venous-catheter
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/mixed-methods-intervention-to-improve-hospitalized-onco-hematologic-patients-rest-and-sleep-quality
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-life-experience-of-nurses-coordinating-device-in-oral-therapy-center-dicto-program
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/gender-differences-in-cancer-care
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/introduction-and-clinical-implementation-of-esmo-consensus-conference-recommendations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/controversy-1-which-are-the-biomarkers-useful-for-molecular-treatments
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/controversy-2-which-are-the-indications-for-chemo-radiotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/controversy-3-which-is-the-management-of-non-endometrioid-histotypes
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/esmo-cpg-in-endometrial-cancer-which-are-the-expected-changes
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/conclusions2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a3
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/happy-wedding-access-and-availability-of-oncology-combination-medicines
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/outcomes-of-fludarabine-melphalan-and-low-dose-total-body-irradiation-as-a-reduced-intensity-regimen-in-allogeneic-peripheral-blood-stem-cell-tran
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/infectious-complications-in-patients-with-acute-graft-versus-host-disease
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invasive-aspergillosis-caused-by-aspergillus-non-fumigatus-in-children-and-adults-after-hematopoietic-stem-cell-transplantation-hsct-chemotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-serum-galactomannan-assay-on-diagnosis-and-outcome-of-invasive-fungal-infections-in-high-risk-febrile-neutropenia-a-prospective-cohort-s
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparison-of-toxicities-of-parp-inhibitors-used-in-gynaecological-cancers-observed-at-a-large-cancer-centre
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/revolutionizing-clinical-trial-units-in-the-pandemic-era
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ambulatory-follow-up-care-and-monitoring-of-cancer-patients-during-sars-cov-2-pandemic-by-collecting-blood-samples-at-home-and-monitoring-systemic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-indicators-for-covid-19-related-deaths-in-patients-with-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-data-cancer-and-sars-cov-2-infection
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/do-cancer-patients-really-do-worse-a-study-in-a-uk-tertiary-hospital-within-a-covid-19-epicentre
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sars-cov-2-infection-induces-emt-like-molecular-changes-including-zeb1-mediated-repression-of-the-viral-receptor-ace2-in-lung-cancer-models
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/elevated-axl-expression-following-sars-cov-2-infection-in-non-small-cell-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/national-approaches-to-managing-cancer-care-responses-of-countries-in-the-mena-region-to-covid-19-pandemic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/covid-19-an-additional-burden-on-caregivers-of-cancer-patients-in-tunisia
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-features-and-prognostic-factors-on-admission-of-a-prospective-cohort-of-covid-19-positive-cancer-patients-in-a-third-level-hospital-in-mad
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/assessing-the-impact-of-covid-19-outbreak-on-the-attitudes-and-practice-of-italian-oncologists-towards-breast-cancer-care-and-related-research-acti
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/triage-procedures-for-covid-19-in-an-italian-cancer-centre
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/outcomes-of-the-reorganisation-of-a-medical-oncology-department-during-the-covid-19-pandemic-real-word-experience
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/infectious-complications-in-patients-with-acute-graft-versus-host-disease
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invasive-aspergillosis-caused-by-aspergillus-non-fumigatus-in-children-and-adults-after-hematopoietic-stem-cell-transplantation-hsct-chemotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-serum-galactomannan-assay-on-diagnosis-and-outcome-of-invasive-fungal-infections-in-high-risk-febrile-neutropenia-a-prospective-cohort-s
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/determinants-of-mortality-from-sars-cov-2-infection-in-european-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sars-cov-2-infections-in-outpatients-with-cancer-most-infected-patients-are-asymptomatic-carriers-without-impact-on-chemotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/first-results-of-the-coco-study-covid-19-outcomes-in-patients-with-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/outcomes-of-cancer-patients-undergoing-radiotherapy-during-the-covid-19-outbreak-in-wuhan-china
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sars-cov-2-infection-and-lung-cancer-management-in-europe
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/scientia-potentia-est-how-the-italian-world-of-oncology-changes-in-the-covid-19-pandemic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/is-cancer-what-determines-covid-19-oncological-patient-s-outcome-or-are-other-external-factors-involved-experience-in-a-hospital-in-madrid-spain
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/coronavirus-or-cancer-what-are-oncological-patients-most-afraid-of
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-beginning-of-the-covid-19-era-the-perception-of-oncological-patients-pts-in-active-treatment-at-the-brindisi-and-mauriziano-hospital-oncolog
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cancer-patients-infected-with-covid-19-at-la-princesa-hospital-real-world-data-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/training-and-information-during-covid-19-pandemic-the-masterpiece-in-young-oncologists
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/practical-issues-faced-by-cancer-patients-during-the-covid-19-pandemic-in-india
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cancer-care-during-covid-19-data-from-157-patient-organisations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/covid-19-severe-pneumonia-in-cancer-patients-impact-and-predictive-factors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/universal-screening-of-sars-cov-2-of-oncology-healthcare-workers-a-brazilian-experience
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/delivery-of-systemic-anti-cancer-therapy-during-the-covid-19-pandemic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/daily-chemotherapy-and-treatment-unit-in-the-covid-19-era-lessons-of-the-first-60-days
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prevalence-severity-and-evolution-of-coronavirus-disease-19-covid-19-infection-in-cancer-patients-from-mediterranean-population
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/developing-a-risk-assessment-score-for-cancer-patients-during-the-covid-19-pandemic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/covid-19-and-lung-cancer-what-do-we-know
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/hypercoagulable-state-cd4-t-lymphocytopenia-dysregulated-cytotoxicity-and-monocyte-upregulation-in-covid-19-positive-cancer-patients-presenting
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/caring-for-cancer-patients-in-the-wake-of-covid-19-pandemic-in-georgia
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-covid-19-crisis-on-multidisciplinary-tumour-board-treatment-decisions-a-cohort-analysis-from-india
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-and-epidemiologic-aspects-of-patients-with-cancer-and-covid-19-in-a-brazilian-cancer-center
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/determinants-of-mortality-from-sars-cov-2-infection-in-european-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sars-cov-2-infections-in-outpatients-with-cancer-most-infected-patients-are-asymptomatic-carriers-without-impact-on-chemotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/first-results-of-the-coco-study-covid-19-outcomes-in-patients-with-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/do-cancer-patients-really-do-worse-a-study-in-a-uk-tertiary-hospital-within-a-covid-19-epicentre
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sars-cov-2-infection-induces-emt-like-molecular-changes-including-zeb1-mediated-repression-of-the-viral-receptor-ace2-in-lung-cancer-models
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/elevated-axl-expression-following-sars-cov-2-infection-in-non-small-cell-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/national-approaches-to-managing-cancer-care-responses-of-countries-in-the-mena-region-to-covid-19-pandemic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/covid-19-an-additional-burden-on-caregivers-of-cancer-patients-in-tunisia
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-features-and-prognostic-factors-on-admission-of-a-prospective-cohort-of-covid-19-positive-cancer-patients-in-a-third-level-hospital-in-mad
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/assessing-the-impact-of-covid-19-outbreak-on-the-attitudes-and-practice-of-italian-oncologists-towards-breast-cancer-care-and-related-research-acti
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/triage-procedures-for-covid-19-in-an-italian-cancer-centre
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/outcomes-of-the-reorganisation-of-a-medical-oncology-department-during-the-covid-19-pandemic-real-word-experience
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/how-i-treat-covid-19-webinars-a-rapid-communication-platform-between-patients-and-physicians
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/behavioral-practices-of-cancer-patients-during-covid-19-pandemic-a-middle-east-and-north-africa-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-french-experience-on-covid-19-and-cancer-from-an-academic-general-hospital-in-paris-area
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-characteristics-and-28-day-mortality-among-patients-with-solid-cancers-and-covid-19-in-a-tertiary-hospital
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/how-do-oncological-patients-perceive-the-covid-19-pandemic-experience-from-chu-liege-in-belgium
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prolonged-positive-sars-cov-2-rt-pcr-in-cancer-outpatients-requires-specific-reorganization-of-cancer-centres
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/happy-wedding-access-and-availability-of-oncology-combination-medicines
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-data-cancer-and-sars-cov-2-infection
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/do-cancer-patients-really-do-worse-a-study-in-a-uk-tertiary-hospital-within-a-covid-19-epicentre
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sars-cov-2-infection-induces-emt-like-molecular-changes-including-zeb1-mediated-repression-of-the-viral-receptor-ace2-in-lung-cancer-models
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/elevated-axl-expression-following-sars-cov-2-infection-in-non-small-cell-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/covid-19-risk-for-patients-undergoing-anticancer-treatment-at-the-outpatient-clinic-of-the-national-cancer-institute-of-milan-the-covint-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/uk-coronavirus-cancer-monitoring-project-ukccmp-a-national-reporting-network-for-real-time-data-of-the-covid-19-pandemic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/covid-19-mortality-in-patients-receiving-anti-cancer-therapy-in-a-uk-national-cancer-centre
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sars-cov-2-infection-among-cancer-patients-receiving-antitumor-treatment-in-italy-a-nationwide-observational-study-cipomo-onco-covid-19
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/implementing-oncology-virtual-clinics-vc-in-response-to-covid-19-pandemic-a-transformation-driven-by-a-crisis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/curecancer-digital-tool-in-the-routine-clinical-oncology-practice-facilitates-pros-communicating-with-hcps-treatment-adherence-and-distancing-in
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/online-survey-on-sars-cov-2-infections-in-cancer-patients-during-a-nationwide-lockdown-in-france
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cancer-patients-perspectives-on-the-real-world-impact-of-covid-19-pandemic-a-multidisciplinary-survey
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sars-cov-2-infection-in-prostate-cancer-patients-data-from-a-high-incidence-area-in-italy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/risk-of-sars-cov-2-infection-and-outcome-after-infection-experience-from-the-day-care-unit-at-chu-liege-in-belgium
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/active-smoking-and-severity-of-covid-19-infection-in-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/change-of-circulating-pro-inflammatory-markers-between-pre-covid-19-condition-and-covid-19-diagnosis-predicts-early-death-in-cancer-patients-the-f
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/plinabulin-plin-is-a-more-favorable-option-for-the-prevention-of-chemotherapy-induced-neutropenia-cin-than-pegfilgrastim-peg-during-the-covid
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/vigil-plasmid-vp-a-dual-bi-shrna-furin-gmcsf-construct-from-cancer-to-sars-cov-2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/behavioral-practices-of-cancer-patients-during-covid-19-pandemic-a-middle-east-and-north-africa-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-french-experience-on-covid-19-and-cancer-from-an-academic-general-hospital-in-paris-area
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-characteristics-and-28-day-mortality-among-patients-with-solid-cancers-and-covid-19-in-a-tertiary-hospital
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/how-do-oncological-patients-perceive-the-covid-19-pandemic-experience-from-chu-liege-in-belgium
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prolonged-positive-sars-cov-2-rt-pcr-in-cancer-outpatients-requires-specific-reorganization-of-cancer-centres
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/longitudinal-analysis-of-biochemical-and-haematological-features-of-cancer-patients-with-covid-19
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/organizational-challenges-and-oncological-activity-volumes-during-the-sars-cov-2-epidemic-peak-in-verona-italy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/changes-in-the-outpatient-and-inpatient-clinic-admissions-during-covid-19-pandemic-anticipating-and-mitigating-risks-for-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/development-and-validation-of-telematic-follow-up-for-cancer-patients-during-the-covid-19-outbreak
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/expanding-the-role-of-medical-oncologist-in-the-management-of-covid-19
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/covid-19-pandemic-impact-on-doctors-in-training
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/evaluation-of-medical-practices-in-oncology-in-a-context-of-covid-19-pandemic-in-france-point-of-view-of-physicians-praticovid-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/influence-of-recent-administration-and-type-of-oncological-treatment-t-in-survival-of-oncological-patients-p-with-covid-19-experience-of-vall
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/electronic-medical-record-emr-assisted-phone-follow-up-pfu-for-breast-cancer-survivors-cs-during-covid-19-pandemic-an-italian-single-institu
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/molecular-diagnostics-for-cancer-patients-and-high-risk-individuals-during-the-sars-cov-2-pandemic-at-the-institute-for-oncology-and-radiology-of-s
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/do-breast-cancer-patients-with-covid-19-have-a-poor-prognosis-experience-in-a-hospital-in-madrid
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/caring-for-cancer-patients-in-the-wake-of-covid-19-pandemic-in-georgia
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-covid-19-crisis-on-multidisciplinary-tumour-board-treatment-decisions-a-cohort-analysis-from-india
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-and-epidemiologic-aspects-of-patients-with-cancer-and-covid-19-in-a-brazilian-cancer-center
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/longitudinal-analysis-of-biochemical-and-haematological-features-of-cancer-patients-with-covid-19
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/organizational-challenges-and-oncological-activity-volumes-during-the-sars-cov-2-epidemic-peak-in-verona-italy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/changes-in-the-outpatient-and-inpatient-clinic-admissions-during-covid-19-pandemic-anticipating-and-mitigating-risks-for-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/development-and-validation-of-telematic-follow-up-for-cancer-patients-during-the-covid-19-outbreak
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/expanding-the-role-of-medical-oncologist-in-the-management-of-covid-19
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/covid-19-pandemic-impact-on-doctors-in-training
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/evaluation-of-medical-practices-in-oncology-in-a-context-of-covid-19-pandemic-in-france-point-of-view-of-physicians-praticovid-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comparison-of-toxicities-of-parp-inhibitors-used-in-gynaecological-cancers-observed-at-a-large-cancer-centre
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/happy-wedding-access-and-availability-of-oncology-combination-medicines
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genetic-testing-and-results-in-chinese-gynecological-tumour-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-novel-methodology-in-producing-clinical-scaled-tumour-infiltrating-lymphocytes-across-multiple-gynecological-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/lio-1-a-phase-ii-study-of-lucitanib-nivolumab-in-patients-pts-with-gynaecological-tumours-co-3810-101-nct04042116-engot-gyn3-ago-lio
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/non-progression-with-avelumab-treatment-in-patients-with-metastatic-merkel-cell-carcinoma-mmcc-is-associated-with-a-clinically-meaningful-better-health-related-quality-of-life-compared-with-progressive-disease
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pod1um-201-a-phase-ii-study-of-retifanlimab-incmga00012-in-advanced-or-metastatic-merkel-cell-carcinoma-mcc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/real-world-rw-clinical-outcomes-in-patients-pts-with-locally-advanced-la-or-metastatic-merkel-cell-carcinoma-mmcc-treated-in-united-states-us-oncology-clinical-practices-results-from-spear-merkel
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-of-post-operative-radiation-therapy-in-non-metastatic-merkel-cell-carcinoma-a-registry-based-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba21-400mo-and-401mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-efficacy-and-immunity-of-combination-therapy-with-nivolumab-and-ido-pd-l1-peptide-vaccine-in-patients-with-metastatic-melanoma-a-phase-i
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/5-year-characterization-of-complete-responses-in-patients-with-advanced-melanoma-who-received-nivolumab-plus-ipilimumab-nivo-ipi-or-nivo-alone
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/final-results-from-illuminate-204-a-phase-i-ii-trial-of-intratumoral-tilsotolimod-in-combination-with-ipilimumab-in-pd-1-inhibitor-refractory-adva
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/activity-safety-and-circulating-tumour-dna-ctdna-dynamics-of-paradox-breaker-braf-inhibitor-plx8394-in-patients-with-advanced-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-benefit-in-biomarker-positive-patients-pts-with-locally-advanced-or-metastatic-solid-tumours-treated-with-the-parp1-2-inhibitor-pamipari
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/vhio-immune-gene-expression-signature-vigex-to-enrich-patient-selection-in-immunotherapy-it-phase-i-clinical-trials
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ib-study-of-tqb2450-in-combination-with-anlotinib-in-patients-with-advanced-solid-tumour
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ib-study-of-bi-836880-a-vegf-ang2-blocking-nanobody-R-in-combination-with-bi-754091-an-anti-pd-1-antibody-initial-results-in-patients-pts
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/first-in-human-study-of-ono-4578-a-pge2-receptor-ep4-antagonist-in-monotherapy-and-combination-with-pd-1-checkpoint-inhibitor-nivolumab-in-patien
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/bgb-a333-an-anti-pd-l1-monoclonal-antibody-in-combination-with-tislelizumab-in-patients-with-urothelial-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-i-first-in-human-safety-pharmacokinetic-and-pharmacodynamic-study-of-oral-dubermatinib-tp-0903-in-patients-with-advanced-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/first-in-human-study-of-jnj-64619178-a-protein-arginine-methyltransferase-5-prmt5-inhibitor-in-patients-with-advanced-cancers
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/anlotinib-in-locally-advanced-or-metastatic-radioiodine-refractory-differentiated-thyroid-carcinoma-a-randomized-double-blind-multicenter-phase
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-randomized-multicentered-phase-iii-study-to-evaluate-apatinib-in-subjects-with-locally-advanced-or-metastatic-radioactive-iodine-refractory-diffe
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/randomized-phase-ii-study-of-radiation-therapy-and-paclitaxel-with-pazopanib-or-placebo-nrg-rtog-0912
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/metabolomic-profile-of-advanced-neuroendocrine-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/survival-and-prognostic-factors-analysis-of-535-grade-3-gastroenteropancreatic-neuroendocrine-neoplasm-gep-nen-data-from-the-spanish-taskforce-o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-evaluation-of-serum-succinate-levels-as-a-new-biomarker-in-sdh-related-paragangliomas-and-pheochromocytomas
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/lanreotide-autogel-lan-and-temozolomide-tmz-combination-therapy-in-progressive-thoracic-neuroendocrine-tumours-tnets-atlant-study-results
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-and-safety-of-lanreotide-autogel-lan-120-mg-every-14-days-in-progressive-pancreatic-or-midgut-neuroendocrine-tumours-nets-clarinet-fo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/reaction-a-phase-ii-study-of-etoposide-and-cis-carboplatin-with-or-without-pembrolizumab-in-untreated-extensive-small-cell-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/durvalumab-d-tremelimumab-t-platinum-etoposide-ep-in-1l-es-sclc-characterization-of-long-term-clinical-benefit-and-tumour-mutational-bur
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impower133-characterisation-of-long-term-survivors-treated-first-line-with-chemotherapy-atezolizumab-in-extensive-stage-small-cell-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/health-related-quality-of-life-hrqol-in-keynote-604-pembrolizumab-pembro-or-placebo-added-to-etoposide-and-platinum-ep-as-first-line-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/three-year-follow-up-results-of-the-merit-trial-a-japanese-phase-ii-study-of-nivolumab-in-malignant-pleural-mesothelioma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/volumetric-pet-response-assessment-outperforms-conventional-criteria-in-patients-receiving-high-dose-pembrolizumab-for-malignant-mesothelioma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc-4-year-survival-update-from-the-phase-iii-pacific-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-single-arm-phase-ii-study-of-gefitinib-with-concurrent-thoracic-radiotherapy-in-unresectable-locally-advanced-non-small-cell-lung-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sakk-16-14-anti-pd-l1-antibody-durvalumab-in-addition-to-neoadjuvant-chemotherapy-in-patients-with-stage-iiia-n2-non-small-cell-lung-cancer-nsc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neoadjuvant-mfolfirinox-and-preoperative-chemoradiation-crt-versus-preoperative-crt-in-patients-with-t3-4-rectal-cancer-surgical-and-quality-of
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-efficacy-of-medi0457-plus-durvalumab-in-patients-pts-with-human-papillomavirus-associated-recurrent-metastatic-head-and-neck-squamous
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/topnivo-a-safety-study-of-nivolumab-in-patients-with-recurrent-and-or-metastatic-platinum-refractory-squamous-cell-carcinoma-of-head-and-neck-r
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/molecular-enrichment-and-outcomes-based-on-escat-levels-in-metastatic-salivary-gland-tumours-msgt-patients-pts-treated-in-early-clinical-trials
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/accuracy-a-phase-ii-trial-of-al101-a-selective-gamma-secretase-inhibitor-in-subjects-with-recurrent-metastatic-r-m-adenoid-cystic-carcinoma-ac
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sar439859-an-oral-selective-estrogen-receptor-er-degrader-serd-in-er-her2-metastatic-breast-cancer-mbc-biomarker-analyses-from-a-phase
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cfdna-analysis-from-phase-i-ii-study-of-lerociclib-g1t38-a-continuously-dosed-oral-cdk4-6-inhibitor-with-fulvestrant-in-hr-her2-advanced-brea
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/divergent-evolution-of-overall-survival-across-metastatic-breast-cancer-mbc-subtypes-in-the-nationwide-esme-real-life-cohort-2008-2016
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/progression-free-survival-with-endocrine-therapy-before-or-after-chemotherapy-in-patients-with-hormone-receptor-positive-her2-negative-metastatic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinicopathological-characteristics-and-prognosis-of-breast-cancer-patients-with-isolated-central-nervous-system-metastases-in-the-multicentre-esme
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/abraxane-plus-cisplatin-compared-with-gemcitabine-plus-cisplatin-as-first-line-treatment-in-patients-with-metastatic-triple-negative-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/repurposing-metformin-as-an-anticancer-drug-preliminary-results-of-randomized-controlled-trial-in-advanced-prostate-cancer-mansmed
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/local-therapy-to-the-primary-tumour-for-newly-diagnosed-oligo-metastatic-prostate-cancer-a-prospective-randomized-phase-ii-open-label-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/factors-associated-with-change-in-overall-survival-and-quality-of-life-between-time-of-approval-and-post-marketing-among-anti-cancer-therapies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pivotal-trial-endpoints-of-drugs-for-rare-and-non-rare-cancers-in-the-us-and-europe
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/how-much-does-it-cost-to-research-and-develop-a-new-medicine-a-systematic-review-and-evaluation-of-40-years-of-literature
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-comparative-study-on-costs-of-cancer-and-access-to-medicines-in-europe
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/opposition-to-a-patent-covering-tisagenlecleucel-using-intellectual-property-ip-legislation-to-defend-sustainable-access-to-cancer-therapies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/income-loss-after-a-cancer-diagnosis-from-the-patient-perspective-an-analysis-based-upon-the-german-socio-economic-panel-soep-survey
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ii-study-of-the-oral-hif-2a-inhibitor-mk-6482-for-von-hippel-lindau-vhl-disease-associated-clear-cell-renal-cell-carcinoma-ccrcc-update
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/an-integrated-study-of-spatial-dynamics-and-genomic-alterations-in-renal-cell-carcinoma-evolution
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ii-multicenter-randomized-study-to-evaluate-efficacy-and-safety-of-avelumab-with-gemcitabine-carboplatin-cg-vs-cg-alone-in-patients-with-u
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/avelumab-first-line-1l-maintenance-best-supportive-care-bsc-vs-bsc-alone-with-1l-chemotherapy-ctx-for-advanced-urothelial-carcinoma-uc-s
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sitravatinib-sitra-in-combination-with-nivolumab-nivo-demonstrates-clinical-activity-in-checkpoint-inhibitor-cpi-naive-platinum-experienced
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/association-between-human-papillomavirus-hpv-infection-and-outcome-of-perioperative-nodal-radiotherapy-for-penile-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/longitudinal-cohort-analysis-of-patients-with-metastatic-penile-cancer-treated-in-a-large-quaternary-academic-centre
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/metachronous-contralateral-testicular-cancer-in-the-cisplatin-era-a-population-based-cohort-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/long-term-efficacy-tolerability-and-overall-survival-in-patients-pts-with-unresectable-or-metastatic-u-m-pdgfra-d842v-mutant-gastrointestinal
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-benefit-with-ripretinib-as-4th-line-treatment-in-patients-with-advanced-gastrointestinal-stromal-tumors-gist-update-from-the-phase-iii
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ripretinib-intra-patient-dose-escalation-ipde-following-disease-progression-provides-clinically-meaningful-progression-free-survival-pfs-in-gas
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/weekly-nab-paclitaxel-for-progressive-or-symptomatic-desmoid-tumors-a-multicenter-single-arm-phase-ii-trial-from-the-spanish-group-for-research-on
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1079mo-1080mo-and-1081mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome15
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1587mo-and-1588mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome16
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba26-and-703mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1158mo-1159mo-and-1166mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-706mo-707mo-and-708mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba85-lba86-1781mo-and-1782mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1624mo-1625mo-and-1626mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba49-1236mo-and-1237mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/outcome-and-prognostic-factors-of-sars-cov-2-infection-in-cancer-patients-a-cross-sectional-study-sakk-80-20-casa
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-gco-002-cacovid-19-cohort-a-french-nationwide-multicenter-study-of-covid-19-infected-cancer-patients-and-consequences-on-cancer-management
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/maintenance-olaparib-bevacizumab-bev-in-patients-pts-with-newly-diagnosed-advanced-high-grade-ovarian-cancer-hgoc-recist-and-or-ca-125-obj
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ii-study-of-olaparib-o-plus-durvalumab-d-and-bevacizumab-b-mediola-initial-results-in-patients-pts-with-non-germline-brca-mutated
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-impact-of-chemosensitivity-assessed-by-modeled-ca-125-kelim-on-the-likelihood-of-long-progression-free-survivorship-ps-after-1st-line-treatme
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ago-desktop-iii-engot-ov20-impact-of-surgical-characteristics-and-time-to-first-subsequent-therapy-tfst
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/single-agent-anti-pd-1-balstilimab-or-in-combination-with-anti-ctla-4-zalifrelimab-for-recurrent-metastatic-r-m-cervical-cancer-cc-preliminary
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ii-study-of-parp-inhibitor-talazoparib-and-pd-l1-inhibitor-avelumab-in-patients-pts-with-microsatellite-stable-mss-recurrent-persistent-e
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-antitumor-activity-of-dostarlimab-in-patients-pts-with-advanced-or-recurrent-dna-mismatch-repair-deficient-dmmr-or-proficient-mmrp
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ace2-and-tmprss2-expression-by-clinical-hla-immune-and-microbial-correlates-across-34-human-cancers-and-matched-normal-tissues-implications-for
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/keeping-exhausted-t-cells-in-check-in-covid-19
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/influenza-like-illness-and-sars-cov-2-in-the-multicenter-prospective-observational-invidia-2-study-influenza-vaccine-indication-during-therapy-w
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/screening-of-covid-19-disease-based-on-chest-ct-and-pcr-for-cancer-patients-undergoing-radiotherapy-in-a-french-coronavirus-hotspot
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prevalence-and-clinical-impact-of-asymptomatic-or-mildly-symptomatic-sarscov-2-infection-among-actively-treated-cancer-patients-during-covid-19-pan
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/outcomes-of-the-2019-novel-coronavirus-in-patients-with-or-without-a-history-of-cancer-a-multi-centre-north-london-experience
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/covid-19-mortality-in-hospitalized-cancer-patients-is-not-significantly-affected-by-chemotherapy-or-other-anti-cancer-treatments
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/association-of-pre-existing-cardiovascular-disease-cvd-in-older-patients-with-breast-cancer-with-treatment-and-survival-outcomes
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/effects-of-oncologic-rehabilitation-during-adjuvant-endocrine-therapy-in-overweight-or-obese-patients-with-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/evaluation-of-early-unplanned-readmissions-and-predisposing-factors-in-an-oncology-clinic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-systemic-inflammation-intramuscular-adipose-tissue-content-and-eortc-qlq-cax24-symptom-scale-on-the-prognosis-of-patients-with-advanced
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome11
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prospective-validation-of-a-radiomics-signature-for-chemoradiotherapy-lung-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/photoreactive-and-intratumorally-injectable-dendrimer-matrix-improves-survival-in-multiple-xenograft-mouse-models
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/effective-tumour-growth-control-by-combined-vaccine-immune-checkpoint-inhibition-in-mlh1-mice
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tumour-infiltrating-macrophages-pd-l1-and-tumour-stroma-ratio-as-independent-prognostic-factors-in-a-well-defined-european-cohort-of-patients-with
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/inhibition-of-fatty-acid-synthase-fasn-activity-induces-cytotoxicity-on-gefitinib-and-osimertinib-resistant-egfr-mutated-non-small-cell-lung-can
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/radiochemotherapy-induced-changes-in-brain-extracellular-matrix-are-associated-with-tumour-development-in-mouse-recurrent-glioblastoma-model
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/senp1-knockdown-suppresses-tumour-progression-in-lung-adenocarcinoma-by-regulating-aat-genes-expression
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/c-myc-regulates-the-cancer-stem-cell-phenotype-differentially-induced-by-the-individual-silencing-of-akt-isoforms-in-pancreatic-adenocarcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tumour-infiltrating-lymphocytes-tils-pd-l1-expression-and-their-dynamics-in-the-neotripapdl1-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/folagli-a-phase-i-study-of-folinic-acid-combined-with-temozolomide-and-radiotherapy-to-modulate-mgmt-gene-promoter-methylation-in-newly-diagnosed
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/usefulness-of-circulating-tumour-dna-detection-from-cerebrospinal-fluid-in-recurrent-high-grade-glioma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/melanoma-leptomeningeal-metastases-a-european-multicenter-cohort
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/delivery-and-activity-of-sn-38-by-sacituzumab-govitecan-in-cns-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/primary-analysis-of-phase-ii-results-for-cemiplimab-in-patients-pts-with-locally-advanced-basal-cell-carcinoma-labcc-who-progress-on-or-are-int
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pd1-blockade-with-pembrolizumab-in-classic-and-endemic-kaposi-sarcoma-a-multicenter-phase-ii-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/mind-dc-a-randomized-phase-iii-trial-to-assess-the-efficacy-of-adjuvant-dendritic-cell-vaccination-in-comparison-to-placebo-in-stage-iiib-and-iiic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/progression-of-braf-mutant-cns-metastases-are-associated-with-a-transcriptional-network-bearing-similarities-with-the-innate-pd-1-resistant-signatu
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-value-of-local-therapy-in-treatment-of-solitary-melanoma-progression-upon-immune-checkpoint-inhibition
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-of-ipilimumab-plus-nivolumab-or-ipilimumab-plus-fotemustine-vs-fotemustine-in-patients-with-melanoma-metastatic-to-the-brain-primary-anal
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-efficacy-and-immunity-of-combination-therapy-with-nivolumab-and-ido-pd-l1-peptide-vaccine-in-patients-with-metastatic-melanoma-a-phase-i
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/5-year-characterization-of-complete-responses-in-patients-with-advanced-melanoma-who-received-nivolumab-plus-ipilimumab-nivo-ipi-or-nivo-alone
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/orient-12-sintilimab-plus-gemcitabine-and-platinum-gp-as-first-line-1l-treatment-for-locally-advanced-or-metastatic-squamous-non-small-cell-lu
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/mhc-ii-antigen-presentation-pathway-as-a-predictive-biomarker-for-sintilimab-plus-chemotherapy-in-first-line-treatment-of-locally-advanced-or-metas
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/activity-of-ose-2101-in-hla-a2-non-small-cell-lung-cancer-nsclc-patients-after-failure-to-immune-checkpoint-inhibitors-ici-step-1-results-of
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-novel-ai-solution-for-auto-segmentation-of-multi-origin-liver-neoplasms
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/maintenance-olaparib-plus-bevacizumab-bev-in-patients-pts-with-newly-diagnosed-advanced-high-grade-ovarian-carcinoma-hgoc-final-analysis-of
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/anti-sars-cov-2-antibody-response-in-patients-with-cancer-and-oncology-healthcare-workers-a-multicenter-prospective-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/provision-of-palliative-care-for-patients-with-cancer-and-sars-cov-2-infection
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/domoncovid-project-a-homecare-model-for-cancer-patients-during-covid-19
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-microsimulation-model-to-assess-the-impact-of-sars-cov-2-on-cancer-outcomes-healthcare-organization-and-economic-burden
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/dutch-oncology-covid-19-consortium-docc-outcome-of-covid-19-in-patients-with-cancer-in-a-nationwide-cohort-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-relevance-of-mir27a-rs895819-polymorphism-and-its-interaction-with-dpyd-variants-for-predicting-grade-4-5-fluoropyrimidine-fp-toxicity
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/personalized-circulating-tumour-dna-assay-for-the-detection-of-minimal-residual-disease-in-crc-patients-after-resection-of-metastases
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sequencing-paired-tumor-dna-and-white-blood-cells-wbcs-increases-sensitivity-to-track-plasma-circulating-tumor-dna-ctdna-for-detecting-minimal
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-4mo-and-5mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-7mo-8mo-1978mo-and-1979mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-6mo-1980mo-and-9mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/orient-12-sintilimab-plus-gemcitabine-and-platinum-gp-as-first-line-1l-treatment-for-locally-advanced-or-metastatic-squamous-non-small-cell-lu
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/mhc-ii-antigen-presentation-pathway-as-a-predictive-biomarker-for-sintilimab-plus-chemotherapy-in-first-line-treatment-of-locally-advanced-or-metas
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/activity-of-ose-2101-in-hla-a2-non-small-cell-lung-cancer-nsclc-patients-after-failure-to-immune-checkpoint-inhibitors-ici-step-1-results-of
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/maintenance-olaparib-plus-bevacizumab-bev-in-patients-pts-with-newly-diagnosed-advanced-high-grade-ovarian-carcinoma-hgoc-final-analysis-of
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/anti-sars-cov-2-antibody-response-in-patients-with-cancer-and-oncology-healthcare-workers-a-multicenter-prospective-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/provision-of-palliative-care-for-patients-with-cancer-and-sars-cov-2-infection
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/domoncovid-project-a-homecare-model-for-cancer-patients-during-covid-19
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-microsimulation-model-to-assess-the-impact-of-sars-cov-2-on-cancer-outcomes-healthcare-organization-and-economic-burden
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/dutch-oncology-covid-19-consortium-docc-outcome-of-covid-19-in-patients-with-cancer-in-a-nationwide-cohort-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-relevance-of-mir27a-rs895819-polymorphism-and-its-interaction-with-dpyd-variants-for-predicting-grade-4-5-fluoropyrimidine-fp-toxicity
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/personalized-circulating-tumour-dna-assay-for-the-detection-of-minimal-residual-disease-in-crc-patients-after-resection-of-metastases
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1421mo-1422mo-and-1423mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-4mo-and-5mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-7mo-8mo-1978mo-and-1979mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-6mo-1980mo-and-9mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba13-162mo-163mo-and-164mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba14-165mo-and-166mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-167mo-168mo-and-169mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba58-and-lba59
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba60-lba61-1261mo-and-lba62
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome13
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome7
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-365mo-366mo-and-367mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-368mo-369mo-and-370mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-371mo-372mo-and-373mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome8
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba47-1077mo-and-1078mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1079mo-1080mo-and-1081mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/vhio-immune-gene-expression-signature-vigex-to-enrich-patient-selection-in-immunotherapy-it-phase-i-clinical-trials
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-ib-study-of-tqb2450-in-combination-with-anlotinib-in-patients-with-advanced-solid-tumour
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ib-study-of-bi-836880-a-vegf-ang2-blocking-nanobody-R-in-combination-with-bi-754091-an-anti-pd-1-antibody-initial-results-in-patients-pts
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/first-in-human-study-of-ono-4578-a-pge2-receptor-ep4-antagonist-in-monotherapy-and-combination-with-pd-1-checkpoint-inhibitor-nivolumab-in-patien
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/bgb-a333-an-anti-pd-l1-monoclonal-antibody-in-combination-with-tislelizumab-in-patients-with-urothelial-carcinoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-i-first-in-human-safety-pharmacokinetic-and-pharmacodynamic-study-of-oral-dubermatinib-tp-0903-in-patients-with-advanced-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/first-in-human-study-of-jnj-64619178-a-protein-arginine-methyltransferase-5-prmt5-inhibitor-in-patients-with-advanced-cancers
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/anlotinib-in-locally-advanced-or-metastatic-radioiodine-refractory-differentiated-thyroid-carcinoma-a-randomized-double-blind-multicenter-phase
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-randomized-multicentered-phase-iii-study-to-evaluate-apatinib-in-subjects-with-locally-advanced-or-metastatic-radioactive-iodine-refractory-diffe
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/randomized-phase-ii-study-of-radiation-therapy-and-paclitaxel-with-pazopanib-or-placebo-nrg-rtog-0912
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome7
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-368mo-369mo-and-370mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba48-1082mo-and-1083mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-529mo-530mo-and-531mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-532mo-533mo-534moand-535mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-536moand-537mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome9
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba88-lba89-and-1914mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1158mo-1159mo-and-1166mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1161mo-and-1162mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome10
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba85-lba86-1781mo-and-1782mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1895mo-and-1896mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba49-1236mo-and-1237mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome11
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba42-and-1023mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1024mo-1025mo-and-1026mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba56-lba57-and-1260mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba60-lba61-1261mo-and-lba62
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome13
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome22
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1811mo-1812mo-1505mo-and-1813mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1814mo-1815mo-and-1816mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1817mo-and-1818mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome23
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-83mo-84mo-and-85mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-86mo-87mo-and-lba10
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-88mo-1931mo-1932mo-and-1933mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba42-and-1023mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1024mo-1025mo-and-1026mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/longitudinal-cohort-analysis-of-patients-with-metastatic-penile-cancer-treated-in-a-large-quaternary-academic-centre
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/metachronous-contralateral-testicular-cancer-in-the-cisplatin-era-a-population-based-cohort-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/long-term-efficacy-tolerability-and-overall-survival-in-patients-pts-with-unresectable-or-metastatic-u-m-pdgfra-d842v-mutant-gastrointestinal
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-benefit-with-ripretinib-as-4th-line-treatment-in-patients-with-advanced-gastrointestinal-stromal-tumors-gist-update-from-the-phase-iii
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ripretinib-intra-patient-dose-escalation-ipde-following-disease-progression-provides-clinically-meaningful-progression-free-survival-pfs-in-gas
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/weekly-nab-paclitaxel-for-progressive-or-symptomatic-desmoid-tumors-a-multicenter-single-arm-phase-ii-trial-from-the-spanish-group-for-research-on
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/abcb1-p-glycoprotein-pgp-expression-as-stratification-factor-for-treatment-of-patients-with-non-metastatic-extremity-high-grade-osteosarcoma-an
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/treatment-expectations-and-preferences-for-quality-versus-quantity-of-life-in-patients-with-advanced-soft-tissue-sarcomas-starting-palliative-1st-l
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/systemic-therapies-in-advanced-epithelioid-haemangioendothelioma-ehe-a-retrospective-international-series-from-the-world-sarcoma-network
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-new-benchmark-for-designing-phase-ii-trials-for-advanced-or-metastatic-leiomyosarcoma-lms-patients-using-progression-free-survival-pfs-as-pri
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/first-line-chemotherapy-ct-in-advanced-well-differentiated-dedifferentiated-liposarcoma-wd-dd-lps-an-eortc-soft-tissue-and-bone-sarcoma-group
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/paclitaxel-with-or-without-pazopanib-in-ovarian-cancer-patients-with-relapse-during-bevacizumab-maintenance-therapy-the-gineco-randomized-phase-ii
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-of-subsequent-chemotherapy-for-patients-with-brca1-2-mutated-platinum-sensitive-recurrent-epithelial-ovarian-cancer-eoc-progressing-on-o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/health-related-quality-of-life-hrqol-in-patients-pts-with-newly-diagnosed-stage-iii-or-iv-ovarian-cancer-treated-with-veliparib-vel-chemoth
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patient-reported-outcomes-pros-in-patients-pts-receiving-niraparib-in-the-prima-engot-ov26-gog-3012-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/maintenance-olaparib-for-patients-pts-with-newly-diagnosed-advanced-ovarian-cancer-oc-and-a-brca-mutation-brcam-5-year-y-follow-up-f-u
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/outcome-and-prognostic-factors-of-sars-cov-2-infection-in-cancer-patients-a-cross-sectional-study-sakk-80-20-casa
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-gco-002-cacovid-19-cohort-a-french-nationwide-multicenter-study-of-covid-19-infected-cancer-patients-and-consequences-on-cancer-management
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/maintenance-olaparib-bevacizumab-bev-in-patients-pts-with-newly-diagnosed-advanced-high-grade-ovarian-cancer-hgoc-recist-and-or-ca-125-obj
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ii-study-of-olaparib-o-plus-durvalumab-d-and-bevacizumab-b-mediola-initial-results-in-patients-pts-with-non-germline-brca-mutated
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/molecular-enrichment-and-outcomes-based-on-escat-levels-in-metastatic-salivary-gland-tumours-msgt-patients-pts-treated-in-early-clinical-trials
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/accuracy-a-phase-ii-trial-of-al101-a-selective-gamma-secretase-inhibitor-in-subjects-with-recurrent-metastatic-r-m-adenoid-cystic-carcinoma-ac
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sar439859-an-oral-selective-estrogen-receptor-er-degrader-serd-in-er-her2-metastatic-breast-cancer-mbc-biomarker-analyses-from-a-phase
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cfdna-analysis-from-phase-i-ii-study-of-lerociclib-g1t38-a-continuously-dosed-oral-cdk4-6-inhibitor-with-fulvestrant-in-hr-her2-advanced-brea
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/divergent-evolution-of-overall-survival-across-metastatic-breast-cancer-mbc-subtypes-in-the-nationwide-esme-real-life-cohort-2008-2016
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/progression-free-survival-with-endocrine-therapy-before-or-after-chemotherapy-in-patients-with-hormone-receptor-positive-her2-negative-metastatic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinicopathological-characteristics-and-prognosis-of-breast-cancer-patients-with-isolated-central-nervous-system-metastases-in-the-multicentre-esme
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/abraxane-plus-cisplatin-compared-with-gemcitabine-plus-cisplatin-as-first-line-treatment-in-patients-with-metastatic-triple-negative-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ipatasertib-ipat-paclitaxel-pac-for-pik3ca-akt1-pten-altered-hormone-receptor-positive-hr-her2-negative-advanced-breast-cancer-abc-prim
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/vandetanib-plus-fulvestrant-versus-placebo-plus-fulvestrant-after-relapse-or-progression-on-an-aromatase-inhibitor-in-metastatic-er-positive-breast
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/metabolomic-profile-of-advanced-neuroendocrine-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/survival-and-prognostic-factors-analysis-of-535-grade-3-gastroenteropancreatic-neuroendocrine-neoplasm-gep-nen-data-from-the-spanish-taskforce-o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-evaluation-of-serum-succinate-levels-as-a-new-biomarker-in-sdh-related-paragangliomas-and-pheochromocytomas
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/lanreotide-autogel-lan-and-temozolomide-tmz-combination-therapy-in-progressive-thoracic-neuroendocrine-tumours-tnets-atlant-study-results
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-and-safety-of-lanreotide-autogel-lan-120-mg-every-14-days-in-progressive-pancreatic-or-midgut-neuroendocrine-tumours-nets-clarinet-fo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/reaction-a-phase-ii-study-of-etoposide-and-cis-carboplatin-with-or-without-pembrolizumab-in-untreated-extensive-small-cell-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/durvalumab-d-tremelimumab-t-platinum-etoposide-ep-in-1l-es-sclc-characterization-of-long-term-clinical-benefit-and-tumour-mutational-bur
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impower133-characterisation-of-long-term-survivors-treated-first-line-with-chemotherapy-atezolizumab-in-extensive-stage-small-cell-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/health-related-quality-of-life-hrqol-in-keynote-604-pembrolizumab-pembro-or-placebo-added-to-etoposide-and-platinum-ep-as-first-line-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/three-year-follow-up-results-of-the-merit-trial-a-japanese-phase-ii-study-of-nivolumab-in-malignant-pleural-mesothelioma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/volumetric-pet-response-assessment-outperforms-conventional-criteria-in-patients-receiving-high-dose-pembrolizumab-for-malignant-mesothelioma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc-4-year-survival-update-from-the-phase-iii-pacific-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-single-arm-phase-ii-study-of-gefitinib-with-concurrent-thoracic-radiotherapy-in-unresectable-locally-advanced-non-small-cell-lung-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sakk-16-14-anti-pd-l1-antibody-durvalumab-in-addition-to-neoadjuvant-chemotherapy-in-patients-with-stage-iiia-n2-non-small-cell-lung-cancer-nsc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neoadjuvant-mfolfirinox-and-preoperative-chemoradiation-crt-versus-preoperative-crt-in-patients-with-t3-4-rectal-cancer-surgical-and-quality-of
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/curative-chemoradiation-for-low-rectal-cancer-early-clinical-outcomes-from-a-multicentre-phase-ii-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/os-and-long-term-dfs-with-3-vs.-6-month-adjuvant-oxaliplatin-and-fluoropyrimidine-based-therapy-for-stage-iii-colon-cancer-patients-a-randomized
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/final-results-of-the-caracas-study-randomized-phase-ii-trial-of-avelumab-alone-or-with-cetuximab-for-unresectable-locally-advanced-or-metastatic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/atezolizumab-in-combination-with-bevacizumab-for-patients-with-unresectable-metastatic-anal-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/outcome-and-prognostic-factors-of-sars-cov-2-infection-in-cancer-patients-a-cross-sectional-study-sakk-80-20-casa
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-gco-002-cacovid-19-cohort-a-french-nationwide-multicenter-study-of-covid-19-infected-cancer-patients-and-consequences-on-cancer-management
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/maintenance-olaparib-bevacizumab-bev-in-patients-pts-with-newly-diagnosed-advanced-high-grade-ovarian-cancer-hgoc-recist-and-or-ca-125-obj
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ii-study-of-olaparib-o-plus-durvalumab-d-and-bevacizumab-b-mediola-initial-results-in-patients-pts-with-non-germline-brca-mutated
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-impact-of-chemosensitivity-assessed-by-modeled-ca-125-kelim-on-the-likelihood-of-long-progression-free-survivorship-ps-after-1st-line-treatme
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ago-desktop-iii-engot-ov20-impact-of-surgical-characteristics-and-time-to-first-subsequent-therapy-tfst
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/single-agent-anti-pd-1-balstilimab-or-in-combination-with-anti-ctla-4-zalifrelimab-for-recurrent-metastatic-r-m-cervical-cancer-cc-preliminary
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-ii-study-of-parp-inhibitor-talazoparib-and-pd-l1-inhibitor-avelumab-in-patients-pts-with-microsatellite-stable-mss-recurrent-persistent-e
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-antitumor-activity-of-dostarlimab-in-patients-pts-with-advanced-or-recurrent-dna-mismatch-repair-deficient-dmmr-or-proficient-mmrp
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ace2-and-tmprss2-expression-by-clinical-hla-immune-and-microbial-correlates-across-34-human-cancers-and-matched-normal-tissues-implications-for
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/keeping-exhausted-t-cells-in-check-in-covid-19
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-815mo-and-816mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba34-lba35-and-lba36
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome21
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1674mo-lba81-and-lba82
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1675mo-1676mo-lba83-and-1677mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome22
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1811mo-1812mo-1505mo-and-1813mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1814mo-1815mo-and-1816mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1817mo-and-1818mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome23
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-83mo-84mo-and-85mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-86mo-87mo-and-lba10
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-88mo-1931mo-1932mo-and-1933mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1424mo-and-1425mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-612mo-614mo-and-lba22
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-615mo-and-616mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome15
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1585mo-and-1586mo_pr
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome16
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba26-and-703mo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/zenith20-a-multinational-multi-cohort-phase-ii-study-of-poziotinib-in-nsclc-patients-with-egfr-or-her2-exon-20-insertion-mutations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/first-analysis-of-rain-701-study-of-tarloxotinib-in-patients-with-non-small-cell-lung-cancer-nsclc-egfr-exon-20-insertion-her2-activating-mutat
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-relevance-of-mir27a-rs895819-polymorphism-and-its-interaction-with-dpyd-variants-for-predicting-grade-4-5-fluoropyrimidine-fp-toxicity
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/personalized-circulating-tumour-dna-assay-for-the-detection-of-minimal-residual-disease-in-crc-patients-after-resection-of-metastases
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/expected-medium-and-long-term-impact-of-the-covid-19-outbreak-in-oncology
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/esmo-presidential-address
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/covid-19-public-health-and-scientific-challenges
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/highlights-of-the-science-weekend
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/how-t-cells-induce-cancer-regressions
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-randomised-double-blind-placebo-controlled-phase-ii-trial-of-palbociclib-combined-with-letrozole-l-in-patients-pts-with-oestrogen-receptor-po
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/radical-hysterectomy-in-cervical-cancer-patients-with-intraoperatively-detected-positive-lymph-node-abrax-multicentric-retrospective-cohort-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/individualized-starting-dose-of-niraparib-in-chinese-patients-with-platinum-sensitive-recurrent-ovarian-cancer-psroc-a-randomized-double-blind
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/inovatyon-study-randomized-phase-iii-international-study-comparing-trabectedin-pld-followed-by-platinum-at-progression-vs-carboplatin-pld-in-patie
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion57
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion7
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/welcome-by-eons
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/welcome-by-spanish-oncology-nursing-society-sociedad-espanola-de-enfermeria-oncologica-seeo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/message-from-the-european-parliament
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cancer-control-in-the-who-europe-region-the-importance-of-nurses
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-year-of-the-nurse-and-midwife-commission-s-priorities-in-the-area-of-occupational-health
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion57
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neoadjuvant-durvalumab-in-resectable-non-small-cell-lung-cancer-nsclc-preliminary-results-from-a-multicenter-study-ifct-1601-ionesco
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neoadjuvant-atezolizumab-a-for-resectable-non-small-cell-lung-cancer-nsclc-results-from-the-phase-ii-princeps-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/consolidation-ipilimumab-and-nivolumab-vs-observation-in-limited-stage-sclc-after-chemo-radiotherapy-results-from-the-etop-ifct-4-12-stimuli-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patient-reported-outcomes-from-a-randomized-phase-ii-trial-comparing-standard-dose-with-high-dose-twice-daily-bid-thoracic-radiotherapy-trt-in
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pembrolizumab-versus-cetuximab-concomitant-with-radiotherapy-rt-in-locally-advanced-head-and-neck-squamous-cell-carcinoma-la-hnscc-results-of
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/primary-results-of-the-phase-iii-javelin-head-neck-100-trial-avelumab-plus-chemoradiotherapy-crt-followed-by-avelumab-maintenance-vs-crt-in-pa
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/3-years-follow-up-of-double-blind-randomized-phase-ii-comparing-concurrent-high-dose-cisplatin-chemo-radiation-plus-xevinapant-or-placebo-in-high-r
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neoadjuvant-nivolumab-and-nivolumab-plus-ipilimumab-induce-near-complete-responses-in-patients-with-head-and-neck-squamous-cell-carcinoma-the-i
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/performance-of-dual-p16-and-hpv-testing-for-determining-prognosis-in-cancer-of-the-oropharynx-the-epic-opc-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/individualized-starting-dose-of-niraparib-in-chinese-patients-with-platinum-sensitive-recurrent-ovarian-cancer-psroc-a-randomized-double-blind
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/inovatyon-study-randomized-phase-iii-international-study-comparing-trabectedin-pld-followed-by-platinum-at-progression-vs-carboplatin-pld-in-patie
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neoadjuvant-durvalumab-in-resectable-non-small-cell-lung-cancer-nsclc-preliminary-results-from-a-multicenter-study-ifct-1601-ionesco
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neoadjuvant-atezolizumab-a-for-resectable-non-small-cell-lung-cancer-nsclc-results-from-the-phase-ii-princeps-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/consolidation-ipilimumab-and-nivolumab-vs-observation-in-limited-stage-sclc-after-chemo-radiotherapy-results-from-the-etop-ifct-4-12-stimuli-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patient-reported-outcomes-from-a-randomized-phase-ii-trial-comparing-standard-dose-with-high-dose-twice-daily-bid-thoracic-radiotherapy-trt-in
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pembrolizumab-versus-cetuximab-concomitant-with-radiotherapy-rt-in-locally-advanced-head-and-neck-squamous-cell-carcinoma-la-hnscc-results-of
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/primary-results-of-the-phase-iii-javelin-head-neck-100-trial-avelumab-plus-chemoradiotherapy-crt-followed-by-avelumab-maintenance-vs-crt-in-pa
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/3-years-follow-up-of-double-blind-randomized-phase-ii-comparing-concurrent-high-dose-cisplatin-chemo-radiation-plus-xevinapant-or-placebo-in-high-r
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neoadjuvant-nivolumab-and-nivolumab-plus-ipilimumab-induce-near-complete-responses-in-patients-with-head-and-neck-squamous-cell-carcinoma-the-i
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/performance-of-dual-p16-and-hpv-testing-for-determining-prognosis-in-cancer-of-the-oropharynx-the-epic-opc-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/advanced-practice-nursing-definition-and-types-of-advanced-nursing-roles
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/overview-of-advanced-practice-in-cancer-nursing-comparison-between-different-countries-with-established-roles-part-i
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/overview-of-advanced-practice-in-cancer-nursing-comparison-between-different-countries-with-established-roles-part-ii
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-live-discussion3
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1928o-and-1929o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion59
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion8
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-398o-and-399o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion9
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1930o-82o-and-1189o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion11
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba69-and-lba70_pr
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion12
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba71-and-1670o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion9
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-396o-and-397o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-impact-of-covid-19-on-oncology-professionals-initial-results-of-the-esmo-resilience-task-force-survey-collaboration
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/oxaliplatin-plus-fluoropyrimidines-as-adjuvant-therapy-for-colon-cancer-in-elderly-patients-a-subgroup-analysis-from-tosca-trial
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/meta-analysis-of-tumour-and-t-cell-intrinsic-mechanisms-of-sensitization-to-checkpoint-inhibition
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/soluble-pd-l1-and-circulating-cd8-pd1-and-nk-cells-enclose-a-highly-prognostic-and-predictive-immune-effector-score-in-immunotherapy-treated-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genomic-alterations-in-solid-tumours-according-to-esmo-scale-for-clinical-actionability-of-molecular-targets-escat
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genomic-evolution-of-metastatic-tumours-under-therapeutic-pressure
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/validation-of-whole-genome-sequencing-in-routine-clinical-practice
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-the-covid-19-pandemic-on-management-of-medical-cancer-treatments-and-psychological-consequence-for-the-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/systemic-cancer-treatment-related-outcomes-in-patients-with-sars-cov-2-infection-a-ccc19-registry-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prospective-data-of-first-1-797-hospitalised-patients-with-cancer-and-covid-19-derived-from-the-covid-19-clinical-information-network-and-internati
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/value-of-nurse-navigators-nns-telemonitoring-for-cancer-patients-pts-tested-positive-for-covid-19
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/how-do-patients-value-the-role-of-the-breast-care-nurse-in-the-catalan-institute-of-oncology
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/health-related-quality-of-life-hrqol-in-patients-pts-treated-with-pembrolizumab-pembro-vs-chemotherapy-as-first-line-treatment-in-microsatell
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prospective-data-of-first-1-797-hospitalised-patients-with-cancer-and-covid-19-derived-from-the-covid-19-clinical-information-network-and-internati
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-impact-of-covid-19-on-oncology-professionals-initial-results-of-the-esmo-resilience-task-force-survey-collaboration
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/spartalizumab-plus-dabrafenib-and-trametinib-sparta-dabtram-in-patients-pts-with-previously-untreated-braf-v600-mutant-unresectable-or-metastat
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/lenvatinib-len-plus-pembrolizumab-pembro-for-advanced-melanoma-mel-that-progressed-on-a-pd-1-or-pd-l1-inhibitor-initial-results-of-leap-004
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/first-report-of-efficacy-and-safety-from-the-phase-ii-study-secombit-sequential-combo-immuno-and-targeted-therapy-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pembrolizumab-versus-placebo-after-complete-resection-of-high-risk-stage-iii-melanoma-final-results-regarding-distant-metastasis-free-survival-fro
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/adjuvant-nivolumab-nivo-vs-ipilimumab-ipi-in-resected-stage-iii-iv-melanoma-4-y-recurrence-free-and-overall-survival-os-results-from-checkma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pembrolizumab-p-combined-with-chemotherapy-c-vs-c-alone-as-first-line-1l-therapy-for-advanced-urothelial-carcinoma-uc-keynote-361
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-iii-randomized-open-label-study-of-first-line-durvalumab-d-with-or-without-tremelimumab-t-vs-standard-of-care-chemotherapy-in-patient
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/trophy-u-01-cohort-1-final-results-a-phase-ii-study-of-sacituzumab-govitecan-sg-in-metastatic-urothelial-cancer-muc-that-has-progressed-after
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba17-lba18-and-273o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba43-lba44-and-lba45
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion15
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion16
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion17
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion18
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patient-experience-according-to-a-patient-advocate
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba46-and-1076o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba23-and-697o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/primary-results-from-impassion131-a-double-blind-placebo-controlled-randomised-phase-iii-trial-of-first-line-paclitaxel-pac-atezolizumab-atez
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion16
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba23-and-697o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion17
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba24-698o-and-699o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion18
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patient-experience-according-to-a-patient-advocate
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba15-and-lba16
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patient-reported-experiences-of-cancer-care-related-to-the-covid-19-pandemic-in-switzerland-a-qualitative-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sars-cov-2-and-the-perspectives-of-people-living-with-cancer-the-aiiao-survey-on-the-italian-lockdown
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/primary-results-from-impassion131-a-double-blind-placebo-controlled-randomised-phase-iii-trial-of-first-line-paclitaxel-pac-atezolizumab-atez
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-iii-randomized-open-label-study-of-first-line-durvalumab-d-with-or-without-tremelimumab-t-vs-standard-of-care-chemotherapy-in-patient
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/trophy-u-01-cohort-1-final-results-a-phase-ii-study-of-sacituzumab-govitecan-sg-in-metastatic-urothelial-cancer-muc-that-has-progressed-after
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patient-reported-outcomes-pros-from-imvigor130-a-global-randomised-partially-blinded-phase-iii-study-of-atezolizumab-atezo-platinum-based
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/avelumab-first-line-1l-maintenance-best-supportive-care-bsc-vs-bsc-alone-for-advanced-urothelial-carcinoma-uc-association-between-clinical
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba1
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion48
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion49
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-696o_pr
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion50
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/osimertinib-adjuvant-therapy-in-patients-pts-with-resected-egfr-mutated-egfrm-nsclc-adaura-central-nervous-system-cns-disease-recurrence
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/lorlatinib-vs-crizotinib-in-the-first-line-treatment-of-patients-pts-with-advanced-alk-positive-non-small-cell-lung-cancer-nsclc-results-of-th
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nivolumab-cabozantinib-vs-sunitinib-in-first-line-treatment-for-advanced-renal-cell-carcinoma-first-results-from-the-randomized-phase-iii-checkm
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/introduction-and-presentation-of-data-from-w4o-authorship-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/women-in-science
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/connecting-the-dots-the-eu-plan-to-beat-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-esmo-vision-for-european-cancer-policy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/this-is-what-we-need-to-achieve-globally
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion3
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion55
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/this-is-what-we-need-to-achieve-globally
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/introduction-and-presentation-of-data-from-w4o-authorship-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/women-in-science
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-esmo-vision-for-european-cancer-policy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion3
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/hepatic-arterial-infusion-chemotherapy-haic-with-oxaliplatin-fluorouracil-and-leucovorin-folfox-versus-transarterial-chemoembolization-tace
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-canadian-cancer-trials-group-pa.7-trial-results-of-a-randomized-phase-ii-study-of-gemcitabine-gem-and-nab-paclitaxel-nab-p-vs-gem-nab-p
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-qolixane-trial-real-life-qol-and-efficacy-data-in-1st-line-pancreatic-cancer-from-the-prospective-platform-for-outcome-quality-of-life-and
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/telomerase-reverse-transcriptase-tert-promoter-mutation-and-o6-methylguanine-dna-methyltransferase-mgmt-promoter-methylation-mediated-sensitivi
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/defining-the-prognostic-role-of-mgmt-methylation-value-by-pyrosequencing-assay-in-glioblastoma-patients-a-large-italian-multicenter-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion19
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba65-and-1525o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-362o-363o-and-364o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba11-159o-and-160o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion20
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion22
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba12-and-161o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion23
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-360o-and-361o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion21
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-canadian-cancer-trials-group-pa.7-trial-results-of-a-randomized-phase-ii-study-of-gemcitabine-gem-and-nab-paclitaxel-nab-p-vs-gem-nab-p
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-qolixane-trial-real-life-qol-and-efficacy-data-in-1st-line-pancreatic-cancer-from-the-prospective-platform-for-outcome-quality-of-life-and
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/telomerase-reverse-transcriptase-tert-promoter-mutation-and-o6-methylguanine-dna-methyltransferase-mgmt-promoter-methylation-mediated-sensitivi
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-981o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion19
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba65-and-1525o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion21
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba11-159o-and-160o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion22
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-360o-and-361o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/survival-analysis-of-the-randomized-phase-iii-geparocto-trial-comparing-neoadjuvant-chemotherapy-nact-of-iddepc-versus-weekly-paclitaxel-liposom
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pallas-a-randomized-phase-iii-trial-of-adjuvant-palbociclib-with-endocrine-therapy-versus-endocrine-therapy-alone-for-hr-her2-early-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/randomized-preoperative-window-of-opportunity-woo-study-with-the-cdk4-6-inhibitor-abemaciclib-in-early-breast-cancer-ebc-patients-and-different
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/management-of-immunotherapy-toxicities-a-new-challenge
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion25
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1020o-and-1021o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion27
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion28
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1157o-and-1913o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba41-and-1019o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/active-apatinib-plus-gefitinib-versus-placebo-plus-gefitinib-as-first-line-treatment-for-advanced-epidermal-growth-factor-receptor-mutant-egfrm
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-randomized-phase-ii-study-of-osimertinib-with-or-without-bevacizumab-in-advanced-lung-adenocarcinoma-patients-with-egfr-t790m-mutation-west-japa
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/leap-005-phase-ii-study-of-lenvatinib-len-plus-pembrolizumab-pembro-in-patients-pts-with-previously-treated-advanced-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/surufatinib-s-for-patients-pts-with-advanced-pancreatic-neuroendocrine-tumours-sanet-p-a-randomized-double-blind-placebo-p-controlled-ph
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-i-studies-of-sym021-an-anti-pd-1-antibody-alone-and-in-combination-with-sym022-anti-lag-3-or-sym023-anti-tim-3
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-i-first-in-human-open-label-dose-escalation-study-of-mgd019-an-investigational-bispecific-pd-1-x-ctla-4-dart-R-molecule-in-patients-with
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-antitumor-activity-of-ak104-a-bispecific-antibody-targeting-pd-1-and-ctla-4-in-patients-with-mesothelioma-which-is-relapsed-or-refract
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/an-international-open-label-study-on-safety-and-efficacy-of-177lu-satoreotide-tetraxetan-in-somatostatin-receptor-positive-neuroendocrine-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-multi-cohort-phase-ii-study-of-durvalumab-plus-tremelimumab-for-the-treatment-of-patients-pts-with-advanced-neuroendocrine-neoplasms-nens-of
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/oral-targeted-therapy-dose-adaptation-in-geriatric-cancer-patients-a-real-life-french-cohort
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1257o-and-1258o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion24
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba50-and-1259o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion25
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba41-and-1019o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1156o-and-1160o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion28
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion26
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1020o-and-1021o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion27
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-antitumor-activity-of-ak104-a-bispecific-antibody-targeting-pd-1-and-ctla-4-in-patients-with-mesothelioma-which-is-relapsed-or-refract
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-multi-cohort-phase-ii-study-of-durvalumab-plus-tremelimumab-for-the-treatment-of-patients-pts-with-advanced-neuroendocrine-neoplasms-nens-of
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-live-discussion6
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion30
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba72-and-lba73
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba74-and-lba75
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion32
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-524o-525o-and-526o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion33
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-527o-and-528o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-live-discussion6
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion34
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/disparities-in-cancer-during-the-covid-19-pandemic-covid-19-and-cancer-outcomes-study-ccos
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-i-dose-escalation-study-of-prs-343-a-her2-4-1bb-bispecific-molecule-in-patients-with-her2-positive-malignancies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/high-activity-of-nivolumab-in-patients-with-pathogenic-exonucleasic-domain-pole-edpole-mutated-mismatch-repair-proficient-mmrp-advanced-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cc-90010-a-reversible-oral-bromodomain-and-extra-terminal-bet-inhibitor-in-patients-pts-with-advanced-solid-tumours-sts-and-relapsed-refrac
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/assessment-of-clinical-and-laboratory-prognostic-factors-in-patients-with-cancer-and-sars-cov-2-infection-the-covid-19-and-cancer-consortium-ccc19
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-orf1ab-of-sars-cov-2-encodes-an-immunodominant-epitope-restricted-by-hla-a-01-01
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/defining-covid-19-outcomes-in-thoracic-cancer-patients-teravolt-thoracic-cancers-international-covid-19-collaboration
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/initial-results-of-a-phase-i-study-of-mk-4830-a-first-in-class-anti-immunoglobulin-like-transcript-4-ilt4-myeloid-specific-antibody-in-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-of-the-randomized-placebo-pl-controlled-phase-ii-study-evaluating-the-efficacy-and-safety-of-regorafenib-reg-in-patients-pts-with-me
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/phase-i-study-of-tk216-a-novel-anti-ets-agent-for-ewing-sarcoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/assessment-of-clinical-and-laboratory-prognostic-factors-in-patients-with-cancer-and-sars-cov-2-infection-the-covid-19-and-cancer-consortium-ccc19
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-orf1ab-of-sars-cov-2-encodes-an-immunodominant-epitope-restricted-by-hla-a-01-01
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/disparities-in-cancer-during-the-covid-19-pandemic-covid-19-and-cancer-outcomes-study-ccos
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/defining-covid-19-outcomes-in-thoracic-cancer-patients-teravolt-thoracic-cancers-international-covid-19-collaboration
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/initial-results-of-a-phase-i-study-of-mk-4830-a-first-in-class-anti-immunoglobulin-like-transcript-4-ilt4-myeloid-specific-antibody-in-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-phase-i-dose-escalation-study-of-prs-343-a-her2-4-1bb-bispecific-molecule-in-patients-with-her2-positive-malignancies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/high-activity-of-nivolumab-in-patients-with-pathogenic-exonucleasic-domain-pole-edpole-mutated-mismatch-repair-proficient-mmrp-advanced-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cc-90010-a-reversible-oral-bromodomain-and-extra-terminal-bet-inhibitor-in-patients-pts-with-advanced-solid-tumours-sts-and-relapsed-refrac
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba72-and-lba73
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba3_pr
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion53
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba4-and-610o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-live-discussion9
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba5_pr
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion54
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/an-international-randomized-trial-comparing-post-operative-conformal-radiotherapy-port-to-no-port-in-patients-with-completely-resected-non-smal
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ipatential150-phase-iii-study-of-ipatasertib-ipat-plus-abiraterone-abi-vs-placebo-pbo-plus-abi-in-metastatic-castration-resistant-prostate-c
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/final-overall-survival-os-analysis-of-profound-olaparib-vs-physician-s-choice-of-enzalutamide-or-abiraterone-in-patients-pts-with-metastatic-c
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/abemaciclib-in-high-risk-early-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/annals-of-oncology
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/esmo-open
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/io-tech
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion58
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/what-is-gender-medicine
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/introduction-with-overview-of-gender-differences-in-the-epidemiology-and-outcomes-of-non-sex-related-cancers
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sex-differences-in-physiology-body-composition-and-pharmacokinetics
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-impact-of-gender-differences-in-gastrointestinal-cancers
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/annals-of-oncology
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/esmo-open
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/where-everything-started-the-esmo-mcbs
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/what-we-need-to-bring-into-the-equation-the-esmo-escat
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion35
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba19
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion36
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba87-1809o-and-1568o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1810o-and-1504o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/long-term-follow-up
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/long-term-follow-up
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/eons-young-cancer-nurses-study-results-and-next-steps
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-live-discussion2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion38
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-274o-275o-and-276o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion35
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/health-related-quality-of-life-hrqol-changes-with-veliparib-in-patients-pts-with-metastatic-or-locally-advanced-breast-cancer-in-the-phase-iii
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-tucatinib-on-health-related-quality-of-life-hrqol-in-patients-with-her2-metastatic-breast-cancer-mbc-with-and-without-brain-metastas
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/geicam-2014-12-flipper-study-first-analysis-from-a-randomized-phase-ii-trial-of-fulvestrant-f-palbociclib-p-versus-vs-f-placebo-pl-as-fi
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-pragmatic-cluster-randomized-trial-of-ambulatory-toxicity-management-in-patients-receiving-adjuvant-or-neo-adjuvant-chemotherapy-for-early-stage
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/geicam-2014-12-flipper-study-first-analysis-from-a-randomized-phase-ii-trial-of-fulvestrant-f-palbociclib-p-versus-vs-f-placebo-pl-as-fi
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-pragmatic-cluster-randomized-trial-of-ambulatory-toxicity-management-in-patients-receiving-adjuvant-or-neo-adjuvant-chemotherapy-for-early-stage
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/trheuma-registry-provides-real-world-data-on-rheumatic-immune-related-adverse-events
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/quality-of-life-in-cancer-patients-treated-with-immune-checkpoint-inhibitors-a-meta-analysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/impact-of-malnutrition-according-to-the-glim-criteria-in-cancer-patients-admitted-to-hospital
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/relationship-between-sarcopenia-and-anthracycline-related-cardiotoxicity-in-patients-with-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/abiraterone-acetate-plus-prednisolone-for-hormone-naive-prostate-cancer-pca-long-term-results-from-metastatic-m1-patients-in-the-stampede-rand
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/disparities-in-access-to-oncology-clinical-trials-in-europe-in-the-period-2009-2019
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/developing-a-real-world-outcomes-forecast-model-using-matched-oncology-clinical-trials-and-real-world-evidence-to-inform-policy-making-and-reimburs
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/precision-immuno-oncology-for-advanced-non-small-cell-lung-cancer-nsclc-patients-pts-treated-with-pd1-l1-immune-checkpoint-inhibitors-icis-a
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/specific-considerations-for-older-adults-undergoing-anti-cancer-therapies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/position-statement-paper-related-to-the-care-for-older-patients-with-cancer-between-siog-eons-cano
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/supportive-and-palliative-care-in-geriatric-oncology
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-609o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-611o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion39
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1581o_pr-and-lba66_pr
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba54-and-lba55
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-live-discussion5
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion40
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba54-and-lba55
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-live-discussion8
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/estimation-of-european-cancer-burden-for-the-year-2020
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-a-phase-i-study-of-amg-160-a-half-life-extended-hle-psma-targeted-bispecific-t-cell-engager-bite-R-immune-therapy-for-metastatic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/abiraterone-acetate-plus-prednisolone-for-hormone-naive-prostate-cancer-pca-long-term-results-from-metastatic-m1-patients-in-the-stampede-rand
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/disparities-in-access-to-oncology-clinical-trials-in-europe-in-the-period-2009-2019
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/developing-a-real-world-outcomes-forecast-model-using-matched-oncology-clinical-trials-and-real-world-evidence-to-inform-policy-making-and-reimburs
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-benefit-of-cancer-drugs-approved-in-switzerland-during-the-last-decade
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/health-technology-assessment-hta-in-england-france-and-germany-what-do-we-know-about-variations-in-cancer-related-hta-outcomes
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/keynote-024-5-year-os-update-first-line-1l-pembrolizumab-pembro-vs-platinum-based-chemotherapy-chemo-in-patients-pts-with-metastatic-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/randomized-phase-iii-trial-of-nivolumab-in-combination-with-carboplatin-paclitaxel-and-bevacizumab-as-first-line-treatment-for-patients-with-adva
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/wjog-be-study-a-phase-ii-study-of-atezolizumab-atez-with-bevacizumab-bev-for-non-squamous-sq-non-small-cell-lung-cancer-nsclc-with-high-p
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/abiraterone-acetate-plus-prednisolone-for-hormone-naive-prostate-cancer-pca-long-term-results-from-metastatic-m1-patients-in-the-stampede-rand
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-utility-of-a-brief-clinical-frailty-scale-cfs-in-predicting-prognosis-and-discharge-destination-in-oncology-inpatients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/video-consultations-with-older-patients-in-the-oncology-nursing-outpatient-clinic
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion60
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-700o-and-701o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion44
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-702o-and-lba25
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion45
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba31-and-805o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion46
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba32-and-807o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion47
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-1o-and-1977o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion42
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-2o-and-3o
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion43
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-study-of-cancer-dissemination-from-metastatic-intermediates-of-hypermethylated-colorectal-patients-reveals-a-new-mode-of-collective-migration
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/functional-inactivation-of-e-cadherin-drives-emt-less-metastasis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/novice-research-dissemination-award-1-abstract-cn42-nurse-and-pharmacist-delivered-gynaecology-telephone-clinic-maintenance-therapies-patient-an
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/novice-research-dissemination-award-2-abstract-cn46-real-life-experience-of-nurses-coordinating-device-in-oral-therapy-centre-dicto-program
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/discussion-and-closing
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/a-study-of-cancer-dissemination-from-metastatic-intermediates-of-hypermethylated-colorectal-patients-reveals-a-new-mode-of-collective-migration
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/functional-inactivation-of-e-cadherin-drives-emt-less-metastasis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/growth-differentiation-factor-15-gdf-15-neutralization-reverses-cancer-cachexia-restores-physical-performance-and-mitigates-emesis-associated-wi
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-of-the-triple-combination-of-estrogen-receptor-cdk4-6-and-pi3k-pathway-inhibitors-in-ex-vivo-models-of-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/kidney-ccrcc-immune-classification-kic-enhances-the-predictive-value-of-t-effector-teff-and-angiogenesis-angio-signatures-in-response-to-nivo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/assessment-of-circulating-cell-free-tumor-dna-ctdna-in-847-patients-pts-with-metastatic-renal-cell-carcinoma-mrcc-and-concordance-with-tissue
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cabozantinib-c-in-combination-with-atezolizumab-a-as-first-line-therapy-for-advanced-clear-cell-renal-cell-carcinoma-ccrcc-results-from-the
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-phase-ii-biomarker-driven-trial-with-nivolumab-n-and-ipilimumab-or-vegfr-tyrosine-kinase-inhibitor-tki-in-naive-metastatic-kid
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/primary-results-from-imagyn050-gog-3015-engot-ov39-a-double-blind-placebo-pbo-controlled-randomised-phase-iii-trial-of-bevacizumab-bev-contain
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/icon8-overall-survival-results-in-a-gcig-phase-iii-randomised-controlled-trial-of-weekly-dose-dense-chemotherapy-in-first-line-epithelial-ovarian
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tisotumab-vedotin-in-previously-treated-recurrent-or-metastatic-cervical-cancer-results-from-the-phase-ii-innovatv-204-gog-3023-engot-cx6-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nivolumab-versus-gemcitabine-or-pegylated-liposomal-doxorubicin-for-patients-with-platinum-resistant-advanced-or-recurrent-ovarian-cancer-open-l
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cancer-nursing-education-and-recognition-in-europe-a-survey-by-the-european-oncology-nursing-society
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patient-and-occupational-safety-in-europe-a-survey-by-the-european-oncology-nursing-society
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-european-cancer-nursing-index-2020-a-tool-for-mapping-cancer-nursing-status-across-europe
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion51
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba6_pr-and-lba7_pr
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba6_pr-and-lba7_pr
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion51
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/invited-discussant-lba8_pr-and-lba9_pr
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion52
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pembrolizumab-plus-chemotherapy-versus-chemotherapy-as-first-line-therapy-in-patients-with-advanced-esophageal-cancer-the-phase-3-keynote-590-study
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/adjuvant-nivolumab-in-resected-esophageal-or-gastroesophageal-junction-cancer-ec-gejc-following-neoadjuvant-chemoradiation-therapy-crt-first-r
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/welcome-and-introduction13
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/improving-outcomes-with-immunotherapy-in-urothelial-cancer-perspectives-on-the-latest-data
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-changing-landscape-of-metastatic-prostate-cancer-challenges-and-evolving-opportunities
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/targeting-akt-next-breaakthrough-therapies-for-prostate-cancer-care
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-24-september-2020-15-30-16-002
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exploring-the-emerging-research-with-immuno-oncology-in-cscc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/broadening-horizons-new-data-and-combinations-with-parp-inhibitors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/combination-checkpoint-inhibitor-studies-in-newly-diagnosed-and-recurrent-endometrial-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patient-journeys-of-2-women-with-recurrent-advanced-ec
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/conclusion2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/welcome-and-introduction5
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/welcome-and-introduction10
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/extensive-stage-sclc-changing-the-paradigm-with-immune-oncology-combinations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/unresectable-stage-iii-nsclc-clinical-advances-in-the-implementation-of-immuno-oncology-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/adcs-as-a-technologically-advanced-treatment-approach-in-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/extensive-stage-sclc-changing-the-paradigm-with-immune-oncology-combinations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/unresectable-stage-iii-nsclc-clinical-advances-in-the-implementation-of-immuno-oncology-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/early-stage-egfrm-nsclc-targeted-treatment-options-following-complete-surgical-resection
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/locally-advanced-or-metastatic-egfrm-nsclc-targeted-treatment-options-to-improve-outcomes-in-the-first-line-setting-and-beyond-progression
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/chair-s-welcome-and-introductions
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pioneering-with-parp-inhibition-rationale-for-maintenance-therapy-in-newly-diagnosed-ovarian-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/optimising-clinical-outcomes-the-case-for-personalised-medicine-in-ovarian-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/recent-clinical-findings-with-novel-adcs-in-colorectal-and-gastric-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/summary-and-close3
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/chair-s-welcome-and-introductions2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exploring-molecular-heterogeneity-in-prostate-cancer-prevalence-and-clinical-significance
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/considerations-for-the-approach-to-hrrm-testing-in-prostate-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/personalizing-treatment-approaches-in-clinical-practice.-part-1-sequencing-of-treatment-in-arcc-following-progression-panel-discussion
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/personalizing-treatment-approaches-in-clinical-practice.-part-2-understanding-the-patient-experience-of-arcc-panel-discussion
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/closing-comments
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/welcome-and-introductions3
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/her-past-looking-back-on-two-decades-of-her2-targeted-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/her-new-potential-new-advances-in-her2-breast-cancer-treatment
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/sharing-her-experience-case-based-panel-discussion
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/closing-remarks
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/emerging-research-with-immune-checkpoint-inhibitors-in-basal-cell-carcinoma-bcc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/welcome-and-introduction8
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/evolution-of-diagnosis-and-classification-of-endometrial-cancer-and-emergence-of-molecular-classification
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/endometrial-cancer-as-an-attractive-target-for-checkpoint-inhibitor-based-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/monotherapy-checkpoint-inhibitor-studies-in-recurrent-endometrial-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-28-september-2020-15-30-16-00
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/broadening-horizons-new-data-and-combinations-with-parp-inhibitors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exploring-the-emerging-research-with-immuno-oncology-in-cscc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/raising-the-bar-in-early-tnbc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/insights-from-the-clinic-hypothetical-etnbc-patient-scenario-s
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/new-frontiers-in-metastatic-tnbc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/insights-from-the-clinic-hypothetical-mtnbc-patient-scenario-s
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/looking-at-the-future-horizon
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/panel-discussion3
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/adcs-as-a-technologically-advanced-treatment-approach-in-solid-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-28-september-2020-17-00-17-30
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/welcome-introduction-and-objectives-and-treatment-for-locally-advanced-metastatic-cutaneous-squamous-cell-carcinoma-cscc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-24-september-2020-15-30-16-002
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-22-september-2020-16-15-16-45
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/welcome-introduction-and-objectives-and-treatment-for-locally-advanced-metastatic-cutaneous-squamous-cell-carcinoma-cscc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-24-september-2020-15-30-16-002
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-22-september-2020-16-15-16-45
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a-23-september-2020-09-30-10-30
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/introduction2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/introduction-to-ret-mutations-and-fusions-and-their-incidence-for-potential-use-as-target-in-cancer-treatment
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ret-fusion-tki-present-results-and-recent-developments-in-lung-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ret-alterations-in-thyroid-carcinomas-results-and-recent-update
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ret-determination-present-recommendation-of-the-esmo-precision-medicine-working-group
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/conclusion-is-ret-targeting-ready-for-an-agnostic-use
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/is-osimertinib-the-best-single-agent-if-1st-line
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/should-chemotherapy-be-combined-upfront-with-egfr-tki
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/is-a-combination-of-anti-angiogenic-with-efgr-tki-a-new-standard
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/do-immune-check-point-work-in-egfr-tki
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/in-a-multiline-setting-what-is-the-best-sequencing
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/conclusions
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/live-q-a2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/introduction4
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/case-presentation
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/assessment-of-nutritional-status-nutritional-requirements-to-prevent-cachexia
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/case-presentation2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pharmacological-management-of-cancer-anorexia-cachexia
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/indication-of-enteral-and-parenteral-nutrition
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/conclusions3
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/introduction6
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/colorectal-cancer-a-paradigm-for-a-multimodal-personalized-approach
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/local-treatment-for-oligometastastic-disease-what-is-the-evidence
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/systemic-treatment-for-oligometastatic-disease
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/oligometastatic-cns-disease-the-role-of-tki-and-io
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/future-options-in-oligometastastatic-disease
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/conclusions4
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/introduction7
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-fine-specificity-of-immune-responses-to-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/introduction5
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/which-systemic-treatments-should-be-centralized-based-on-rarity-and-required-specific-expertise
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/which-data-underline-a-positive-correlation-between-patient-volume-and-outcome
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/comprehensive-cancer-centres-as-a-means-to-divide-tasks
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/should-there-be-more-tumour-specialised-experts-or-more-general-practicing-oncologists
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/conclusions5
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/introduction8
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/melanoma-treatment-a-door-opened-but-not-a-closed-case
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/presentation-of-case-patient-on-bevacizumab-and-pulmonary-embolism
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cancer-associated-hyper-coagulopathy-identification-and-treatment
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/presentation-of-case-a-glioblastoma-patient-with-post-op-pulmonary-embolism
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/expert-discussion
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/full-dose-low-dose-or-no-dose-how-to-evaluate-the-risk-and-benefit-of-anticoagulation-in-patients-with-high-risk-of-bleedings
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/drug-drug-interaction-ddi-with-direct-anticoagulants-in-cancer-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/introduction9
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tumour-biology-guided-breast-cancer-therapy-less-can-be-more
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/bringing-innovation-to-cancer-patients-science-weekend-highlights-translate-into-practice-of-care
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/histology-and-biomarkers
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/progress-in-immunotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/surgical-strategies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/advances-in-radiotherapy-for-mesothelioma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-complexity-of-triple-negative-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/hr-breast-cancers-are-they-all-the-same
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/future-research-priorities
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/hope-and-shared-decision-making
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-trial-design
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-complexity-of-triple-negative-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/hr-breast-cancers-are-they-all-the-same
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/future-research-priorities
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/hope-and-shared-decision-making
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-health-care-perspective
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-trial-design
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ethical-issues-in-the-perspective-of-short-life-and-in-patients-with-cognitive-deficits
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/histology-and-biomarkers
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/progress-in-immunotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/surgical-strategies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ai-for-drug-discovery-and-precision-medicine-in-oncology-hype-or-reality
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/driving-the-revolution-of-ai-in-healthcare
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-health-care-perspective
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ethical-issues-in-the-perspective-of-short-life-and-in-patients-with-cognitive-deficits
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/chemotherapy-immunotherapy-or-combinations-what-is-the-best-option-in-the-face-of-new-evidence
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/what-to-do-if-immunotherapy-fails
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/her2-breast-cancer-is-there-anything-else-to-do
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/hr-her2-cancers-can-we-do-better
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/desmoid-tumors-new-paradigms
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/recent-discoveries-in-genetic-abnormalities-in-young-adult-sarcomas
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/new-treatment-options-in-ewing-sarcoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion114
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion80
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion81
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion67
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion68
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genomic-profiling-to-enable-precision-oncology-therapeutic-development-precision-panc-initial-experience
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/increasing-cure-rate-neo-adjuvant-treatment-strategies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/modern-therapy-algorithms-for-metastatic-and-recurrent-stage
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/molecular-characterisation-of-urothelial-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/can-we-treat-tnbc-better
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion67
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion68
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/her2-breast-cancer-is-there-anything-else-to-do
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/new-treatment-options-in-ewing-sarcoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/rhabdomyosarcoma-at-young-adult-age-the-way-forward
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome-and-introduction-of-the-speaker2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-microbiome-and-its-impact-on-molecular-treatment-decisions-in-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/treatment-of-the-primary-in-metastatic-prostate-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/how-does-the-clinician-use-quality-of-life-data-to-decide-between-chemotherapy-and-hormonal-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genetic-counselling-for-patients-diagnosed-with-metastatic-disease
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion93
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion104
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion72
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion73
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/surgery-and-radiation-who-when-and-how
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/systemic-management-of-cns-progression
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/leptomeningeal-disease-an-unmet-challenge
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/glutaminolysis
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/metabolic-regulation-in-the-tumour-microenvironment
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/how-does-the-clinician-use-quality-of-life-data-to-decide-between-chemotherapy-and-hormonal-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/treatment-of-the-primary-in-metastatic-prostate-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/current-and-future-systemic-treatments-of-mcspc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genetic-counselling-for-patients-diagnosed-with-metastatic-disease
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/age-and-gender-aspects-do-we-need-to-take-them-into-account
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/terminology-classification-and-staging-of-gep-nens
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-management-of-patients-with-low-intermediate-grade-gep-nets
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-management-of-patients-with-net-g3-necs
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/new-drugs-new-horizons
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/how-to-guide-and-scan-patients-on-long-term-tki-treatment
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion91
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion102
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion116
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion66
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion103
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/checkpoint-inhibition-in-adaptive-and-innate-immunity
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cellular-therapies-in-2020
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/emerging-concepts-and-combinations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nsclc-diagnostics-in-tissue
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nsclc-and-sclc-diagnostics-in-blood-are-we-ready
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion116
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/emerging-concepts-and-combinations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/why-do-we-make-bad-decisions-for-our-health
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-global-burden-of-smoking-related-cancers-the-iarc-data
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/is-it-really-never-too-late-to-stop-smoking-what-is-the-evidence-that-smoking-cessation-improves-the-outcomes-of-cancer-treatment
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/european-vision-towards-cancer-prevention-and-the-current-and-potential-key-role-of-esmo-in-this-field
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/many-cancer-patients-are-living-active-lives-with-cancer-who-are-they-and-what-are-the-challenges
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/how-can-palliative-and-supportive-care-be-organised-in-order-to-contribute-to-optimise-patients-qol
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-guidelines-to-treat-symptoms-and-maintain-functions
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/competence-needed-for-an-oncologist-in-palliative-and-supportive-care-how-is-the-training-performed-and-formalised
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/many-cancer-patients-are-living-active-lives-with-cancer-who-are-they-and-what-are-the-challenges
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/how-can-palliative-and-supportive-care-be-organised-in-order-to-contribute-to-optimise-patients-qol
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-guidelines-to-treat-symptoms-and-maintain-functions
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/competence-needed-for-an-oncologist-in-palliative-and-supportive-care-how-is-the-training-performed-and-formalised
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/current-systemic-treatment-for-first-line
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/future-options
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-opioid-epidemic-how-to-start-and-when-to-stop
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/towards-safer-opioids-new-concepts-and-mechanisms
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/strong-versus-weak-opioids
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/opioid-availability-in-low-and-middle-income-countries
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion79
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion112
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tailoring-systemic-adjuvant-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pre-habilitation-for-surgery-and-beyond
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/is-cancer-biology-the-same-in-older-adults
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/challenges-for-radiotherapy-from-radiosurgery-to-omission
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/balancing-benefit-harm-and-patient-priorities-in-older-adults-with-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-opioid-epidemic-how-to-start-and-when-to-stop
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/towards-safer-opioids-new-concepts-and-mechanisms
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/strong-versus-weak-opioids
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/opioid-availability-in-low-and-middle-income-countries
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/current-systemic-treatment-for-first-line
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/setting-the-scene
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/follow-up-of-paediatric-and-adolescents-patients-in-their-adulthood-the-pancare-project
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/how-tech-help-in-the-return-to-work-after-recovering-from-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/creating-a-voice-to-challenge-change-in-spain-early-diagnoses-drives-better-outcomes-in-survivorship
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/how-molecular-biology-influences-radical-surgical-treatment-in-first-line-ovarian-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/future-options
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genomic-determinants-and-tumour-heterogeneity-of-checkpoint-inhibitor-response
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/current-overview-and-how-to-select-patients-in-first-line
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/beyond-the-use-of-checkpoint-inhibitor
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/imaging-and-targeting-premetastatic-niches-in-melanoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion83
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion84
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion110
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion113
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion117
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/precision-medicine-personalised-medicine-and-pharmacogenomics
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/promise-versus-reality-of-precision-medicine-in-current-clinical-care
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-importance-of-partnerships-and-collaboration-in-precision-medicine
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neurotoxicity-from-the-head-to-the-toes
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/integrating-proms-for-adverse-effects-into-clinical-practice
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/update-on-the-ich-gcp-renovation-process
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-implementation-of-the-eu-clinical-trials-regulation-let-s-get-it-right
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/is-good-clinical-practice-becoming-poor-clinical-care
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tearing-down-barriers-to-access-clinical-trials
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/beyond-the-use-of-checkpoint-inhibitor
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immunotherapy-in-npc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tumour-micro-environmental-and-systemic-barriers-to-t-cell-immunotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/genomic-determinants-and-tumour-heterogeneity-of-checkpoint-inhibitor-response
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/tumour-micro-environmental-and-systemic-barriers-to-t-cell-immunotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/intratumour-heterogeneity-and-its-influence-on-immune-response
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/present-and-future-of-cancer-immunotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome-and-introduction-of-the-speaker3
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-next-generation-immune-targets-and-possible-combinations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/practical-use-of-immunotherapy-in-colorectal-cancer-in-2020
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion74
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion82
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion88
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion78
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion111
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/egfr
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/alk-and-ros1
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/her2-nrg1-ntrk
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/braf-ras-ret-etc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/rational-treatment-combination-an-urgent-clinical-need-of-the-future
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/radiomics-a-critical-step-towards-integrated-healthcare
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/translating-cancer-genetics-into-medicines-and-disease-insights
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-trials-successes-and-pitfalls
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/improving-aya-access-and-recruitment-to-trials-of-innovative-therapies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/colorectal-tumour-immunology-update
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immune-parameters-and-other-potential-biomarkers-for-treatment-selection
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-next-generation-immune-targets-and-possible-combinations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/practical-use-of-immunotherapy-in-colorectal-cancer-in-2020
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/controversies-in-the-surgical-management-of-stage-iii-melanoma
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/adjuvant-and-neo-adjuvant-therapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/translational-research-ready-for-patient-selection
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cfdna-in-cns-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cell-free-dna-methylomes-and-early-stage-cancers
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/leveraging-mutational-signatures-for-mutational-calling-in-cell-free-tumour-dna
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion115
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cancer-burden-and-prevention-initiatives-around-the-world-what-are-the-preventable-diseases
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion64
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/fgfr-inhibitors
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/antibody-drug-conjugate-adc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/epigenetic-drugs-ezh2-bet-and-ldsd1
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/future-strategies-of-using-radiotherapy-as-an-immune-stimulating-agent
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/leveraging-mutational-signatures-for-mutational-calling-in-cell-free-tumour-dna
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/biomarkers
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/what-to-do-post-io-failure
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/emerging-targets-in-immunotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/who-should-get-an-i-o-combination
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cfdna-in-cns-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/cell-free-dna-methylomes-and-early-stage-cancers
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/high-sensitivity-ctdna-assays-to-detect-low-burden-disease
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/evidence-based-screening-interventions-state-of-the-art
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-clinical-perspective-trials-fit-for-purpose-in-2020-and-beyond
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-regulatory-perspective-how-to-look-for-certainty-in-terra-incognita
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-hta-perspective-is-tissue-independent-approval-the-next-top-model
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/implementation-of-ngs-diagnostics-in-the-nhs-the-example-of-belgium
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/high-sensitivity-ctdna-assays-to-detect-low-burden-disease
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/emerging-targets-in-immunotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prrt-new-insights
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prrt-for-nen-how-and-in-whom
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prrt-and-surgery
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prrt-and-chemo
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-relevance
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion105
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion71
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion77
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion87
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion62
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/new-targeted-therapies-for-er-positive-breast-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-next-generation-of-her2-targeting-therapies
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/new-approaches-for-triple-negative-breast-cancer-non-io-approaches
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/multidisciplinary-computation-techniques-for-drug-discovery-and-clinical-application-in-oncology
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ai-big-data-and-machine-learning-in-clinical-drug-development-in-oncology-a-new-paradigm
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/biology-and-patho-physiology-of-the-blood-brain-barrier
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/artificial-intelligence-in-cancer-imaging-clinical-challenges-and-applications
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/biomarkers2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion62
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/biomarkers2
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immune-therapy-combinations
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/which-trials-are-missing-in-bladder-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/from-bench-to-bedside-future-perspectives-of-immunotherapy-combinations-in-mrcc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/from-bench-to-bedside-future-perspectives-of-immunotherapy-combinations-in-bladder-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion90
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion89
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion99
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion109
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/metastatic-soft-tissue-sarcoma-the-need-for-novel-trial-designs
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/from-bench-to-bedside-future-perspectives-of-immunotherapy-combinations-in-mrcc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/which-trials-are-missing-in-mrcc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/synthetic-lethality-screens-to-identify-genes-that-control-the-response-of-cancer-cells-to-dna-damaging-agents
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/mutation-signatures-as-biomarkers-for-selecting-treatment-options
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nucleolar-stress-as-a-cancer-driver-and-a-vulnerability
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-efficacy-of-agents-targeting-dna-replication-stress-in-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/introduction-and-hpv
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/hpv
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nasal-para-nasal-and-skull-base-tumours
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/from-bench-to-bedside-future-perspectives-of-immunotherapy-combinations-in-bladder-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/which-trials-are-missing-in-bladder-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/providing-holistic-support-to-each-cancer-patient
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pre-habilitation-at-the-time-of-diagnosis-or-relapse-as-important-as-post-treatment-rehabilitation
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/improving-cancer-patient-s-mental-health-the-war-on-cancer-project
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/patients-navigating-patients-when-the-best-support-comes-from-a-peer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/open-welcome-and-introduction-of-the-speaker
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/linking-genetic-alterations-to-dependencies-for-new-cancer-therapeutics
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion75
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion101
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion120
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion121
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion100
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion106
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/the-cytoskeleton-of-cancer-cells-regulates-the-immune-system-during-tumour-dissemination-and-therapy-resistance
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/primary-and-metastatic-tumour-ecosystems
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/radiotherapy-with-systemic-effect
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/oncolytic-viruses-and-sting-agonist-tlr-agonists-flt3
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/integrating-microenvironment-tumour-and-clinical-features-to-predict-immunotherapy-response-in-metastatic-melanomaes
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/microenvironment-regulates-chemosensitivity
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion100
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion101
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/update-on-predictive-and-prognostic-roles-of-circulating-tumor-dna
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/immune-checkpoint-inhibitors-clinical-use-and-response-prediction
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/biomarker-of-gastroesophageal-cancer-what-s-standard-of-care-and-what-s-on-the-horizon
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/biomarker-of-hepatobiliary-and-pancreatic-cancer-is-there-a-standard-of-care-and-what-s-on-the-horizon
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/risk-stratification-who-gets-screened
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/breath-biopsy-for-lung-cancer-screening
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/liquid-biopsy-for-lung-cancer-screening
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/how-to-implement-screening-in-your-country-lessons-learned-from-screening-trials
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/breath-biopsy-for-lung-cancer-screening
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/liquid-biopsy-for-lung-cancer-screening
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/how-to-implement-screening-in-your-country-lessons-learned-from-screening-trials
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion70
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion76
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion92
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion94
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion108
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/current-status-of-neo-adjuvant-immunotherapy-in-early-stage-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-and-molecular-characteristics-of-resistance-to-immunotherapy
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion76
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/q-a-and-live-discussion94
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/unresectable-stage-iii-nsclc-pacific-and-beyond
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/emergence-of-neuroendocrine-prostate-cancer-and-the-clinical-relevance-of-tumour-evolution
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/early-stage-nsclc-immunotherapy-which-biomarkers-matter
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/dealing-with-comorbidities-and-toxicities-in-stage-i-iii-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/challenges-when-using-prostate-biopsies-for-genomics
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/liquid-biopsies-challenges-and-opportunities-for-implementing-into-clinical-practice
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/oncotaxi-safe-and-free-transport-for-cancer-patients-to-hospitals-and-clinics-during-pandemia-time
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/hta-why-it-matters-to-patients
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/liquid-biopsies-challenges-and-opportunities-for-implementing-into-clinical-practice
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/emergence-of-neuroendocrine-prostate-cancer-and-the-clinical-relevance-of-tumour-evolution
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/selection-strategies-for-immunotherapy-in-prostate-cancer
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/current-status-of-neo-adjuvant-immunotherapy-in-early-stage-nsclc
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prevention-mammo-mobile-providing-access-to-screening-services-in-hard-to-reach-areas-turkey
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/oncotaxi-safe-and-free-transport-for-cancer-patients-to-hospitals-and-clinics-during-pandemia-time
